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Abstract 
 
Cardiac hypertrophy often develops to compensate for hemodynamic overload and 
therefore, in its early stages, hypertrophy is considered to be an adaptive response. 
Nonetheless, prolonged exposure to a hypertrophic stimulus is associated with heart 
failure.  
In the heart, the compartmentalisation of the cAMP/ PKA signalling pathway plays a 
critical role to achieve the specificity of response and maintains regular cardiac function. 
Alterations in this signalling pathway have been linked to the pathophysiology of cardiac 
hypertrophy. Phosphodiesterases (PDEs) provide the only means of hydrolysing cAMP 
and therefore are essential components in the spatial and temporal control of the cAMP 
response. By restricting the diffusion of cAMP, PDEs prevent unspecific activation of 
PKA and phosphorylation of downstream targets. PDEs are therefore able to regulate the 
kinetics of cAMP signalling dynamics.  
 
In this study, an in vitro model of chronic catecholamine-induced cardiac hypertrophy of 
adult rat ventricular myocytes (ARVM) was utilised. This model allowed the investigation 
of the function of PDEs in regulating compartmentalised cAMP signals in cardiac 
hypertrophy. Using FRET-based cAMP sensor Epac1_camps fused to the unique 
dimerisation/docking domain sequences that anchors PKA‐RI and PKA‐RII subunits to 
AKAPs, this study demonstrated that, similar to neonatal rat ventricular myocytes 
(NRVM), adult myocytes also display restricted cAMP diffusion. These cAMP 
microdomains are regulated by different families of PDEs. In particular, PDE2, PDE3 and 
PDE4 appear to control the pool of cAMP generated in the PKA-RI compartment, whereas 
only PDE2 and PDE4 were found to modulate cAMP in the PKA-RII compartment in 
ARVM. 
 
In the in vitro cardiac hypertrophy model, a reduction in cAMP generation was detected 
upon β-adrenergic stimulation and altered PDE activity was visualised using FRET-based 
imaging. This investigation showed that PDE2 activity is significantly increased in the 
PKA-RII compartment of hypertrophic cardiac myocytes, while an overall reduction in 
PDE3 activity was detected. Immunofluorescence experiments revealed altered PDE4 
localisation in hypertrophic myocytes.  
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Advances in cyclic nucleotide signalling research, in particular of the activity and 
regulation of PDEs, have shown that an interaction between the cAMP and cGMP 
signalling pathways exists. Integration between these two pathways is mediated by the 
modulation of cAMP‐degrading PDEs by cGMP. Allosteric binding of cGMP to the GAF 
domains of PDE2 enhances its activity, whereas cGMP reduces the activity of PDE3 by 
acting as a competitive inhibitor. PDE2 and PDE3 therefore may act as a connection 
between these two signalling cascades and it is possible to predict the existence of distinct 
signalling units in vivo in which cGMP, by acting on PDE2 or PDE3, can selectively 
modulate cAMP levels. 
 
Intracellular cGMP generated by stimulation of the particulate GC (pGC) by atrial 
natriuretic peptide (ANP) or stimulation of the soluble GC (sGC) by the NO donor SNAP 
is compartmentalised into discrete microdomains. Stimulation of the pGC had no effect on 
cAMP signalling in the PKA-RII compartment. Activation of sGC generated a pool of 
cGMP which lead to a reduction in cAMP response in the PKA-RII compartment upon β-
AR stimulation. Both GCs generated cGMP in the PKA-RI compartment which lead to an 
increase in cAMP response. Further investigation revealed that cGMP is able to modulate 
cAMP signalling in the PKA-RI compartment by PDE3 and by PDE2 in the PKA-RII 
compartment. 
It was hypothesised that the observed differences in cAMP signalling and PDE 
contribution in hypertrophic myocytes in the PKA-RI and PKA-RII subcellular 
compartments may be due to variations in the pools of cGMP. Employing genetically 
encoded FRET-based biosensors for cGMP targeted to PKA‐RI and PKA‐RII 
compartments, basal levels of cGMP were found to be significantly increased in both 
compartments of hypertrophic myocytes which could explain the altered PDE2 and PDE3 
activity in hypertrophic ARVM. 
 
Finally, this study shows that PDE2 activity is necessary to achieve full development of the 
catecholamine-induced hypertrophic response. Pharmacological inhibition of PDE2 with 
Bay 60-7550 prevents NE-induced cardiomyocyte hypertrophy. Overexpression of 
PDE2A2 was found to induce hypertrophic growth, even in the absence of increased 
adrenergic drive, thus indicating that PDE2 activity promotes development of 
cardiomyocytes hypertrophy. PDE2 localisation is vital for its regulation of hypertrophic 
growth. Displacement of endogenously active PDE2 from its specific intracellular 
localisation, using a catalytically inactive PDE2A2, was sufficient to counteract 
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catecholamine-induced hypertrophic growth As PDE2 is a dual specific PDE, it was 
important to establish whether the anti-hypertrophic effects of PDE2 inhibition were 
mediated by activation of the cGMP/ PKG or cAMP/ PKA signalling pathways. The data 
presented here, show that the effects of pharmacological inhibition of PDE2 is PKA 
dependent.  
Together, these findings confirm the involvement of PDE2 in the progression of 
hypertrophy in cardiomyocytes and indentify PDE2, specifically coupled to the PKA-RII 
compartment, as a possible novel target for the development of therapeutic treatment for 
hypertrophy. 
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1  Introduction 
 
 
1.1 Signal transduction by cyclic nucleotides 
(concept of second messenger). 
Signal transduction is the process by which information, provided externally to the cell in 
the form of hormones, ions, and other signalling molecules, is converted into intracellular 
information that regulates the internal function of the cell. This external stimulus acts as 
the “first messenger”, whereas an intermediate molecule, which transmits the signal from 
receptor to target inside the cell, is the “second messenger”. Many second messenger 
molecules are small and therefore diffuse rapidly through the cytoplasm, enabling signals 
to move quickly throughout the cell. By binding and activating protein kinases, channels or 
other proteins, second messengers mediate specific intracellular responses. The most 
studied second messengers are cyclic nucleotides, such as 3’, 5’ cyclic adenosine 
monophosphate (cAMP) and 3’, 5’ cyclic guanosine monophosphate; calcium (Ca2+) and 
phosphatidylinositol derivatives, such as phosphatidylinositol-trisphosphate (PIP3), 
diacylglycerol (DAG) and inositol-triphosphate (IP3), controlling the release of 
intracellular Ca
2+
 stores. 
 
 cAMP was first discovered by Dr. Earl W. Sutherland while studying phosphorylase, the 
enzyme responsible for the conversion of glycogen to glucose. The activity of this enzyme 
was increased by hormones, such as glucagon and norepinephrine (Sutherland and Cori 
1951). While purifying phosphorylase from dog liver extracts, Sutherland found another 
enzyme which catalyses the inactivation of phosphorylase. Later this inactivating enzyme 
was confirmed as a phosphatase (Wosilait and Sutherland 1956). Further studies lead to the 
discovery that the activation/ inactivation of the phosphorylase were a result of an 
enzyme‐catalysed phosphorylation‐dephosphorylation reaction that required ATP and 
Mg
2+
.  The way in which AMP promoted phosphorylase activation was eventually elucidated 
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when Krebs and Fisher discovered phosphorylase kinase, an enzyme that phosphorylates 
phosphorylase (Krebs and Fischer 1956). 
 
Sutherland and colleagues continued studying the effect of hormones on glycogen 
breakdown. Fractionation of the cells revealed this process was mediated by a heat stable 
factor which could activate phosphorylase (Berthet et al. 1957). This factor was identified 
as an adenine ribonucleotide that could be produced from ATP by the particulate fraction 
from different tissues, including liver, heart, skeletal muscle and brain (Rall and Sutherland 
1958). The structure of this compound was reported by Lipkin et al. as adenosine 
3’‐5’‐monophosphate (cyclic AMP or cAMP) (Lipkin 1959). By the early 1960s, cAMP, 
the synthetic activity (adenylyl cyclase) and the degrading activity (phosphodiesterase 
(PDE)) had been described. Moreover, the hormone receptors and adenylyl cyclase activity 
were found to be confined to membranes (Rall and Sutherland 1958; Sutherland and Rall 
1958; Beavo and Brunton 2002).  
 
Sutherland was awarded the 1971 Nobel Prize for “his discovery concerning the 
mechanism of the action of the hormones”, which would prove to be the first of five Nobel 
Prizes recognising research on this molecule. cAMP is now recognised as a universal 
regulator of cellular function. 
 
 
 
1.2  cAMP signalling pathway 
Cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger responsible 
for a huge number of cellular processes, including memory formation, cardiac frequency 
and strength of contraction, differentiation and gene transcription, cell growth and 
tumour genesis.  
The generation of cAMP begins when an extracellular first messenger (neurotransmitter, 
hormone, chemokine, lipid mediator, or drug) binds to a G protein-coupled receptor 
(GPCR) on the plasma membrane. GPCRs are coupled to a stimulatory G protein (Gs) and 
ligand binding produces and exchange of GDP for GTP on the Gs protein resulting in the 
dissociation of the alpha subunit (Gαs). As shown in Figure 1-1, the release of the Gαs 
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subunit stimulates adenylyl cyclase (AC) to catalyse the cyclisation of ATP to generate 
cAMP and pyrophosphate (PPi). 
 
 
 
Figure 1-1. The cyclisation of ATP to form cAMP. 
 
 
The intracellular level of cAMP depends on the balance between synthesis and 
degradation, thereby results from the activities of adenylyl cyclases (AC), the only 
enzymes that can generate cAMP, and phosphodiesterases (PDEs), the only enzymes 
capable of degrading cAMP into 5-AMP.  
cAMP exerts its effects by the activation of a limited number of effectors. These are the 
cAMP-dependent protein kinase (PKA), the exchange proteins directly activated by cAMP 
(Epac1 and Epac2) and the cAMP-gated ion channels (CNG). 
 
 
 
1.3  cAMP synthesis: Adenylyl Cyclases 
Adenylyl cyclases (ACs) are ATP‐pyrophosphate lyases that synthesise ATP to cAMP and 
pyrophosphate. To date there are 10 known AC isoforms that are differentially expressed 
in various cell types – nine membrane‐bound isoforms (AC1‐AC9) and one soluble form 
(sAC). Membrane-bound AC isoforms are large proteins of approximate 120–140 kDa that 
share a common secondary structure comprising of an intracellular N-terminus, that retains 
the regulatory properties of ACs, two repeats of a module composed of six transmembrane 
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spans (Tm1 and Tm2) separated by two large cytoplasmic domains (C1 and C2) (Figure 
1-2). The overall similarity of the different adenylyl cyclases is ~ 60% and C1 and C2 
contain a region of approximately 255- 330 amino acids that are highly conserved (C1a 
and C2a). On the contrary, the N- and C-terminal of C1 and C2 domains (C1b and C2b) 
are the most variable portions of the enzyme for all the AC isoforms (Sunahara et al. 
1996). C1a and C2a dimerisation constitutes, in fact, the ATP-binding site. Within these 
motifs two aspartic acid residues coordinate two Mg
2+
 metal ions necessary for catalytic 
activity. These mediate the attachment of the ATP, promoting the cyclisation of the cAMP 
and the release of PPi (Cooper 2003).  
 
 
 
 
Figure 1-2. Schematic representation of adenylyl cyclase. Adapted from (Willoughby and 
Cooper 2007). 
 
 
Although AC isoforms share a highly conserved secondary structure, these enzymes differ 
in tissue distribution (as shown in Table 1-1), as well as specific regulation. AC5 and AC6 
are major isoforms in the heart, with AC5 being expressed in adult tissue and AC6 in fetal 
and adult cardiac tissue, AC1 and AC8 are mainly expressed in the brain, whereas AC2, 
AC4, AC7 and AC9 are widely expressed in multiple tissues (Defer et al. 2000). 
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Table 1-1. Tissue distribution of ACs. Adapted from (Sadana and Dessauer, 2009). 
AC 
Isoform 
 
Tissue expression 
AC1 
AC2 
AC3 
AC4 
AC5 
AC6 
AC7 
AC8 
AC9 
sAC 
Brain, adrenal medulla 
Brain, lung, skeletal muscle, heart 
Olfactory epithelium, pancreas, brain, heart, lung, testis, BAT 
Widespread 
Heart, striatum, kidney, liver, lung, testis, adrenal, BAT 
Heart, kidney, liver, lung, brain, testis, skeletal muscle, adrenal, BAT 
Widespread 
Brain, lung, pancreas, testis, adrenal 
Widespread 
Testis and detected in all tissues 
 
 
All ACs, with the exception of sAC, are stimulated by the GTP-bound α subunit of Gs 
(Gsα), which are released from inactive heterotrimeric G-protein complexes after the 
agonist binds to the receptor. AC can also integrate signals from intracellular calcium, from 
other G-protein subunits, such as Gβγ and the inhibitory Gi and G0, and from protein kinase 
C (PKC).  
 
PKC can also regulate the activity of AC5 (Kawabe et al. 1994) and AC6 (group III) 
(Cheung et al. 2005). PKA-mediated phosphorylation inhibits the activity of AC5 and AC6 
(Beazely and Watts 2006). 
 
The key to regulation of AC is the interface between the C1 and C2 domains which forms 
a single ATP-binding site. Forskolin, a potent AC activator, stimulates AC1-AC8 and 
promotes the interaction between the two cytosolic domains (C1 and C2), resulting in 
formation of an active catalytic site (Zhang et al. 1997). Both forskolin and Gsα increase 
the affinity between the C1 and C2 domains by ∼10-fold (Sunahara et al. 1997). Further 
studies suggest that Gsα and forskolin may induce a 7° rotation of the two domains that 
brings key catalytic elements from the two domains close to each other. 
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1.4 Cyclic nucleotide degradation: 
phosphodiesterases 
Phosphodiesterase (PDE) are a superfamily of phosphohydrolases that selectively catalyse 
the hydrolysis of the 3’, 5’ cyclic phosphate bonds of 3’, 5’‐ adenosine monophosphate 
(cAMP) or 3’, 5’‐ guanosine monophosphate (cGMP) to produce the corresponding 
5’‐nucleotide, 5’‐AMP and 5’‐GMP. 
To date, 21 genes encoding PDEs have been identified in mammals. These genes 
transcribe multiple protein products by alternative splicing and/or the use of alternative 
promoters and it is estimated that this results in more than 100 different mRNA products, 
most of which can be translated into different proteins (Bender and Beavo 2006). The table 
below (Table 1-2) shows the 21 genes which have been categorised into 11 distinct 
families of PDEs (PDE1 – PDE11) based on their amino acid sequence, substrate 
selectivity, regulatory and pharmacological properties, and kinetics (Beavo 1995; Bender 
and Beavo 2006). Of the 11 PDE families, 3 selectively hydrolyse cAMP (PDEs 4, 7, and 
8), 3 families are selective for cGMP (PDEs 5, 6, and 9), and 5 families hydrolyse both 
cyclic nucleotide with varying efficiency (PDE 1, 2, 3, 10, and 11) (Conti and Beavo 
2007). PDEs 1, 2, 3, and 4 are expressed in many tissues, whereas others are more 
restricted. In most cells, PDE3 and PDE4 provide the major portion of cAMP-hydrolysing 
activity (Francis et al. 2011). 
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Table 1-2. The families of phosphodiesterases, detailing specificity for either cAMP or 
cGMP. Adapted from (Mehats et al. 2002). 
PDE Family Name cAMP Km (µm) cGMP Km (µm) 
PDE1 Ca
2+
–CaM-stimulated 1–30 3 
PDE2  cGMP-stimulated 30–100 10–30 
PDE3 cGMP-inhibited 0.1–0.5 0.1–0.5 
PDE4 cAMP-specific 0.5–4 >50 
PDE5 cGMP-specific >40 1.5 
PDE6 Photoreceptor 2000 60 
PDE7 cAMP-high affinity 0.2 >1000 
PDE8 cAMP-high affinity 0.7 >100 
PDE9 cGMP-high affinity >100 0.07 
PDE10 Dual substrate 0.5 3 
PDE11 Dual substrate 1 0.5 
 
 
The 11 families of mammalian PDEs all share a common structure (Figure 1-3), with a 
conserved catalytic domain (with 18%-46% sequence identity (Zhang et al. 2004)) of 
approximately 270 amino acids at the C-terminus, and regulatory domain, placed between 
the amino terminus and the catalytic domain. 
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Figure 1-3. Schematic representation of phosphodiesterase structure. Adapted from 
(Mehats et al. 2002). 
 
 
1.4.1 The catalytic domain 
The functional structure of the catalytic domain, which constitutes the core of the PDE, is 
highly conserved in all PDEs, where the sequence of any catalytic domain family express 
between 25 to 51% amino acid sequence identity with any other  (Francis et al. 2011). The 
x-ray crystallographic structure of the catalytic domain of nine families of PDEs has been 
resolved. The catalytic domains adopt a compact α-helical structure, consisting of 15-17 α-
helices, which can be divided into three sub-domains. These domains define a deep 
binding-pocket where the substrates (cAMP or cGMP) or inhibitors attach (Francis et al. 
2011). Below this binding-pocket are two divalent metal binding sites (Zn
+
 and Mg
2+
). The 
metal binding site that binds zinc has two histidine and two aspartic acid residues that are 
absolutely conserved among all PDEs and are responsible for interaction with the cyclic 
nucleotide purine. Structural studies have revealed that the cyclic nucleotide specificity of 
the catalytic site depends largely on one particular invariant glutamine. This glutamine 
functions as the key specificity determinant by a “glutamine switch” mechanism, and 
stabilises the binding of the purine ring in the binding pocket through hydrogen bonds that 
form with either cAMP or cGMP or both, depending on the orientation of the glutamine 
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(Zhang et al. 2004). In one orientation the hydrogen bond (H‐bond) network supports 
guanine binding leading to cGMP selectivity and in the other orientation the network 
supports adenine binding resulting in selectivity toward cAMP. In dual-specific PDEs a 
key histidine residue may enable the invariant glutamine to toggle between cAMP and 
cGMP (Zhang et al. 2004). 
 
 
1.4.2 The Regulatory domain 
Unlike the catalytic domain, the N-terminus regulatory domain is highly variable between 
PDEs, resulting in the unique characteristics of each PDE family. Of the several domains 
mapped to the N terminus, three types are present in multiple PDE families. These include 
domains for ligand binding, oligomerisation, kinase recognition/ phosphorylation, and 
regions that auto-inhibit the catalytic domain. Docking domains are also present at the N-
terminus.  
 
Numerous types of protein domains provide regulatory control over the catalytic domains. 
PDE2, PDE5, PDE6, PDE10 and PDE11 include at their N-terminal regulatory region two 
tandem protein domains named GAF (GAF-A and GAF-B). The acronym GAF is derived 
from cGMP-activated PDEs, adenylyl cyclase, and Fh1A, enzymes where they were first 
documented (see Figure 1-4). GAF domains are known to function as regulatory elements 
that bind nucleotides or other small molecules. Studies investigating the crystal structure of 
the region of PDE2 containing its tandem GAF domains, have indicated that GAF-A is 
likely involved in dimerisation, whereas GAF-B is involved in cGMP binding (Martinez et 
al. 2002). In PDE5 and PDE6, cGMP binds to the GAF-A domain. PDE1 contains a Ca
2+
/ 
calmodulin (CaM)-binding site. Binding of Ca
2+
/ calmodulin to PDE1 induces a 10-fold 
increase in the enzyme Vmax without affecting affinity for the substrate (Conti and Beavo 
2007). PDE4 has upstream conserved regions (UCRs), UCR1 and UCR2. UCR2 
corresponds to an auto-inhibitory domain that negatively regulates PDE catalytic activity, 
while phosphorylation sites have been identified in the UCR1 region (Sette and Conti 
1996; Houslay and Adams 2003). 
PDE8 has a response regulator receiver (REC) domain and a per–arnt–sim (PAS) domain. 
Like GAF domains, PAS domains are involved in ligand binding and protein-protein 
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interactions, and they share some structural similarities (Wang et al. 2008). PDE3, PDE7 
and PDE9 have no available data on their oligomerisation state, although some indicate 
that they too exist as dimers (Huai et al. 2004; Scapin et al. 2004). 
 
The other conserved types of regulatory domain at the N-terminus are phosphorylation 
sites. PDE1 isoforms A, B and C can be phosphorylated by PKA or CaM-kinase II 
(CaMKII), at the N-terminus. These phosphorylations decrease the binding and calmodulin 
induced activation in vitro (Florio et al. 1994). It has been reported that PDE2A can be 
phosphorylated by tyrosine kinase (Bentley et al. 2001). PDE3 has an amino-terminal 
transmembrane domain that contains six hydrophobic helices and numerous PKA and PKB 
phosphorylation sites; PKB‐mediated phosphorylation of PDE3B increases the catalytic 
activity of the enzyme (Kitamura et al. 1999; Zmuda-Trzebiatowska et al. 2006). At the 
N‐terminus of UCR1 of all long forms of PDE4, there is a highly conserved motif 
(RRESF), that can be phosphorylated by PKA and thus leading to increased catalytic 
activity of the enzyme (Sette and Conti 1996). cGMP binding to the GAF domain of 
PDE5, increases the accessibility of the Ser 92/102 residue and promotes PKG‐mediated 
phosphorylation. This phosphorylation then activates the catalytic domain and decreases 
the Km for the substrate (Bessay et al. 2007).  
 
Some PDEs possess also auto inhibitory domains, PDE6 for example has an inhibitory 
subunit (Pγ) whose affinity for the enzyme is enhanced by the binding of cGMP to the 
GAF domains (Cote 2004). PDE7 and PDE9 have no identified specific protein domains. 
Phosphorylation or prenylation sites have been described at the C‐terminal domains of 
some PDEs; however, nothing is yet known about the function of these C‐terminal regions 
of PDEs (Conti and Beavo 2007).  
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Figure 1-4. Schematic representation of the structures of the mammalian 
phosphodiesterase (PDE) families. Adapted from (Conti and Beavo 2007).  
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1.5  Effectors of cyclic nucleotides 
1.5.1 PKA 
Protein kinase A (PKA) was the first effector of cAMP to be identified. It was originally 
isolated in the laboratory of Ed Krebs in 1968, and is considered to be the principal cellular 
receptor for cAMP (Walsh et al. 1968). Under basal conditions, PKA is a heterotetramer 
composed of two catalytic (C) subunits non-covalently bound to a regulatory (R) subunit 
dimer. cAMP binds cooperatively to two sites, termed A and B, on each R subunit, 
however in PKAs inactive form, only the B site is available for binding. When site B is 
occupied by cAMP, the binding of cAMP to the A site is enhanced. Binding of four cAMP 
molecules, two to each R subunit, leads to a conformational change and dissociation into 
an R subunit dimer with four cAMP molecules bound and two C monomers. Active 
catalytic subunits are then free to phosphorylate Serine and Threonine residues in target 
proteins (Krebs and Beavo 1979; Taylor et al. 1990; Smith et al. 1999; Taylor et al. 1999; 
Kopperud et al. 2002; Tasken and Aandahl 2004). 
 
The C subunit isoforms (Cα, Cβ and Cγ) have indistinguishable kinetic and biochemical 
properties (Buechler and Taylor 1990; Taylor et al. 1990). In contrast, the two classes of R 
subunits (type I: isoforms RIα, RIβ, and type II: isoforms RIIα, RIIβ) show different 
functional and biochemical properties. PKA holoenzymes are classified as either type I or 
type II, depending on the subtype of regulatory subunit present. PKA type-I is more readily 
dissociated by cAMP then PKA type-II (showing a Kact of 50-100 nM and 200-400 nM, 
respectively) (Dostmann et al. 1990; Cummings et al. 1996). R isoforms are differentially 
expressed in tissues and their subcellular distribution also appears to be distinct. PKA-RII 
is predominately associated with cellular structures and organelles as it has the ability to 
bind to A kinase anchoring proteins (AKAPs) (Wong & Scott 2004). Traditionally, PKA-
RI was thought to be mainly cytosolic (Corbin and Keely 1977). However, it has been 
shown that PKA-RI also binds to AKAPs, although with a lower affinity than PKA-RII 
(Colledge and Scott 1999). Dual specific AKAPs have been described (Huang et al. 1997) 
as well as RI‐selective AKAPs (Angelo and Rubin 1998). 
 
Intracellular localisation of PKA is mediated by the N‐terminal dimerisation/ docking 
(D/D) domain of the R‐subunits. The Figure below (Figure 1-5) illustrates the regulatory 
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subunits of PKA with a D/D domain, followed by a PKA inhibitor site and two tandem 
cAMP binding domains (CBDs) (Heller et al. 2004). Structural studies have indicated that 
the RII subunits dimerise at the NH2 terminus in an anti-parallel fashion forming a four-
helix bundle motif which is necessary for both AKAP binding and dimerisation (Newlon et 
al. 1999; Newlon et al. 2001). The first 23 amino acids in the D/D domain sequence of the 
RII subunit are reported to be involved in AKAP binding. Deletion of the 1-5 sequence in 
PKA-RII abolishes the AKAP binding without interfering with the dimer formation 
(Hausdorff et al. 1990; Hausken et al. 1994). Anchoring of PKA occurs through an 
amphipathic helical motif of 14–18 amino acid residues present in the AKAP and a 
hydrophobic grove formed on top of the NH2 terminal helices at the D/D domain (Newlon 
et al. 1999). The PKA-RI D/D domain contains a similar helix bundle formation; however 
the dimerisation motif of RI is shifted further from the NH2 terminus and involves amino 
acids 12 to 61. It is thought that the NH2 terminus in RI is helical and folds back onto the 
four-helix bundle and has a Y-like shape as opposed to the X-like shape of the RII motif, 
and thus may contribute to differences in AKAP binding specificity.(Banky et al. 1998; 
Banky et al. 2000). 
 
 
 
 
 
 
Figure 1-5. Regulatory subunits of protein kinase A (PKA).  
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Subunits present a dimerisation/docking domain (D/D) (responsible for binding to A-Kinase 
Anchoring Proteins (AKAPs)), an inhibitory site (IS) and two cAMP binding domains 
(Domain A and Domain B). Adapted from (Taylor et al. 2008). 
 
1.5.2 Epac 
The exchange proteins activated by cAMP (Epacs) were first discovered in 1998, when de 
Rooij and colleagues showed that the small GTPase Rap1 could be activated by cAMP 
independently of PKA. They discovered a new protein containing a cAMP-binding site and 
similar to that of GEFs (guanine-nucleotide-exchange factor) for Ras and Rap1 (de Rooij 
et al. 1998).  
The small G protein Rap, which is part of the larger Ras family, switches between the 
inactive guanosine diphosphate (GDP), bound state and the active guanosine triphosphate 
(GTP) bound state. cAMP‐dependent activation of Epac promotes the exchange of GDP 
for GTP, hence switching on the Rap GTPases. Epac represents a crucial intracellular 
effector for cAMP and is responsible for many of its effects from cardiac contraction 
through regulation of some calcium channels in cardiomyocytes and permeability of 
vascular epithelium to insulin secretion in pancreatic beta cells (Bos 2003; Ruiz-Hurtado et 
al. 2013). In cardiac myocytes, Epac signalling increases Cx43 (connexin43) recruitment at 
cell–cell contact and enhances adherens junctions formation which is a prerequisite for gap 
junction (GJ) assembly which mediates electrical excitation (Somekawa et al. 2005). 
Following β-AR (β-adrenergic receptor) stimulation, a Epac/Rap/PLCϵ/PKCϵ/CaMKII 
(Ca
2+
/calmodulin-dependent protein kinase II) signalling pathway regulates SR 
(sarcoplasmic reticulum) Ca
2+
 release in mouse cardiac myocytes (Oestreich et al. 2007). 
In rat ventricular myocytes, acute stimulation with Epac-specific cAMP analogue 8-pCPT-
2′-O-Me-cAMP induces a decrease in the [Ca2+]i transient amplitude and this is correlated 
with an increase in cardiac myocyte contraction via PLC-, PKC- and CaMKII-dependent 
phosphorylation of sarcomeric proteins such as cardiac myosin-binding protein C (MBP-C) 
and troponin (Pereira et al. 2007; Cazorla et al. 2009).  
 
Two variants of Epac have been identified, Epac1 and Epac2 (see Figure 1-6), which are 
present in most tissues with varying levels of expression. Epac1 and Epac2, are encoded by 
two distinct genes, RAPGEF3 and RAPGEF4 (de Rooij et al. 1998; Kawasaki et al. 1998) 
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and contain an N-terminal regulatory domain that has one (Epac1) or two (Epac2) cyclic 
nucleotide-binding domain (CNB) domains and a DEP (Dishevelled, Egl-10, and 
Pleckstrin) region, known to be involved in membrane localisation (de Rooij et al. 2000). 
The relevance of the additional CNB domain in Epac2 is unknown. This domain does bind 
cAMP, but with lower affinity than the other CNB domain. Moreover, its deletion does not 
affect auto‐inhibition or the binding of cAMP to the other CNB domain (de Rooij et al. 
2000). 
 
The C‐terminal catalytic region activates Rap1. This region is comprised of the enzymatic 
GEF domain, CDC25‐homology domain (HD) and the Ras exchange motif (REM), which 
is required for stability of the GEF domain. An additional Ras-association domain (RA) 
lies between REM and CDC25-HD domains (de Rooij et al. 1998; de Rooij et al. 2000).  
The regulatory region at the N-terminal domain of Epac is an auto-inhibitory domain that 
blocks GEF activity. In the inactive conformation, Epac is folded and the regulatory 
domain inhibits the Rap association to the catalytic site preventing Rap binding to the 
CDC25-HD. Binding of cAMP to Epac induces a conformational changes, unfolding the 
protein and releasing the auto‐inhibitory effect of the regulatory region, exposing the 
catalytic domain resulting in Rap activation (Rehmann et al. 2006). 
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Figure 1-6. The multi domain structure of Epac.  
(A) Domain structure of Epac1 and Epac2, signifying the regulatory region with the cyclic 
nucleotide-binding domain(s) (CNB) and the catalytic region with the CDC25-homology 
domain (CDC25HD) responsible for the guanine-nucleotide-exchange activity. The 
Desheveled-Egl-10-Pleckstrin (DEP) domain is involved in membrane localisation, the Ras 
exchange motif (REM) stabilises the catalytic helix of CDC25HD and the Ras-association 
(RA) domain is a protein-interaction motif. (B) Schematic activation of Epac2 by cAMP 
results in a conformational change and enables the interaction with Rap and, consequently, 
the conversion of RapGDP to RapGTP. Adapted from (Bos 2006). 
 
 
1.5.3 CNG 
Cyclic nucleotide-gated channels (CNG) are ion channels, belonging to the superfamily of 
voltage-gated ion channels, which are activated by cAMP or cGMP binding. Cyclic 
nucleotides regulate the opening of these channels by binding directly to a conserved 
cyclic nucleotide-binding (CNB) domain on the channel (Yu et al. 2005). Binding induces 
a conformational change that serves to open the channel pore. CNG channels are cation 
channels, and allow the flow of Na
+
, K
+
 and Ca
2+
 ions across membranes, thus converting 
Chapter 1 – Introduction 
 
37 
cyclic nucleotide signals into changes in membrane potential and intracellular calcium 
levels.  
 
CNG channels were first identified in cone photoreceptors (Haynes and Yau 1985) in 
olfactory sensory neurons (OSNs) (Nakamura and Gold 1987) and in the pineal gland 
(Dryer and Henderson 1991). CNG channels are also present at high levels in the sino-
atrial node and conduction system of the heart, where they are involved in the control of 
cardiac automaticity (Baruscotti et al. 2010). 
 
 
 
1.6  cAMP signalling in the heart 
cAMP/ PKA signalling mediates the sympathetic control of excitation-contraction 
coupling (ECC) in cardiomyocytes. ECC is the process in which electrical excitation of the 
cardiomyocytes is coupled to contraction and relaxation of the heart (Bers 2008).  
Calcium (Ca
2+
) is a key mediator of the ECC process. During the cardiac action potential 
(AP) and membrane depolarisation, Ca
2+
 entry through L-type Ca
2+
 channels (L-TCC) 
triggers the Ca
2+
induced Ca
2+
release (CICR) from the sarcoplasmic reticulum (SR), a 
specialised intracellular Ca
2+
 store. Increasing ICa via L-TCC leads to a local increase in 
Ca
2+
 in a region where the SR is in close proximity to the sarcolemma and where 
ryanodine receptors (RyR) are localised. The local rise in Ca
2+
 concentration triggers the 
release of large concentrations of stored Ca
2+
 from the SR into the cytosol via RyR. 
Ca
2+
influx and release lead to an increase of the intracellular Ca
2+ 
concentration, allowing 
Ca
2+
 to bind to the myofilament protein troponin C (TnC), resulting in cardiac contraction 
(Bers 2008). In order for the bound Ca
2+ 
to dissociate from TnC and the cardiac muscle to 
relax (lusitropy) the cytosolic concentration of Ca
2+
 must decline. This is mainly achieved 
by the SR Ca ATPase (SERCA), which pumps Ca
2+
 back into SR, and the sarcolemmal 
Na
+
/ Ca
2+
 exchange (NCX), which removes Ca
2+
 from the myocyte (Bers and Guo 2005).  
 
Regulation of cAMP/ PKA signalling is crucial for the appropriate 
catecholamine‐mediated modulation of cardiac contractility (Bers 2008). As shown in 
Figure 1-7, β-ARs stimulation activates ACs to generate cAMP; cAMP in turn activates 
PKA. PKA then phosphorylates several proteins involved in the ECC process such as L-
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TCC, RyR, troponin I (TnI), myosin binding protein C (MBP-C) and phospholamban 
(PLB).  
PKA mediates the phosphorylation of L-TCCs and RyRs, increasing the open probability 
of the channels and thus increasing Ca
2+
 influx into the cell. PKA phosphorylation of these 
targets increases the amount of Ca
2+
 released from the SR, and as a result, a larger amount 
of Ca
2+
ions are available for sarcomere contraction at systole (Bers and Guo 2005). 
The lusitropic effect occurs upon PKA phosphorylation of TnI, PLB and MBP-C. 
Phosphorylation of TnI reduces the sensitivity of the sarcomeric myofilaments to Ca
2+
 and 
encourages the rapid dissociation of Ca
2+
 from the myofilaments (Zhang et al. 1995). Both 
TnI and MCB-P play an imperative role in modulating the crossbridge cycling in heart 
muscle (Winegrad 1999). PLB exhibits an inhibitory effect on the transport of Ca
2+ 
by the 
SERCA pump. When PLB is closely associated with SERCA, the rate of Ca
2+ 
transport is 
reduced. PKA phosphorylation of PLB dissociates it from SERCA, blocking the inhibitory 
effect of PLB (Verboomen et al. 1992), resulting in a more efficient Ca
2+
 re-uptake in the 
SR and results in relaxation. 
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Figure 1-7. Activation of β-adrenergic receptors triggers the PKA-mediated phosphorylation 
of several targets involved in the excitation-contraction coupling (ECC) process. 
(AC, adenylyl cyclase; ACh, acetylcholine; AKAP, A kinase anchoring protein; β-AR, β -
adrenergic receptor; M2-Rec, M2-muscarinic receptor; PLB, phospholamban; Reg, PKA 
regulatory subunit; SR, sarcoplasmic reticulum). Adapted from (Bers 2002). 
 
 
It has also been demonstrated that cAMP-activated PKA controls the frequency of 
contraction by phosphorylation of ryanodine receptors and other Ca
2+
-cycling proteins in 
the sino-atrial node (SAN), leading to altered calcium cycles and increased diastolic 
currents through Na
+
/Ca
2+
exchangers (Lakatta et al. 2010).  
Pacemaker activity in the heart originates in the SAN. Myocytes in the SAN produce 
spontaneous action potentials; these propagate, through specialised conduction systems, 
first to the atria and then to the ventricles, and thus drive cardiac rhythmic contraction. It 
has been shown that spontaneous diastolic depolarisation of SAN cells initiate action 
potentials to set the rhythm of the heart. This mechanism of spontaneous depolarisation has 
traditionally been attributed to a "voltage clock" mechanism, mediated by voltage-sensitive 
membrane currents, such as the hyperpolarisation-activated pacemaker current (If) 
regulated by cyclic adenosine monophosphate (cAMP) (Brown et al. 1979). This current is 
also referred to as a "funny" current because, unlike the majority of voltage-sensitive 
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currents, it is activated by hyperpolarisation rather than depolarisation. The funny channel 
becomes activated at the end of the action potential (at voltages from -40/-50 mV to -100/-
110 mV), which corresponds to the range in which diastolic depolarisation occurs. The 
funny channel then depolarises the membrane to a level at which L-type Ca2+ channels open to 
initiate the upstroke in the SA node action potential. If is a mixed Na
+
-K
+
 inward current 
activated by hyperpolarisation and modulated by the autonomic nervous system 
(DiFrancesco 1985; DiFrancesco et al. 1986).  
 
The f-channels are encoded by the hyperpolarisation-activated, cyclic nucleotide-gated 
(HCN) channel gene family. These are  intermembrane proteins that serve as non-selective 
ligand-gated cation channels in the plasma membranes of heart cells. Of the four known 
HCN subunits, HCN4 is the most highly expressed in the mammalian SAN (Ishii et al. 
1999; Liu et al. 2007). cAMP exerts its modulatory effects on the If current by directly 
binding to HCN channels (DiFrancesco and Tortora 1991). This is more likely to occur 
when channels are in the open state and binding of cAMP to the channel stabilises this 
open configuration. This mechanism results in a shift of the If activation curve to more 
positive voltages, accelerates activation and slows deactivation kinetics. Point mutations of 
HCN4 are associated with baseline sinus bradycardia, though the maximum heart rate 
achieved during exercise is normal (Nof et al. 2007). This implies that If is not the only 
mechanism of SAN automaticity, especially during sympathetic activation. 
 
Recently, spontaneous Ca
2+
 release from the sarcoplasmic reticulum (SR) has been 
suggested to modulate sinus rhythm (Vinogradova et al. 2005). When the SR is full, the 
probability of spontaneous Ca
2+
 release increases. Because the SR Ca
2+
 content is 
controlled in part by the membrane voltage, it is important to recognise that the activation 
of the Ca
2+
 clock and the membrane ionic clock are interdependent. Lakatta et al. proposed 
that the Ca
2+
 clock is manifested by spontaneous, but precisely timed, rhythmic, local Ca
2+
 
releases from sarcoplasmic reticulum (SR) that appear shortly before firing of the next AP 
(Bogdanov et al. 2001; Vinogradova et al. 2002; Vinogradova et al. 2006). The elevated 
Cai activates NCX inward current causing diastolic depolarisation, which co-ordinately 
regulates the sinus rate along with the voltage clock. PKA-dependent phosphorylation of 
proteins that regulate cell Ca
2+
 balance and spontaneous SR Ca
2+
 cycling, ie, PLB and L-
TCC, controls the phase and size of SR Ca
2+
 release, NCX current and thus is crucial for 
pacemaker function (Vinogradova et al. 2006). 
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Therefore cAMP regulation of ECC results in an increase in contractile force and 
frequency of the heart in response to acute catecholamine exposure. However, prolonged 
catecholamine stimulation of the cAMP pathway results in detrimental effects such as 
cardiac remodelling, cardiac hypertrophy and the development of heart failure which is 
accompanied by a marked down-regulation of β1-AR expression and thus a significant 
desensitisation of the heart to inotropic β-adrenergic stimulation (Fowler et al. 1986; 
Engelhardt et al. 1999; Lohse et al. 2003; Barry et al. 2008).  
 
Both β1- and β2-ARs are expressed in cardiac myocytes and mediate an increase in 
contractility via Gs-dependent coupling to adenylyl cyclase to generate cAMP (Xiao and 
Lakatta 1993). However, β2-ARs can also couple to signalling pathways independent of 
cAMP or Gs and, in particular, to a pertussis toxin (PTX)–sensitive pathway mediated by 
Gi. Overexpression of β2-AR in transgenic mice resulted in a limited contractile response 
due to Gi signalling (see 1.10.1.3), which inhibits adenylyl cyclase (Milano et al. 1994). 
Only when Gi proteins were inactivated by PTX treatment did these animals with 
overexpressed β2-ARs fully stimulate contractility (Xiao and Lakatta 1993). In addition to 
this, activation of Gi has the potential to couple β2-ARs to other important signalling 
pathways, such as the MAP kinases (Daaka et al. 1997).  
It has been reported that selective stimulation or transgenic overexpression of β2-AR 
coupled to cAMP, does not lead to hypertrophy, cardiomyocyte apoptosis and heart failure 
(Milano et al. 1994; Communal et al. 1999). Communal and colleagues measured 
apoptosis using flow cytometry and terminal deoxynucleotidyl transferase (TdT)–mediated 
nick end-labelling (TUNEL) staining in isolated adult rat ventricular myocytes (ARVM) 
and found that β-AR–stimulated apoptosis was abolished by the β1-AR–selective 
antagonist but was potentiated by the β2-AR–selective antagonist. The effect of β2-AR was 
found to be mediated by Gi and the authors suggest that β2-AR stimulation may even be 
protective (Communal et al. 1999).  A number of other studies have confirmed protective 
and anti-apoptotic effect of β2-AR stimulation via Gi (Ahmet et al. 2004; Ahmet et al. 
2005). Chesley et al. demonstrate that β2-ARs activate a PI3K–dependent, pertussis toxin–
sensitive signalling pathway in neonatal rat cardiac myocytes that is required for protection 
from apoptosis-inducing stimuli (Chesley et al. 2000). 
 
cAMP signalling via Epac seems to be one of the key factors downstream of chronic 
catecholamine stimulation of β1-ARs, which mediates the development of cardiac 
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hypertrophy via the activation of the pro-hypertrophic gene transcription and via the 
activation of CaMKII (see 1.10.1) (Metrich et al. 2008; Breckler et al. 2011). Metrich and 
co-workers demonstrated that Epac1 expression is increased in the hearts of thoracic aortic 
constriction (TAC) treated rats. ARVM isolated from these animals displayed exaggerated 
cellular growth in response to Epac activation. This response involved the small GTPase 
Ras, the phosphatase calcineurin, and Ca
2+
/calmodulin-dependent protein kinase II rather 
than its classic effector, Rap1 (1.5.2) (Metrich et al. 2008). Although these effects were 
shown to be PKA-independent, PKA does play a major role in a number of hypertrophy 
models associated with chronic catecholamine stimulation and activation of the cAMP 
pathway (discussed in detail in 1.10.1.4). 
 
 In cardiac myocytes, a variety of proteins other than those involved in the ECC process, 
are also affected by cAMP and PKA phosphorylation. These proteins include metabolic 
enzymes and transcription factors (Muller et al. 2001; Sheridan et al. 2002). Moreover, β-
ARs are not the only receptors that signal via cAMP and activation of PKA; many other 
GPCRs whose activation leads to cAMP production are expressed in cardiomyocytes. The 
result is that an overabundance of chemical signals will propagate responses in the heart, 
some of which will lead to the generation of cAMP and activation of PKA. This raises the 
question of how myocytes can translate the multiple signals generated in response to 
individual extracellular stimuli appropriately, so to achieve the required functional 
outcome, while avoiding off-target phosphorylation and unwanted effects. 
 
 
1.7  Compartmentalisation of cAMP/ PKA signalling 
in cardiomyocytes. 
The cAMP/ PKA pathway mediates a large number of extracellular signals and is 
responsible for a large variety of physiological effects. cAMP is a small and hydrophilic 
molecule and has been defined as a ‘long range’ second messenger (Kasai and Petersen 
1994) as it has the potential to quickly diffuse within the intracellular environment. Thus 
property of cAMP, however, raises the question of how a second messenger that can 
rapidly fill the entire cell can avoid non-selective activation of all the PKA subsets present 
in the cell and maintain fidelity of response. As cells can respond specifically to different 
Chapter 1 – Introduction 
 
43 
extracellular stimuli that signal via cAMP, therefore there must be some mechanism to 
maintain specificity of cAMP/ PKA signalling and prevent phosphorylation of unsuitable 
targets upon GPCR stimulation. A number of studies conducted over recent years have 
proposed that accuracy of  signalling in this pathway is due to compartmentalisation of 
cAMP and of the other molecular components involved in signal propagation (Kasai and 
Petersen 1994; Fischmeister et al. 2006; Lissandron and Zaccolo 2006; Vandecasteele et al. 
2006; Zaccolo et al. 2006; Zaccolo 2009). This concept is based on the idea that cAMP is 
generated in different and distinct compartments, thus making the cyclic nucleotide 
available for activation of only a limited subset of PKA enzymes, with the subsequent 
phosphorylation of only a defined number of substrates. 
The first evidence in support of the hypothesis of compartmentalisation of cAMP 
signalling came from experiments performed more than 30 years ago by Brunton and co-
workers in isolated perfused hearts (Brunton et al. 1979) and in primary ventricular 
myocytes (Buxton and Brunton 1983). They observed that isoproterenol (ISO), a specific 
agonist of β-adrenergic receptors, and prostaglandin E1 (PGE1) elevated intracellular 
cAMP to comparable levels, yet the two stimuli caused the activation of different pools of 
PKA in cardiomyocytes. PGE1 activated PKA present in the soluble fraction of the cells, 
whereas ISO activated subsets of PKA in both the soluble and particulate fractions 
(Brunton et al. 1979; Buxton and Brunton 1983). Further investigation demonstrated that 
ISO caused phosphorylation of phosphorylase kinase (Keely 1977), TnI (Brunton et al. 
1979) and several other PKA phosphorylation targets, whereas no changes in these 
substrates was observed upon PGE1 stimulation (Hayes et al. 1979). Based on these 
observations, it was postulated that not only PKA is targeted to specific locations within 
the myocyte, but also that different pools of cAMP must coexist within the cell. 
 
More recently, Jurevicius and colleagues combined whole-cell patch-clamp recordings and 
a double capillary for extracellular microperfusion to study subcellular compartmentation 
upon β-AR stimulation of the L-TCC currents. The authors inserted the two capillaries at 
two positions, separated by a 5µm thin wall, in a sealed frog ventricular myocyte. They 
reported that a local application of a saturating concentration of ISO (1 µM) caused local 
activation of ICa (non-maximal increase was detected), whereas local application of 30µM 
forskolin (a non-selective AC activator) caused maximal activation of ICa throughout the 
cell (Jurevicius and Fischmeister 1996). Dose response curves indicated that ISO induced a 
40-fold, higher cAMP concentration close to the Ca
2+
 channels, in the part of the cell 
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exposed to the stimuli, than it did in the rest of the cell, whereas forskolin only induced a 
4-fold increase. cAMP compartmentalisation was disrupted upon addition of 3-isobutyl-
methylxanthine (IBMX), a non-selective PDE inhibitor. Jurevicius and Fischmeister 
concluded that β-ARs are functionally coupled to nearby Ca2+ channels via local elevations 
of cAMP and that PDE activity may be responsible for limiting the rise of cAMP. 
 
 
 
1.7.1 Compartmentalisation of PKA by A-kinase 
anchoring proteins 
It has been established that the specificity of cAMP signal transduction is achieved, in part, 
by spatial control of its main effector PKA. If PKA is in close proximity of its targets there 
is a greater chance of phosphorylation of the intended protein. The identification of A-
kinase anchoring proteins (AKAPs) has confirmed that the spatial control of PKA is an 
important factor in the compartmentalisation of the cAMP signalling pathway. AKAPs are 
a large family of structurally unrelated proteins that have in common the ability to bind to 
PKA and thereby tether it to a specific location within the cell (Wong and Scott 2004). 
Table 1-3 details AKAPs which have been identified thus far and the tissue and subcellular 
localisation of each.  
Microtubule-associated protein-2 (MAP2) was the first AKAP to be characterised as it co-
purifies with PKA-RII isolated from brain extracts (Lohmann et al. 1984). Since then, the 
AKAP family has grown to over 50 members that are classified by their ability to co-purify 
with PKA catalytic activity from tissues. Although structurally diverse, all AKAPs share 
several common features including PKA-anchoring, unique localisations and the ability to 
form complexes with other signalling molecules. 
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Table 1-3. A kinase anchoring proteins (AKAPs) distribution and properties. Adapted from 
(Pidoux and Tasken 2010). 
AKAP (gene 
nomenclature 
committee name) 
Tissue Subcellular 
localisation 
Properties 
S-AKAP84/ DAKAP1/ 
AKAP121/ AKAP149 
(AKAP1) 
Testis, thyroid, heart, 
lung, liver, skeletal 
muscle, and kidney 
Outer mitochondrial 
membrane/endoplasmic 
reticulum/nuclear 
envelope/sperm midpiece 
Dual-specific AKAP. 
Binds lamin B and PP1 
AKAP-KL (AKAP2) Kidney, lung, thymus, 
and cerebellum 
Actin cytoskeleton/apical 
membrane of epithelial 
cells 
Multiple splice variants 
AKAP110 (AKAP3) Testis Axoneme Binds Gα13 
AKAP82/ FSC1 
(AKAP4) 
Testis Fibrous sheath of sperm 
tail 
Dual-specific AKAP 
AKAP75/79/150 
(AKAP5) 
Bovine/human/rat 
orthologs 
 Plasma membrane/post-
synaptic density 
Binds PKC, calcineurin 
(PP2B), β-AR, SAP97, 
and PSD-95 
mAKAP (AKAP6) Heart (mAKAPβ, 
shorter), skeletal muscle 
and brain (mAKAPα, 
longer) 
Nuclear membrane Binds PDE4D3, Epac, 
MEKK/MEK5/E RK5 
and PDK1 (only 
mAKAPα) 
AKAP15/18 α β γ δ 
(AKAP7) 
Brain, skeletal muscle, 
pancreas, and heart 
Basolateral (α) and apical 
(β) plasma membrane, 
cytoplasm (γ), secretory 
vesicles (δ) 
 
AKAP95 (AKAP8) Heart, liver, skeletal 
muscle, kidney, and 
pancreas 
Nuclear matrix Binds Eg7/condensin 
Zinc-finger motif. Binds 
PDE7A 
AKAP450/AKAP350/
Yotiao/CG-
NAP/Hyperion 
(AKAP9) 
Brain, pancreas, kidney, 
heart, skeletal muscle, 
thymus, spleen, 
placenta, lung, and liver 
Post-synaptic 
density/neuromuscular 
junction/centrosomes/ 
Golgi 
Binds PDE4D3, PP1, 
PP2A, PKN, and PKCϵ 
D-AKAP2 (AKAP10) Liver, lung, spleen, and 
brain 
 Dual-specific AKAP 
AKAP220/hAKAP220 
(AKAP11) 
Testis and brain Vesicles/peroxisomes/centr
osome 
Binds PP1. Dual-
specific AKAP 
Gravin (AKAP12) Endothelium Actin 
cytoskeleton/cytoplasm 
Binds PKC and β-AR 
Xgravin-like (Xgl) is 
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also a putative AKAP 
AKAP-Lbc/Ht31/Rt31 
(AKAP13) 
Ubiquitous Cytoplasm Ht31 RII-binding site 
used in peptides to 
disrupt PKA anchoring. 
Rho-GEF that couples 
Gα12 to Rho 
MAP2B Ubiquitous Microtubules Binds tubulin. 
Modulation of L-type 
Ca
2+
 channels 
Ezrin/AKAP78 Secretory epithelia Actin cytoskeleton Dual-specific AKAP 
T-AKAP80 Testis Fibrous sheath of sperm 
tail 
 
AKAP80/MAP2D Ovarian granulosa cells  FSH-regulated protein, 
identified as MAP2D 
SSeCKS (Src-
supressed C kinase 
substrate) 
Testis and elongating 
spermatids 
Actin remodelling  Gravin-like 
Pericentrin Ubiquitous Centrosome Binds dynein and γ-
tubulin 
WAVE-1/Scar Brain Actin cytoskeleton Binds Abl and Wrp 
Myosin VIIA Ubiqitous Cytoskeleton Binds RI 
PAP7 Steroid-producing cells 
(adrenal gland and 
gonads) 
Mitochondria Binds RI 
Neurobeachin Brain Golgi apparatus  
AKAP28 Primary airway cells Ciliary axonemes  
Myeloid translocation 
gene (MTG) 8 and 
16b 
Lymphocytes Golgi apparatus Binds PDE7A 
AKAP140 Granulosa cells and 
meiotic oocytes 
  
AKAP85 Lymphocytes Golgi apparatus   
BIG2 (Brefeldin A-
inhibited guanine 
nucleotide-exchange 
protein 2) 
 Cytosol and Golgi 
apparatus 
Binds RIα/RIβ and 
RIIα/RIIβ through three 
separate PKA-binding 
domains 
Rab32  Mitochondria Binds RI 
Synemin Heart ntercalated discs, 
sarcolemma, IFs, and Z-
lines 
PKA–RII-binding 
AKAP Is increased 
significantly in failing 
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hearts 
Myospryn Muscle-specific The costamere of striated 
muscle 
Harbors three bona fide 
PKA-anchoring domains 
that bind to RIIα 
Alpha4 integrins  Plasma membrane Binds PKA type I 
Sphingosine kinase 
type 1-interacting 
protein (SKIP) 
Heart 
 
Ventricular tissue Shows a partly similar 
sequence to AKAP11 
MyRIP (myosin Va–
Rab27a-interacting 
protein) 
 Perinuclear region Homolog to zebrafish 
Ze-AKAP2 PKA–RII-
binding AKAP 
SFRS17A (splicing 
factor, arginine–
serine-rich 17A) 
 Nucleus and sliceosome Dual specific AKAP 
 
 
 
Anchoring of PKA to AKAPs is achieved by binding the N-terminal D/D domain of the R 
subunit of PKA to an amphipathic helix of 14–18 residues within the AKAP (Carr et al. 
1991). This binding motif of AKAPs is arranged to form five turns of an amphipathic helix 
which exposes a hydrophobic face on one side and charged residues along the other side, 
thereby allowing extensive hydrophobic interactions between the two proteins (Newlon et 
al. 1999; Newlon et al. 2001). To date, the majority of AKAPs identified bind to the PKA-
RII regulatory domain of PKA (Wong and Scott 2004), although several RI-specific 
AKAPs have now been discovered (Angelo and Rubin 1998). One example of AKAPs 
which anchors PKA-RI exclusively is sphingosine kinase interacting protein (SKIP), which 
has been found to be expressed in mitochondria in the heart (Means et al. 2011). The 
structural differences were investigated and it was discovered that anchoring of PKA-RII 
to AKAPs occurs when the hydrophobic side of the α-helix in the AKAP lies across the 
four helix bundle formed by the PKA-RII D/D (Newlon et al., 2001). Whereas, the extreme 
N-terminus of RI subunit is believed to be helical. This additional helix folds back on the 
four helix bundle causing a steric hindrance for high affinity anchoring to AKAPs (Banky 
et al. 2000). Dual-affinity AKAPs have also been identified. These include for example D-
AKAP1 and D-AKAP2, which can anchor both of the PKA R subunits (Huang et al. 1997; 
Wang et al. 2001). Dual-affinity AKAPs contain an additional binding motif, RISR (RI 
specific region) at the N-terminus of the conserved helix, which enhances the affinity of 
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AKAPs for PKA-RI by providing an additional site of contact for the AKAP-RI interaction 
(Jarnaess et al. 2008). 
 
The importance of AKAP tethering of PKA was emphasised in studies utilising disrupter 
peptides to impair the PKA-AKAP interaction. The Human thyroid PKA anchoring protein 
(Ht31) was the first PKA-AKAP disruptor peptide generated (Carr et al. 1992). Fink and 
colleagues have shown that in cardiac myocytes anchoring of PKA by AKAPs is crucial 
for appropriate response to β‐adrenergic stimulation. The authors used the Ht31 peptide 
which binds the PKA regulatory subunit type II (RII) with high affinity. This peptide 
competes with endogenous AKAPs for PKA-RII binding. As a result, cardiomyocytes 
exhibited an increased rate and amplitude of cell shortening and relaxation upon ISO 
stimulation and PKA-dependent phosphorylation of TnI and MBP-C on ISO stimulation 
was significantly reduced in Ht31-expressing cells due to a delocalisation of PKA-RII 
(Fink et al. 2001). A number of other peptides have now been developed to specifically 
disrupt interactions between PKA-RI-AKAPs or PKA-RII-AKAPs. These disruptor 
peptides, such as SuperAKAP-IS (Gold et al. 2006) and the RI-anchoring disruptor (RIAD) 
(Carlson et al. 2006) have further elucidated the individual contribution of anchored PKA-
RII or PKA-RI in mediating different cellular responses (Di Benedetto et al. 2008; Roder 
et al. 2009). 
 
In cardiac tissue several AKAPs have been identified. These include AKAP18α, 
AKAP18δ, AKAP79, AKAP250, Yotiao, muscle AKAP (mAKAP), AKAP-Lbc, 
AKAP220, D-AKAP1 and -2, AKAP95, MAP2, Brefeldin A-inhibited guanine nucleotide-
exchange protein 2, ezrin, sphingosine kinase type 1-interacting protein (SKIP), gravin, 
synemin, myospryn, troponin T, and the phosphoinositide 3-kinase p110γ (Diviani et al. 
2011). 
 
AKAP18α (also called AKAP15) is a membrane associated anchoring protein that directs 
PKA to the L-TCC through a direct interaction between the C-terminal region and the 
cytoplasmic domain of the channel. Therefore β-AR stimulation generates a pool of cAMP 
which activates PKA held in close proximity of the L-TCC. Thus rapid and efficient 
phosphorylation of the channel is achieved, leading to an increase in its open probability 
(Fraser et al. 1998; Gray et al. 1998). 
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The L-TCC also forms a complex with AKAP79/150 (AKAP79, human form; and 
AKAP150, murine form). Recent investigations in adult mice cardiomyocytes has revealed 
that AKAP79/150 forms a macromolecular signalling complex containing the β -AR, 
adenylyl cyclase 5 and 6, PKA, calcineurin, caveolin-3, and a subset of L-TCC specifically 
phosphorylated in response to sympathetic stimulation (Nichols et al. 2010). Nicols and co-
workers showed that in a knockout model of AKAP150 that PKA-mediated 
phosphorylation of RyRs receptors and PLB was also inhibited. It was proposed that 
generation of cAMP microdomains by AKAP150 recruitment of AC5 and AC6, 
encourages PKA mediated regulation of L-TCC, PLB and RyRs located in caveolin-3-
associated T-tubule/SR junctions (Nichols et al. 2010). 
 
AKAP18δ, another variant of the AKAP18 gene, regulates the activity of the sarcoplasmic 
reticulum Ca
2+‐ATPase (SERCA2) and mediates cardiac relaxation upon β‐adrenergic 
stimulation. AKAP18δ achieves this activity by favouring the PKA-mediated 
phosphorylation of PLB, thus promoting cardiomyocytes relaxation via SERCA2-mediated 
Ca
2+
 reuptake into the SR. Disruption of the AKAP18δ-PLB complex in cardiomyocytes 
with Ht31 or AKAP18δ knock-down, was shown to impair β-AR-induced Ca2+ reuptake 
from the cytosol and inhibits lusitropic effects (Lygren et al. 2007).  
 
Another AKAP present in cardiac tissue is mAKAP. mAKAP is an example of an AKAP 
which, apart from its primary function of anchoring and targeting PKA, also acts to multi-
scaffold proteins, linking upstream activators with their downstream targets and allowing 
for specificity of transduction as well as for integration and linear relay of multiple 
signalling pathways (Bauman et al., 2006). mAKAP is reported to form a complex with 
RyR2 channel, PKA, FKBP12.6 (a protein that binds and modulates the RyR2 by 
stabilising a closed conformation of the channel), protein phosphatase PP1 and PP2A, and 
PDE4D3 (Marx et al. 2000; Dodge et al. 2001; Carlisle Michel et al. 2004). PKA 
phosphorylation events are controlled by a negative feedback loop within this signalling 
complex. Under normal basal conditions, PKA is inactive at this complex. However β-AR 
stimulation increases cAMP levels causing the release of the catalytic subunit of mAKAP-
anchored PKA and consequent phosphorylation of Ser54 on PDE4D3. This results in a 2- 
to 3-fold increase of PDE4D3 catalytic activity (Sette and Conti 1996) leading to a 
reduction in local cAMP concentration in the vicinity of the RyR where mAKAP anchors 
PDE4D3. Marx and colleagues have proposed that mAKAP binding results in PKA-
mediated phosphorylation of Ser2809 on RyR2, thereby decreasing the binding affinity for 
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FKBP12.6 and resulting in an increased open probability of the Ca
2+-
release channel (Marx 
et al. 2000). Excessive PKA-mediated phosphorylation of RyR2 leads to a “leaky” Ca2+ 
channel in heart failure patients and results in cardiac dysfunction and arrhythmias 
(Lehnart et al. 2005). The proposed model is that PDE4D3 anchored to mAKAP would 
ensure the generation of a local negative feedback loop at the RyR2, preventing 
hyperphosphorylation of the channel (Lehnart et al. 2005). The authors found that in the 
failing heart, the complex between PDE4D2 and RyR2 is reduced. Using mice models 
containing a mutant where RyR2 could not be PKA phosphorylated, they showed a 
suppression of cardiac arrhythmias and dysfunction while PDE4D-/- mice present a 
progressive cardiomyopathy, and exercise-induced arrhythmias despite normal global 
cAMP signalling (Lehnart et al. 2005). 
mAKAP has also been shown to organise another macromolecular complex composed of 
PKA, PDE4D3, Epac1 and extracellular signal-regulated kinase 5 (ERK5) and by 
anchoring Epac1 and ERK5 via their direct interaction with PDE4D3, mAKAP creates a 
second negative feedback loop (Dodge-Kafka et al. 2005). mAKAP-associated ERK5 
kinase module suppresses PDE4D3 activity thus producing a local increase in cAMP, 
which sequentially activates Epac1. Epac1 can activate the small GTPase Rap1, which in 
turn inhibits the MAP/ERK kinase-kinase thus releasing the inhibition of PDE4D3 by 
ERK5 (Dodge-Kafka et al. 2005). 
 
Yatiao (AKAP9) is another AKAP which has been suggested to be an important regulator 
of cardiac function. Marx and colleagues showed that Yatio forms a complex with protein 
phosphatase 1 (PP1), the RII and the C-subunit of PKA and to the IKS channel subunit 
hKCNQ1 (human α subunit of the slowly activating cardiac K+ channel) (Marx et al. 
2002). The KCNQ1 channel mediates repolarisation of the cardiomyocytes plasma 
membrane and is vital for the regulation of the cardiac action potential (AP) duration. 
Mutations have been identified in the KCNQ1-binding region of Yotiao (S1570L) (Chen et 
al. 2007) and in the Yotiao-binding region of KCNQ1 (G589D) (Fodstad et al. 2004) in 
patients with long QT syndrome (LQTS). In 2009, PDE4D3 was also discovered to be an 
important component of this complex (Terrenoire et al. 2009). PDE4D3 contributes to 
finely tune local cAMP levels regulation of the IKS channel activity resulting in another 
negative feedback loop whereby β-AR stimulation leads to active PKA which 
phosphorylates PDE4D3 increasing its activity and terminating the local cAMP signal 
(Terrenoire et al. 2009). 
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1.7.2 GPCR and AC compartmentalisation 
The signalling components upstream of PKA signalling have also been reported to be 
compartmentalised. cAMP is generated in response to hormone or neurotransmitter 
binding to a specific G-protein coupled receptor (GPCR) leading to a release of a Gs 
protein which activates an adenylyl cyclase (AC) to convert ATP to cAMP. If AC and 
GPRC were able to move freely within the plasma membrane, then there would be a non-
specific activation of all PKA subsets and therefore superseding the advantages of having 
PKA tethered in close proximity of its targets. GPCRs, including β‐adrenergic receptors 
and serotonin receptors, have been shown to localise in two related membrane 
microdomains, lipid rafts and caveolae (Patel et al. 2008). Lipid rafts are regions in the 
lipid bilayer of the plasma membrane rich in cholesterol and other lipids and caveolae are a 
subset of lipid-rafts forming invaginations of the plasma membrane and enriched in the 
protein caveolin (Patel et al. 2008). Calaghan and co-workers have demonstrated that, in 
adult rat ventricular myocytes, caveolae can modulate excitation-contraction coupling and 
β2-AR signalling by regulating the efficiency of Ca
2+
-induced Ca
2+
 release from the 
sarcoplasmic reticulum (Calaghan and White 2006). The same authors have recently 
published data showing caveolae play a direct role in the compartmentalisation of cAMP 
by restricting β2-AR cAMP signals to the sarcolemmal compartment in adult myocytes 
(Calaghan et al. 2008). They showed, using FRET based biosensors for cAMP, that 
disruption of caveolae resulted in β2-AR cAMP signals in the PKA-RII compartment and 
promoted selective PKA-mediated phosphorylation of PLB (Macdougall et al. 2012). 
Nikolaev and colleagues have also shown, using FRET imaging, that β2-ARs are localised 
in T-tubules in adult rat myocytes, whereas β1-ARs are more evenly spread throughout the 
plasma membrane (Nikolaev et al. 2010). The authors provided evidence that, in a rat 
model of chronic heart failure (CHF), β2-ARs are redistributed from the T-tubules to the 
cell crest making the β2-AR cAMP signal more propagating (Nikolaev et al. 2010). 
Redistribution of the receptor may result on a loss of β2-AR signalling which normally has 
cardioprotective properties and may acquire the characteristics of the β1-AR response, thus 
contributing to the heart failure phenotype. 
 
Additionally, diverse ACs isoforms have been shown to localise in different locations on 
the plasma membrane. The Ca
2+-
sensitive isoforms of ACs (AC1, AC3, AC5, AC6, AC8) 
but not the Ca
2+
-insensitive isoforms (AC2, AC4, AC7) have been detected in lipid-rafts 
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membrane structures (Willoughby and Cooper 2007). Interestingly, as discussed above, 
adenylyl cyclases have also been found to form complexes with AKAPs (Dessauer 2009). 
AC5 has been shown to associate with the AKAP79 complex in the heart as well as brain 
extracts. AC5 cyclase activity is inhibited by PKA phosphorylation, thus AKAP79 binding 
creates a PKA-dependent negative feedback regulation of cAMP synthesis (Bauman et al. 
2006). In cardiac myocytes, AC5 also forms a complex with mAKAPs and in brain tissue, 
AC1, AC2, AC3 and AC9 are associated with Yotiao (Dessauer 2009). 
 
 
 
1.7.3 Compartmentalisation of cAMP 
3’, 5 ’-cyclic adenosine monophosphate (cAMP) is a hydrophilic molecule, with a 
diffusion constant in the range of 270–780 μm2/s (Kasai and Petersen, 1994). As 
mentioned above, if cAMP were free to diffuse in the cell, ligand binding to any GPCRs 
would generate a global rise in cAMP levels and subsequent activation of all PKA subsets, 
whatever their subcellular localisation, resulting in phosphorylation of all PKA targets 
within the cell. This would abolish any specificity in the response to cAMP elevation. 
Recent evidence suggests that the cAMP signal is itself compartmentalised to restrict 
diffusion and to prevent the unsuitable activation of effectors. Rich and colleagues used an 
adenovirus encoding the α subunit of the rat olfactory CNG channel (CNG2, CNCα3) with 
mutations C460W and E583M, to monitor cAMP levels near the surface membrane in both 
human embryonic kidney (HEK) cell populations and single cells. Total cAMP 
accumulation in cell populations by measuring the conversion of [3H]ATP into 
[3H]cAMP. They reported that prostaglandin E1 (PGE1) stimulation of human embryonic 
kidney cells caused a transient increase in cAMP concentration near the membrane while 
the total cellular cAMP rose to a steady level. Pre-treatment with phosphodiesterase (PDE) 
inhibitors blocked the decline in cAMP levels near the membrane (Rich et al. 2001a). 
DiPilato and co-workers utilised FRET based fluorescent indicators to report intracellular 
cAMP dynamics through its effectors Epac1 in HEK cells. They generated a cAMP FRET-
based sensor targeted to the plasma membrane by inserting a sequence to the C terminus of 
the cytosolic sensor. This study revealed a faster cAMP response at the membrane than in 
the cytoplasm and mitochondria upon β–AR stimulation (DiPilato et al. 2004). Mongillo et 
al. used a similar method to study cAMP signalling dynamics in neonatal rat ventricular 
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myocytes (NRVM) and the compartmentalisation of PDEs. The authors reported 
compartmentalised cAMP signalling in this cell type using fluorescent FRET based 
indicators fused to the regulatory and catalytic subunits of PKA. Real-time FRET imaging 
and selective PDE inhibitors revealed that PDE4, rather than PDE3, appears to be 
responsible for modulating the amplitude and duration of the cAMP response to β-agonists. 
Immunocytochemistry established that these PDE families are localised to distinct 
compartments in cardiomyocytes (Mongillo et al. 2004).  
 
Several hypotheses have been put forward to explain the mechanism of the spatial 
restriction of cAMP. One such mechanism suggests that cAMP is restricted by a physical 
barrier, formed by elements of the endoplasmic reticulum underneath the plasma 
membrane, limiting cAMP diffusion inside the cytosol (Rich et al. 2000). The authors use 
adenovirus expressed cyclic nucleotide-gated channels as sensors for cAMP in HEK cells. 
They find that upon forskolin stimulation the endogenous adenylyl cyclase in C6-2B 
glioma cells produced high concentrations of cAMP near the channels, yet the global 
cAMP concentration remained low. The authors suggest a 3-D barrier to cAMP diffusion 
in addition to a 2-D colocalisation of membrane proteins (Rich et al. 2000). Another 
hypothesis proposed is “PKA mediated buffering” suggesting that cAMP binding to the R 
subunit of PKA reduces the diffusion rate (Saucerman et al. 2006). Saucerman et al. 
employed the A-kinase activity reporter 2 (AKAR2), a real-time indicator of PKA-
mediated phosphorylation, to study cAMP/ PKA signalling in rat neonatal cardiomyocytes. 
This sensor revealed that PGE1 stimulated higher PKA activity in the cytosol than at the 
sarcolemma, whereas ISO caused similar increases in emission levels for both cytosolic 
and membrane-tagged PKA sensors but triggered faster sarcolemmal responses than 
cytosolic. The authors propose that PKA signalling may generate both “spatially 
heterogeneous and asynchronous phosphorylation signals”. In this study, localised UV 
photolysis of “caged” cAMP triggered gradients of PKA-mediated phosphorylation, 
enhanced by phosphodiesterase activity and PKA-mediated buffering of cAMP 
(Saucerman et al. 2006). 
 
There are different hypothesis on how spatial propagation of cAMP is regulated but the 
majority of the available data point to an important role played by PDEs which are thought 
to limit diffusion of cAMP within the cell.  
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1.7.4 Compartmentalisation of cAMP by PDEs 
The first indication that PDE activity may control cAMP compartmentalisation came from 
the study performed by Jurevicius and co-workers, as previously mentioned (see 1.7). 
Briefly, the authors investigated Ca
2+
 transients in two physically isolated portion of an 
isolated frog ventricular myocyte (Jurevicius and Fischmeister 1996) using whole cell 
patch clamp recordings and found that isoproterenol stimulation resulted in activation of 
ICa localised at the site of stimulus application, whereas non-selective ACs activator 
forskolin results in activation of ICa both at local and distant sites. Interestingly, they found 
that after the addition of 3-isobutyl-1-methylxanthine (IBMX), a non-selective PDE 
inhibitor, cAMP compartmentation was greatly reduced (Jurevicius and Fischmeister 
1996), suggesting PDEs play a major role in ‘shaping’ and maintaining the subcellular 
cAMP gradients. 
 
Utilising advances in real-time imaging techniques, such as fluorescence resonance energy 
transfer (FRET)-based imaging, Zaccolo and Pozzan established that, in rat neonatal 
myocytes (NRVM), β-AR stimulation causes a local increase of cAMP, providing the first 
direct visualisation of microdomains of cAMP (Zaccolo and Pozzan 2002). Upon addition 
of IBMX, cAMP was found to be free to diffuse in the cytosol and subsequent loss of 
specificity of signal (Zaccolo and Pozzan 2002), again indicating that PDEs play a key role 
in limiting the spatial propagation of the cAMP signal.  
 
Further investigation of cAMP dynamics in cardiomyocytes showed that different PDE 
isoforms are localised in defined intracellular compartments and confirmed their role in 
shaping cAMP gradients. Mongillo and colleagues revealed, using real-time imaging in 
neonatal rat ventricular myocytes (NRVM), that the cAMP generated by β AR stimulation 
is controlled mainly by PDE4 whereas PDE3, although representing about 30% of the total 
PDE activity, exerts only a marginal effect (Mongillo et al. 2004). Interestingly, 
immunostaining experiments showed that PDE3 and PDE4 localise in distinct 
compartments within cardiac myocytes which may account for the different effect of their 
inhibition seen upon β-AR activation (Mongillo et al. 2004). More recently, the same 
author discovered that PDE2 also plays a significant role in the compartmentalised 
signalling of cAMP in cardiomyocytes (Mongillo et al. 2006). PDE2 was shown to 
significantly blunt cAMP increase upon β-AR stimulation, although it represents only 1% 
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of the total PDEs activity in cardiac myocytes and was again shown to have a unique 
localisation, corresponding to cell to cell junctions and sarcomeric Z-lines in NRVM 
(Mongillo et al. 2006).  
 
In the same year, Terrin et al. published further evidence confirming the importance of the 
intracellular localisation of individual PDE isoforms using a dominant negative approach 
(Terrin et al. 2006). This technique exploits a catalytically inactive PDE isoform that, when 
overexpressed in a cell, will displace the endogenous PDE enzyme by removing it from 
any intracellular site where it may be anchored , thus exerting a dominant-negative effect 
locally and effectively abolishing the enzymatic activity at that specific site (Baillie et al. 
2003). Displacement of endogenous PDE4D isoforms was shown to be sufficient to disrupt 
the cAMP gradients between the bulk cytosol and plasma membrane upon PGE1 
stimulation in HEK293 cells (Terrin et al. 2006). The same paper also proposed the idea 
that rather than creating a physical barrier, PDEs act as “sinks” draining cAMP from 
discrete locations and thus keeping the concentration of cAMP low to protect effectors 
from inappropriate phosphorylation, thus ensuring the specificity of the signal. Multiple 
PDE families are expressed in the same cell and each may include multiple genes and 
several splice variants, therefore, the number of isoforms expressed within a cell may be 
substantial all with unique functional roles due to their intracellular localisation and 
regulatory mechanisms. The activity of different PDEs that are uniquely regulated and 
localised within the cell thus results in multiple and simultaneous domains with varying 
cAMP concentrations irrespective of their distance from the AC that generated the cAMP 
(Terrin et al. 2006). 
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1.8  cAMP hydrolysing PDE families expressed in 
the heart 
In the heart several PDE families have been identified, including PDE1, PDE2, PDE3, 
PDE4, and PDE8 (Lugnier 2006). In recent years, advances in molecular biology 
techniques, such as dominant-negative, knock-down or knock-out models and the use of 
selective PDE inhibitors has allowed for a better understanding of how each individual 
PDE enzyme contributes to the compartmentalisation of cAMP signalling pathways in 
cardiomyocytes. 
 
 
1.8.1 PDE2  
PDE2 is a dual-specific enzyme with the ability to hydrolyse both cAMP and cGMP 
(Martins et al. 1982). PDE2, originally referred to as cGMP-stimulated PDE (cGS-PDE), 
was first recognised by Beavo and colleagues in 1971 (Beavo et al. 1971). They reported 
that cGMP increased the rate of cAMP hydrolysis when added to both soluble and 
particulate PDE preparations in a number of different tissues from an adult rat, including 
liver, brain, kidney, heart, and thymus (Beavo et al. 1971). Further investigation lead to the 
discovery that PDE2 degrades both cAMP and cGMP, with Km values of 30 μmol/L for 
cAMP and 10 μmol/L for cGMP, and displays positive co-operativety for both cyclic 
nucleotides (Erneux et al. 1981; Martins et al. 1982). Martins et al. also reported that in the 
presence of low levels of cGMP, the rate of PDE2 hydrolysis of cAMP is increased by 
almost 6-fold (Martins et al. 1982). 
 
The crystal structure of the PDE2A was determined by Martinez and colleagues, who 
revealed the regulatory region of PDE2 contains two tandem GAF domains (GAF-A and 
GAF-B) (Martinez et al. 2002). The results of this study indicated that the first GAF 
domain (residues 215-366, GAF-A) is followed by a “connecting helix” (residues 367-
398), a short linker (residues 399-402), and the second GAF domain (residues 403-555, 
GAF B). GAF-A is involved in dimerisation, whereas GAF-B domain binds cGMP with 
high affinity and selectivity (Martinez et al. 2002; Martinez et al. 2005).  
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More recently, Pandit et al. analysed the X-ray crystal structure of human PDE2A. PDE2A 
is a protein of 941 amino acids, organised in four domains: N terminus (1–214), GAF-A 
(215–372), GAF-B (393–541), and catalytic (579–941) which functions as a homodimer 
(Pandit et al. 2009). They produced a construct PDE2 (residues 215-900), which 
crystallised, while still maintaining the essential characteristics of the full-length protein. 
PDE2A (215–900) shows a linear extended organisation of the GAF-A, GAF-B and 
catalytic domains, which were connected by long α-helices. Comparison of this construct 
with that of the full length PDE2 structure, suggests that cGMP binding induces a 
conformational change in GAF-B and the adjoining linker that connects it to the catalytic 
domain (Figure 1-8). They described that the catalytic domain of PDE2A presents an 
“open” and a “closed” conformation, which is determined by the orientation of the H-loop 
(residues 702-723). In the “closed” conformation the H-loop is folded into the active site 
thereby completely occluding the substrate-binding site. For the catalytic site to adopt the 
“open” conformation the H-loop has to swing out, allowing the substrate to get access to 
the binding pocket (Pandit et al. 2009). Pandit and colleagues report that that cGMP 
binding to GAF-B domain of PDE2 causes a conformational change at the linker region of 
the catalytic domain, freeing the H-loops from the dimer interface, where it adopts the 
“open” structure to allow substrate access (Pandit et al. 2009).  
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Figure 1-8. Schematic representation of cGMP-induced conformational changes of PDE2 
resulting in activation. Adapted from (Francis et al. 2011). 
 
 
 
PDE2, as with other PDEs, is confined in discrete regions or cell types within tissues. 
PDE2 has been found to localise at the Golgi (Geoffroy et al. 1999)the nuclear envelope 
(Lugnier et al. 1999), sarcoplasmic reticulum (Lugnier and Komas 1993),  Z-bands of 
neonatal rat ventricular cardiomyocytes (Mongillo et al. 2006) and at lipid rafts of brain 
cells (Noyama and Maekawa 2003). The specific localisation of PDE2 is responsible for 
the compartmentalised regulation of determined cellular functions depending on cyclic 
nucleotide levels. In endothelial cells, under basal conditions, PDE2A is present in veins 
and capillaries in cardiac and renal tissue, but not in larger vessels, i.e. arterial endothelial 
cells (Sadhu et al. 1999).  
 
PDE2 is encoded by a single gene (PDE2A), and currently three variants of this enzyme 
have been identified (PDE2A1, PDE2A2 and PDE2A3), which are all identical, except for 
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the N-terminal-region (17 - 24 amino acids). (Sonnenburg et al. 1991; Rosman et al. 1997). 
This unique N-terminal sequence is thought to be responsible for the differences in 
intracellular localisation. PDE2A1 lacks the amino-terminal targeting sequence and is, 
therefore, mainly soluble (Bender and Beavo 2006). There are no known differences in 
kinetic behaviour between the PDE2A variants. All PDE2 isoforms have been identified in 
cardiac tissue, including both atrial and ventricular myocytes of a number of different 
species (Miller and Yan 2010) 
 
A unique function of PDE2 is its ability to mediate “cross-talk” between the cAMP and 
cGMP signalling pathways, as PDE2 hydrolysis of cAMP and cGMP is enhanced by 
binding of cGMP to its GAF-B domain. This is best exemplified by the atrial natriuretic 
peptide (ANP)-mediated control of blood pressure, where in adrenal glomerulosa cells, 
stimulation of cGMP by ANP activated PDE2 and resulted in a reduction of cAMP levels 
within the cell (MacFarland et al. 1991). When administered acutely, ANP elicits potent 
and short-lasting systemic hypotension in a wide variety of mammalian and non-
mammalian species (Brenner et al. 1990) due to cGMP synthesis and subsequent activation 
of PDE2. In platelets, high levels of nitric oxide (NO) stimulate the production of cGMP, 
which activates PDE2 and reduces intracellular cAMP concentrations (Dickinson et al. 
1997). Numerous studies have indicated that PDE2 mediated “cross-talk” between the two 
cyclic nucleotide pathways is crucial for normal heart function (Mery et al. 1995; Rivet-
Bastide et al. 1997; Vandecasteele et al. 2001; Fischmeister et al. 2005; Mongillo et al. 
2006; Stangherlin et al. 2011).  
 
In myocytes, PDE2 has been exposed as being a major regulator of cyclic nucleotide 
signalling and to modulate the ECC process. For example, at the L-TCC, PDE2 was found 
to mediate the cGMP-induced inhibition of the Ica in both human atrial myocytes (Rivet-
Bastide et al. 1997) and frog ventricular myocytes (Mery et al. 1995). In adult rat cardiac 
fibroblasts, NO attenuates cAMP accumulation via sGC–cGMP‐PDE2 stimulation 
(Gustafsson and Brunton 2002). Similarly, in pacemaker cells, the effect of NO on heart 
rate is mediated by inhibition of L-type Ca
2+
current via a signalling pathway involving the 
synthesis of cGMP and stimulation of PDE2 (Han et al. 1995).  
 
In addition, cGMP activation of PDE2 was shown to regulate the cAMP response to β-AR 
stimulation in rat neonatal ventricular myocytes (Mongillo et al. 2006). Using a FRET-
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based imaging approach, Mongillo and colleagues demonstrated that activation of soluble 
guanylyl cyclase (sGC) by sodium nitroprusside (SNP) leads to activation of PDE2 and a 
50% reduction in the amplitude of the cAMP response to norepinephrine (NE). Although 
PDE2 could not block the rise in cAMP levels after the addition of adenylyl cyclase 
activator forskolin, PDE2 effectively blocks the increase in cAMP concentration induced 
by stimulation of the β1 and β2-adrenergic receptors (Mongillo et al. 2006). The authors 
found that the mechanism by which NE treatment activates PDE2 to hydrolyse cAMP 
involves activation of β3-ARs and a subsequent activation of endothelial nitric oxide 
synthase (eNOS), which generates NO and in turn cGMP via activation of sGC (Mongillo 
et al. 2006) Recently Stangherlin et al. published experiments performed in NRVMs using 
targeted FRET-based sensors that allow monitoring of cAMP or cGMP in defined 
subcellular compartments (Stangherlin et al. 2011). These FRET-based sensors for cAMP 
were targeted to either RI- or RII-selective AKAPs. This paper indicated that cGMP can 
regulate localised cAMP responses in cardiac myocytes. The authors reported that PDE2 
activity appears to be mainly coupled to the PKA-RII compartment, whereas PDE3 activity 
is coupled to the PKA-RI compartment. Stimulation of sGC increases the cAMP response 
to isoproterenol selectively in the PKA-RI compartment via inhibition of PDE3, whereas 
the cAMP response is reduced in PKA-RII compartment via cGMP-mediated activation of 
PDE2 (Stangherlin et al. 2011). Activation of pGC by atrial natriuretic peptide (ANP) 
showed an effect selectively in the PKA-RII compartment, where the rise in cGMP 
reduced cAMP via activation of PDE2 upon catecholamine stimulation. The cAMP 
response in the PKA-RI compartment was unaffected. These data demonstrate that cGMP 
signals are also compartmentalised and the effects of cGMP in regulating cAMP signalling 
are related to the source of cGMP. 
 
PDE2 family members are also referred to as cGMP-stimulated PDEs as cGMP binding to 
the N-terminal GAF domains of the enzyme stimulates its catalytic activity markedly. 
Most functional data published on the PDE2 family was gathered using the PDE2 inhibitor, 
erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA). However, this compound may generate 
artefacts as it is known to inhibit adenosine deaminase therefore increasing extracellular 
adenosine levels which may increase intracellular cAMP upon binding to Gs coupled 
receptors (Miller and Yan 2010). Recently new, more selective inhibitors have been 
developed, these include 9-(6-phenyl-2-oxohex-3-yl)-2-(3, 4-dimethoxybenzyl)-purin-6one 
(PDP), and BAY60-7550 and have been successfully used in a number of functional 
Chapter 1 – Introduction 
 
61 
studies (Diebold et al. 2009; Stangherlin et al. 2011). PDE2 is selectively inhibited by 
Bay60-7550 with a Ki value of ~ 3.8 nM (Masood et al. 2009).  
 
 
1.8.2 PDE3 
The PDE3 family contains two variants, PDE3A and PDE3B. PDE3 isoforms bind both 
cAMP and cGMP with a similar affinity (cAMP (Km ~ 80 nmol/L) and cGMP (Km ~ 20 
nmol/L), which act as mutually competitive substrates. Due to the higher catalytic rate for 
cAMP, PDE3 is inhibited by cGMP (Degerman et al. 1997). PDE3 is selectively inhibited 
by a number of nonglycosidic cardiotonic agents (e.g., cilostamide, amrinone and 
milrinone) (Osadchii 2007). PDE3 is selectively inhibited by cilostamide with a Ki value of 
~11.5 µM (Yamamoto et al. 1983). 
Cardiac myocytes express 3 isoforms of PDE3A, PDE3A1, PDE3A2 and PDE3A3 which 
all share an identical sequence except for differences in the lengths of the N-terminal 
region, which is involved in intracellular localisation and contains phosphorylation sites. 
PDE3A1 contains 2 intracellular localising domains, NHR1 and NHR2. NHR1 consists of 
hydrophobic loops that insert into intracellular membranes, whereas NHR2 appears to 
localise the enzyme through protein–protein interactions and sites for PKA and PKB 
phosphorylation. PDE3A2 has a similar structure to PDE3A1, but lacks the NHR1 and the 
PKB phosphorylation site. PDE3A3 is primarily cytosolic and lacks the NHR1, NHR2, 
domains and the 3 phosphorylation sites (Hambleton et al. 2005). 
 
PDE3A is downregulated in heart failure and this leads to the induction of the pro-
apoptotic transcriptional repressor ICER (Inducible Cyclic AMP Early Repressor) (Smith 
et al. 1997). Elevated ICER represses anti-apoptotic proteins such as Bcl-2 and the PDE3A 
gene, thus creating a positive feedback loop (Ding et al. 2005). 
Recently, Patrucco and co-workers established that PDE3B accounts for ~30% of the total 
PDE3 cAMP-hydrolysing activity in mouse hearts (Patrucco et al. 2004). PDE3B is 
associated with phosphoinositide 3-kinase γ (PI3Kγ) and Epac1 in a macromolecular 
complex at the level of the sarcolemmal membrane which is critical for controlling local 
cAMP homeostasis and may play an important role in regulating cardiac function 
(Patrucco et al. 2004). Perino et al. showed that p110γ-anchored PKA activates PDE3B 
thus enhancing cAMP degradation and phosphorylating p110γ to inhibit PIP3 production. 
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However these results are controversial, as loss of PI3Kγ selectively abolishes PDE4, but 
not PDE3 activity in subcellular compartments containing the SR Ca
2+
-ATPase and not 
RyR2 or L-TCCs (Kerfant et al. 2007). Furthermore, a number of different authors were 
not able to detect PDE3B expression in mouse cardiac myocytes (Kerfant et al. 2007; 
Osadchii 2007). 
 
Inhibition of PDE3 activity in cardiomyocytes isolated from a number of different species 
was shown to increase Ca
2+
-current at the L-TCC and thus enhance the rate and magnitude 
of developed contraction and relaxation (Vandecasteele et al. 2001). These inotropic 
effects lead to the development and clinical use of PDE3 inhibitors for the acute treatment 
of congestive heart failure (CHF). By inhibiting cAMP hydrolysis in cardiac muscle, PDE3 
inhibitors should overcome the reduction in intracellular cAMP content thereby increasing 
myocardial contractility. However, despite short-term inotropic effects, adverse effects 
such as increased mortality due to arrhythmias and sudden death were commonly found in 
several clinical trials using PDE3 inhibitors, such as milrinone, in heart failure patients 
(Movsesian and Alharethi 2002; Movsesian and Kukreja 2011). The concept of 
compartmentalised cAMP signalling has been invoked to explain these unexpected long 
term deleterious effects. It has been suggested that long-term use of PDE3 inhibitors results 
in an increase in the phosphorylation of a large number of PKA substrates, with both 
beneficial and adverse effects on the heart. As cAMP signalling is compartmentalised, the 
idea of selectively increasing cAMP concentration in certain subcellular compartments 
rather than increasing the total cellular cAMP, might prove to be more effective 
(Movsesian 2002). 
Again PDE3 allows for cAMP and cGMP interplay as cGMP binding to PDE3 results in an 
inhibition of the enzyme and increased levels of cAMP. At a concentration of <50 nM, 
cGMP inhibits PDE3; at concentrations between 200 and 500 nM, cGMP activates PDE2 
(Zaccolo and Movsesian 2007). As already discussed, Mery and colleagues identified that 
low concentrations of cGMP increased the L-type Ca
2+
 current via PDE3 inhibition, 
whereas a higher concentration of cGMP strongly reduced L-TCC current via activation of 
PDE2 in frog ventricular myocytes (Mery et al. 1995). More recently, it has been reported 
that, in adult rat cardiac myocytes isolated from failing hearts, treatment with natriuretic 
peptide C (CNP) resulted in enhanced β1‐AR mediated contractile response via PDE3 
inhibition (Qvigstad et al. 2010). 
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1.8.3 PDE4 
In contrast to PDE2 and PDE3, PDE4 is cGMP-independent. In human ventricular tissue, 
the Km values of PDE4 for cAMP were shown to be about 25-fold lower as compared to 
Km values for cGMP, indicating high specificity for cAMP hydrolysis (Reeves et al. 
1987). In murine ventricular myocytes, the PDE4 family is the major regulator of the 
cAMP increase generated in response β-AR stimulation, (Mongillo et al. 2004; Xiang et al. 
2005) and in regulating PKA-mediated phosphorylation of vitally important components of 
the ECC process, including L-TCC, RyR2, and PLB (Lehnart et al. 2005; Kerfant et al. 
2007; De Arcangelis et al. 2008). PDE4 activity is selectively inhibited by rolipram and Ro 
20-1724 with Ki values of 2– 3 μM (Osadchii 2007).  
The PDE4 family consists of four genes (PDE4A, PDE4B, PDE4C and PDE4D) encoding 
18 different enzyme isoforms. 90% of the total PDE4 cAMP-hydrolysing activity in rat 
cardiomyocytes is provided by PDE4D and PDE4B, while only 10% of the activity is 
formed by PDE4A and PDE4C (Mongillo et al. 2004; Rochais et al. 2006). PDE4B and 
PDE4D have unique intracellular localisations due to their distinctive N-terminal domains 
and thus can regulate specific intracellular responses. In neonatal rat cardiac myocytes 
PDE4B is localised to the sarcomeric M-line, whereas PDE4D is localised to the Z-line of 
sarcomere (Mongillo et al. 2004). In mouse ventricular myocytes, IP experiments revealed 
that both PDE4B and PDE4D are anchored at the L-TCC in adult rat ventricular myocytes 
(ARVM) (Leroy et al. 2011). PDE4B seems to regulate L-type Ca²⁺-current during β-AR 
stimulation but PDE4D does not appear to have any effect (Leroy et al. 2011). Patch-clamp 
experiments were performed in AMVMs isolated from mice deficient in the corresponding 
genes (Pde4b
–/–
, and Pde4d
–/–
 mice). ICaL potentiation by ISO remained unchanged for 
Pde4d
–/–
, while treatment with rolipram strongly enhanced the effect of ISO on ICaL, 
suggesting that this isoforms does not modulate the β-AR stimulation of ICaL. In contrast, β-
AR stimulation was significantly enhanced in ventricular myocytes isolated from Pde4b
–/–
 
mice compared with that from WT mice (Leroy et al. 2011). 
Among the PDE4D family, PDE4D3, PDE4D5, PDE4D8, and PDE4D9 have been 
detected as active proteins in the heart (Fischmeister et al. 2006) and the PDE4D3 isoform 
has been reported to be an essential component of the ryanodine receptor (RyR) 
macromolecular complex (Lehnart et al. 2005). PDE4D3 was found to be part of at least 
two macromolecular complexes organised by Yotiao and mAKAP (See 1.7.1). In the 
Yotiao complex, PDE4D3 is recruited at the KCNQ1/KCNE1 potassium channel together 
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with PKA and PP1. PDE4D3 regulates the PKA-mediated phosphorylation of the KCNQ1 
subunit, which is involved in controlling the IKS current and the action potential (AP) 
duration (Terrenoire et al. 2009). In the mAKAP complex at the SR, PDE4D3 joins with 
RyR2 channel, PKA, FKBP12.6, PP1 and PP2A to tightly regulate Ca
2+
 cycling (Marx et 
al. 2000) 
Additionally, it has been shown that PDE4D5 can be dynamically engaged by β-arrestin in 
close proximity of β2-ARs. Upon agonist activation, β2-AR couples to Gs to generate 
cAMP, which activates the AKAP79-anchored PKA (Lynch et al. 2005). PKA mediated 
phosphorylation of β2-AR triggers a shift in receptor coupling for Gs to Gi (Baillie et al. 
2003). Recruiting PDE4D5 to the plasma membrane specifically decreases the sub-plasma 
membrane cAMP concentration inhibiting the subsequent PKA-mediated phosphorylation 
of the β2-AR and rapidly terminates the PKA signalling.(Baillie et al. 2003). 
 
PDE4D8 and PDE4D9 have also been shown to interact with β-ARs via β-arrestin. 
PDE4D8 forms a complex with β1-AR and dissociates upon agonist binding to the receptor 
(Richter et al. 2008). Recently, De Arcangelis and colleagues established that β2-AR 
stimulation induces PDE4D9 dissociation from the receptor and encourages PDE4D8 
recruitment (De Arcangelis et al. 2010).  
 
Richter and colleagues recently published evidence that antagonist occupancy of the β1-AR 
receptor in HEK cells, activates a previously unreported signal at the cell membrane by 
promoting the release of a PDE4, resulting in a local increase in cAMP levels and 
activation of PKA in the proximity of the receptor (Richter et al. 2013). The authors 
reported that treatment with various β1-AR antagonists, including alprenolol (ALP), CGP-
20712A (CGP), metoprolol (MET), propranolol (PRO) and carvedilol (CAR), induced β1-
AR/PDE4 complex dissociation. Treatment of β1-AR-Hek293 cells with PRO, ALP and 
CAR triggered a significant increase in global cellular cAMP as measured by 
radioimmunoassay (RIA). This rise in cAMP occurs without stimulation of cAMP 
synthesis by adenylyl cyclase (Richter et al. 2013).  
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1.9  Real-time detection of cAMP 
The greatest advancement in the study of temporal and spatial regulation of cAMP signal 
transduction came from the development of real time detection approaches to measure 
cAMP in intact living cells. Currently there are two methods for measuring cAMP in intact 
living cells: biosensors based on cyclic nucleotide gated (CNG) ion channels or biosensors 
based on Fluorescence Resonance Energy Transfer (FRET). These methods have been 
produced as classical approaches, such as radioimmuno assays (RIA) or other antibody-
based detection methods; provide information about cAMP dynamics that is averaged over 
the whole cell population whereas information at the single cell level may be more 
physiologically relevant.  
 
 
 
1.9.1 CNG based sensors 
One method for studying cAMP signalling dynamics in intact living cells exploits the over-
expression of an olfactory CNG channel (Rich et al. 2000; Rich et al. 2001a). CNGs are 
directly opened by cyclic nucleotides (1.5.3) and their activation can be measured by 
electrophysiological recordings of Ca
2+
 activated chloride currents or Ca
2+
 imaging with a 
Ca
2+‐indicator (e.g.Fura‐2). Wild‐type CNG channels show several limitations. They 
exhibit a lower affinity for cAMP than for cGMP (Rich et al. 2001a; Rich et al. 2001b), 
they can be directly opened by nitric oxide (Broillet 2000) and they are negatively 
regulated by Ca
2+
-calmodulin binding via a feedback loop mechanism (Liu et al. 1994). To 
overcome these issues, a mutated and deleted version of the CNG channel, Δ61-
90/C460W/E583M, was generated (Rich et al. 2001a). This new sensor is almost 
insensitive to cGMP and sensitive to low cAMP concentrations. In addition, the regulation 
of the channel by Ca
2+‐calmodulin has been removed by deletion of residues 61–90. 
However there are still some problems with this detection method, for example, it can only 
monitor cAMP dynamics at the plasma membrane and the increased calcium influx can 
modulate the activity of ACs and calcium sensitive PDEs. As a consequence, the cAMP 
concentration that is detected by the sensor may not be physiological. 
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1.9.2 FRET 
Fluorescence resonance energy transfer (FRET), also called Förster resonance energy 
transfer, was first described in 1940 by Theodor Förster (Förster 1948). Although the 
technique itself is not new, it has found novel biological applications with the development 
of recent fluorescent dyes and also new optical methods with higher spatial resolution. 
FRET is a physicochemical phenomenon that occurs between a donor fluorescent molecule 
in the excited state and an acceptor fluorescent molecule in the ground state. The energy 
transfer between donor and acceptor does not involve emission of photons therefore it is 
defined as energy of resonance. With FRET, the intensity of the donor's fluorescence 
emission decreases and in parallel, there is an increase in the acceptor's emission intensity. 
In order for FRET to occur, the donor‐acceptor distance must be between 1 and 10 nm, the 
two fluorophores must be appropriately oriented in space, and there must be a substantial 
overlap (at least 30%) between the donor’s emission spectrum and the acceptor’s excitation 
spectrum (Clegg 1996). FRET efficiency decreases with the sixth power of the distance 
between donor and acceptor, and therefore a minimal perturbation of the spatial 
relationship between the two fluorophores can drastically alter the efficiency of energy 
transfer. These factors make FRET a sensitive technique for investigating a variety of 
biological phenomena that produce changes in molecular proximity. 
 
 
 
1.9.3 FRET-based cAMP indicators  
A new generation of FRET-based indicators provides a means of visualising localised 
cAMP fluctuations in intact living cell with high spatial resolution. There are two major 
components of cAMP FRET-based indicators: there must be a sensor which consists of 
two protein domains or a protein domain undergoing a conformational change upon cAMP 
binding; and a donor and acceptor fluorophore pair which are fused to the sensor. 
 
The first FRET-based sensor that allowed the real-time imaging of cAMP in living cells 
was FlCRhR (Adams et al. 1991). The authors produced a sensor based on PKA, where the 
regulatory (R) and catalytic (C) subunits of PKA were labelled with rhodamine and 
fluoresceine, respectively. In the absence of cAMP, R and C subunits are associated to 
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form a tetramer (R2C2) and the two dyes are close enough for FRET to occur. When 
cAMP binds to the R subunits, the C subunits dissociate and FRET is impaired (Adams et 
al. 1991). However this probe for cAMP has some technical limitations and has therefore 
not found wide application. These include: the requirement to microinject a large amount 
of protein complex (µM) (procedure not applicable to all cells type the labelled subunits 
generate aggregates; the labelled subunits interact non-specifically with cellular structures 
(Goaillard et al. 2001). 
 
To overcome these limitations, a new group of genetically encoded cAMP-biosensors were 
developed which could be introduced into cells by transfection. Zaccolo and colleagues 
generated a sensor, R‐CFP/C‐YFP, where the regulatory (RIIβ) and the catalytic subunit 
(Cα) of PKA are fused to the cyan and the yellow mutants of GFP, respectively (see Figure 
1-9) (Zaccolo et al. 2000). The sensor has been shown to have high sensitivity for cAMP 
with EC50 = 0.3 µM and can therefore be used as a measurement for intracellular cAMP 
(Mongillo et al. 2004). Furthermore, the RIIβ subunit of the probe binds via its D/D 
domain to endogenous AKAPs present in the cell, allowing detection of cAMP fluctuations 
in specific compartments. Transfection of cells with the R‐CFP/C‐YFP has made it 
possible to visualise microdomains of cAMP in various cell types, including NRVM, to 
clarify the role different PDE families play in shaping intracellular cAMP gradients 
(Zaccolo et al. 2000; Mongillo et al. 2004). 
 
 
 
Figure 1-9. Schematic representation of PKA-GFP based sensor. 
 
 
 
There are, however, still some limitations with using this type of sensor, for example, since 
the C and R subunits are expressed from two distinct plasmids, it is difficult to predict if 
equal concentrations of C and R are present in transfected cells. Taylor et al. also showed 
Chapter 1 – Introduction 
 
68 
that the cAMP‐dependent dissociation of R and C subunits occurs through a cooperative 
mechanism and therefore the kinetics reported by the sensors may be slower than the actual 
kinetics of cAMP (Taylor et al. 2005). The C subunit of the sensor is also catalytically 
active and can therefore phosphorylate downstream targets of the cAMP/ PKA pathway 
resulting in an alteration of cAMP dynamics. 
 
 
1.9.4 Epac-based sensors 
A new generation of uni‐molecular indicators based on Epac proteins have been developed 
that do not have the same issues which have been reported with PKA sensors. Epac 
undergoes a structural change upon cAMP binding and this mechanism has been used to 
develop FRET-based indicators by fusing the Epac1 protein to cyan and yellow GFP 
variants (Nikolaev et al. 2004). When CFP is excited at 440 nm, FRET will occur and 
result in YFP emission at 545 nm at the expenses of CFP emission at 480 nm. However, 
when cAMP levels rise, cAMP binds to Epac1 resulting in a conformational change in the 
structure of the FRET probe. The two fluorophores move further apart and there is a 
reduction in FRET, where CFP excitation at 440 nm results in reduced emission of YFP at 
545 nm and an increase of CFP emission at 480 nm. 
 In the same year, two other groups used the full length Epac1 protein sandwiched between 
cyan fluorescent protein (CFP) and the yellow florescent protein (YFP), forming the ICUE 
sensor (DiPilato et al. 2004), and the CFP-Epac-YFP sensor (Ponsioen et al. 2004). This 
sensor was localised to the nuclear envelope and to perinuclear compartments, so to obtain 
a cytosolic indicator, the DEP domain (amino acids 1–148) was detected. Moreover, in 
order to render the indicator catalytically dead, other mutations were introduced (T781A, 
F782A) leading to the generation of CFP-Epac (δDEP-CD)-YFP, also called H30 
(Ponsioen et al. 2004; Terrin et al. 2006). 
 
More recently our lab generated targeted cAMP sensors based on the soluble Epac1 camps 
sensor (Nikolaev et al. 2004). RI_epac and RII_epac were generated by fusing the 
N‐terminus of Epac1‐camps to the dimerisation and docking domain sequences of the PKA 
regulatory subunit RIα and RIIβ respectively  (Di Benedetto et al. 2008). As PKA-RI and 
PKA-RII display different subcellular localisation, these sensors would localise to different 
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compartments by AKAP binding (see 1.7.1) once expressed in intact cells. When 
expressed in cardiac myocytes, these probes demonstrate a different distribution pattern, 
with RI_epac showing a tight striated pattern overlaying with both the Z and the M 
sarcomeric lines whereas RII_epac shows a very strong localisation that corresponds to the 
M line and a much weaker localisation overlaying the Z line. The two targeted reporters 
show equal sensitivity to cAMP (Di Benedetto et al. 2008). A study using RI_epac and 
RII_epac to detect cAMP dynamics in intact cardiac myocytes revealed that stimulation of 
different GPCR leads to the activation of specific PKA isoforms and, in turn, to specific 
phosphorylation of downstream targets. The authors of this study also demonstrated that 
the pool of cAMP generated in either the PKA-RI or PKA-RII compartment, is regulated 
by a unique subsets of cAMP degrading phosphodiesterases (PDEs). 
 
 
1.10 Cardiac Hypertrophy 
Cardiovascular disease (CVD) is one of the leading causes of disease-related mortality 
worldwide, accounting for 17.3 million deaths per annum (WHO estimated in 2008 
http://www.who.int/mediacentre/factsheets/fs317/en/). In many forms of CVD, 
hypertrophic growth of the heart occurs in an attempt to manage the increased 
hemodynamic demand caused by an excessive cardiac workload. This process, known as 
hypertrophy, is classified as “pathological” hypertrophy.  Hypertrophic growth which 
occurs in healthy individuals following exercise or pregnancy is characterised as 
“physiological” hypertrophy and is not linked to cardiac damage. Although the augmented 
heart size during the early stages of pathological hypertrophy is considered an adaptive 
response required to sustain cardiac output after increased biomechanical stress; prolonged 
pathological hypertrophy is associated with a significant increase in the risk for sudden 
death or progression to heart failure, independent of the underlying cause of hypertrophy 
(Levy et al. 1990; Vakili et al. 2001). During pathological hypertrophy, the heart remodels 
and becomes less elliptical and more spherical (Douglas et al. 1989). With the 
development of ventricular dilation comes a progressive decline in cardiac output despite 
continuous activation of the hypertrophic program to adjust the pressure overload. The 
late-phase “remodelling” process that leads to failure is associated with functional 
perturbations of cellular Ca
2+
 homeostasis (Bers 2002) and ionic currents (Hill 2003), 
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predisposing the heart to ventricular dysfunction and malignant arrhythmia. In addition to 
this, morphological changes include increased rates of apoptosis (Haunstetter and Izumo 
2000), fibrosis, and chamber dilation. Currently there is no cure for heart failure, and long 
term survival of heart failure patients remains poor, with one third dying within one year of 
diagnosis (McMurray and Pfeffer 2005).  
 
Hypertrophic growth develops in two ways, either concentric hypertrophy, caused by 
chronic pressure overload in which increase in myocyte length is less than increase in 
myocyte width, leading to reduced left ventricular volume and increased wall thickness. Or 
eccentric hypertrophy, which occurs due to volume overload in which the increase in 
myocyte length is greater than the increase in myocyte width, leading to dilatation and 
thinning of the heart wall (Beltrami et al. 2001). 
 
Cardiac hypertrophy is defined as an increase in the size, but not in the number, of 
individual cardiac myocytes. In addition to this, cardiomyocytes develop enhanced protein 
content and a higher organisation of the sarcomere (Chien et al. 1991; Sugden and Clerk 
1998). These processes are due to activation of the immediately early genes (c-jun, c-fos, 
c-myc) and the fetal genes [atrial natriuretic peptide (ANP), β-myosin heavy chain (β-
MHC) and skeletal alpha actin (SKA)], which are considered to be common markers of 
cardiac hypertrophy (Chien et al. 1991; Komuro and Yazaki 1993). These so-called fetal 
genes are normally only expressed in the developing heart and are repressed in the adult 
myocardium, however hypertrophic growth results in a reactivation of these genes in adult 
hearts. Activation of the fetal gene program allows co-ordinated synthesis of the proteins 
needed to bring about increased cardiac myocyte size and adjustment to the increased 
cardiac workload (Barry et al. 2008). 
 
A growing number of intracellular signalling pathways have been characterised as 
important transducers of the hypertrophic response (Molkentin and Dorn 2001). Some of 
these pathways are required for successful adaptation to the increased overload to the heart 
whereas others have been classed as maladaptive, as they result in contractile dysfunctions 
leading ultimately to heart failure (Levy et al. 1990; Vakili et al. 2001; Selvetella et al. 
2004). 
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1.10.1  Signalling pathways regulating cardiomyocyte 
hypertrophy 
A growing number of intracellular signalling pathways have been characterised as 
important transducers of the hypertrophic response (as shown in Figure 1-10). These 
include specific G-protein isoforms, calcineurin and nuclear factor of activated T-cells 
(NFAT), protein kinase G (PKG), Phosphoinositide 3-kinase (PI3K) and Mitogen-
Activated Protein Kinase (MAPK), to name but a few (Frey and Olson 2003; Barry et al. 
2008). These molecules operate in an orchestrated manner to generate interdependent 
pathways and complex cross-talking signalling networks and therefore the mechanisms 
involved in cardiac hypertrophy are still not fully understood. However the more recent 
development of genetically modified mouse models has greatly advanced our 
understanding of the complexities that surround the cardiac growth response, and have 
contributed to a greater understanding on the role of individual signalling molecules 
involved in cardiac hypertrophy.  
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Figure 1-10. Signalling pathways involved in cardiac hypertrophy and the progression to 
heart failure.  
Proliferative signalling pathways that mediate cardiac hypertrophy. The PI3K/PIP3/Akt 
pathway is activated when insulin, insulin growth factor (IGF), and growth hormone (GH) 
bind to receptor tyrosine kinases (RTK). Phosphorylation of phosphatidylinositol tris 
phosphate (PIP3) by phosphoinositide 3′-OH kinases (PI3K) activates Akt, a protein kinase 
that phosphorylates mammalian target of rapamycin (mTOR) and inhibits glycogen 
synthetase kinase 3 (GSK-3). Neurohumoral mediator binding to G-protein–coupled 
receptors (GPCR) activates adenylyl cyclase (AC) to form cAMP, which stimulates PKA. Gαq 
and Gβγ activate phospholipase C (PLC) to form diacylglycerol (DAG) and inositol tris 
phosphate (InsP3). DAG stimulates protein kinase C (PKC). Calcium released by InsP3 
activates PK C and calcium/ calmodulin kinase (CAMK). Calcium also activates calcineurin, 
a protein phosphatase that dephosphorylates nuclear factor of activated T cell (NFAT) 
which activates transcription factors MEF2C and GATA4. Peptide growth factor binding to 
RTKs and cytoskeletal signalling pathways activate Ras which stimulates mitogen-activated 
protein kinase (MAPK) pathways; the latter include extracellular receptor-mediated kinases 
(ERK), c-Jun kinase (JNK), and p38 kinase (p38K). Activated cytokine receptors release an 
inhibitory effect of IκB on nuclear factor-κB (NFκB) and activate gp130-mediated signalling 
pathways that stimulate janus kinase (Jak) to activate signal transducer and activator of 
transcription (STAT) and MAP kinases. Pathways in red mediate mainly maladaptive 
hypertrophy; those in blue, mainly adaptive hypertrophy. Cytokine-activated pathways 
(black) can activate both adaptive and maladaptive growth. Adapted from (Katz 2008). 
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1.10.1.1 cGMP/ PKG 
One well-described signalling pathway involved in the regulation of hypertrophic 
responses is the 3’, 5-cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG) 
signalling pathway. Generation of cGMP by NO activation of soluble guanylyl cyclases 
(sGC) was shown to reduce the hypertrophic response to norepinephrine (NE) (Calderone 
et al. 1998) or angiotensin II (Ang II) stimulation (Ritchie et al. 1998). Atrial and brain 
natriuretic peptides (ANP and BNP) which, by activating the membrane-bound particulate 
guanylyl cyclases (sGC) stimulate the production of cGMP, have also been found to exert 
anti-hypertrophic effects in vitro (Calderone et al. 1998; Rosenkranz et al. 2003). ANP and 
BNP are found at high levels during embryonic development and in early neonates but are 
absent in healthy adults (Gardner 2003), however in the hypertrophic heart the expression 
levels of ANP and BNP are found to be significantly increased (Silberbach and Roberts 
2001; Tremblay et al. 2002; Molkentin 2003). In fact, expression of the genes encoding 
ANP and BNP is one of the most reliable markers for activation of the hypertrophic 
program in clinical states and experimental models associated with hypertrophy. Some 
recent studies have reported that natriuretic peptides exert a regulatory influence over 
cardiac hypertrophy. Neonatal rat ventricular myocytes (NRVM) stimulated with an ANP 
receptor antagonist lead to increased protein syntheses and cell size as well as reactivation 
of the fetal gene program. Zaprinast, a cGMP analogue and an inhibitor for a cGMP-
specific phosphodiesterase, suppressed the basal and PE-stimulated protein syntheses 
(Horio et al. 2000). Thus, ANP may play a role as an autocrine factor in the regulation of 
cardiac myocyte growth. Another study reported that in NRVM and cardiac fibroblasts, 
treatment with ANP or the NO donor S-nitroso-N-acetyl-D, L- penicillamine (SNAP) 
attenuated the effects of NE-induced hypertrophy. The authors suggest that this effect was 
most likely by a cGMP-mediated inhibition of NE-stimulated Ca
2+
 influx (Calderone et al. 
1998).  
 
Recent studies using targeted gene deletion in mice have been particularly informative with 
regard to the role of the NPs in modulating cardiac hypertrophy. Deletion of the Npr1 gene 
encoding the natriuretic peptide receptor A (NPR-A) in mice resulted in moderate 
elevations in blood pressure, with a disproportionate increase in cardiac weight (i.e. 
hypertrophic growth) and interstitial fibrosis (Lopez et al. 1995; Oliver et al. 1997). 
Knowles and colleagues used transverse aortic constriction (TAC) to induce pressure 
overload in the Npr1 -/- mice, which resulted in a 15-fold increase in atrial natriuretic 
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peptide (ANP) expression, a 55% increase in left ventricular weight/body weight 
(LV/BW), dilatation of the LV, and significant decline in cardiac function (Knowles et al. 
2001). In TAC treated wild-type mice, the authors described only a three-fold increase in 
ANP expression, an 11% increase in LV/BW, a 0.2 mm decrease in LV end diastolic 
dimension, and no change in fractional shortening (Knowles et al. 2001). These results 
suggest that the NPR-A system has direct anti-hypertrophic actions in the heart. 
Failure of the natriuretic peptide system, at the ligand, receptor or post-receptor level, 
could account for the progression in cardiac dysfunction that accompanies longstanding 
hypertrophy and heart failure. 
 
The role of cGMP/ PKG effect in cardiac hypertrophy has been described in various 
knockout mice lacking elements of this signalling pathway. Holtwick and colleagues 
showed that mice with a cardiomyocyte specific deletion of constituently active guanylyl 
cyclase-A (GC-A), which is normally activated by natriuretic peptides to produce cGMP, 
exhibited mild cardiac hypertrophy and an increase in mRNA expression of fetal genes 
ANP, α-skeletal actin and β-myosin heavy chain. Pressure overload induced by transverse 
aortic constriction (TAC) in this mouse model lead to an exaggerated hypertrophic 
response as well as enhanced cardiac fibrosis and marked cardiac dysfunction (Holtwick et 
al. 2003). In the same year, Zahabi et al engineered transgenic mice that overexpressed a 
catalytic fragment of the GC-A domain of the atrial natriuretic peptide receptor in a 
cardiomyocyte-specific manner. They found increased GC-A attenuated the effects of both 
ISO treatment and abdominal aortic constriction on cardiac wall thickness, cardiomyocyte 
size and prevented the onset of the fetal gene expression program (Zahabi et al. 2003). 
Mice lacking eNOS and/or nNOS also develop cardiac hypertrophy, dysfunction and 
increased premature mortality (Barouch et al. 2003; Li et al. 2004; Flaherty et al. 2007). 
Conventional PKG-I knockout mice die young and perhaps too early to develop any 
cardiac hypertrophy (Pfeifer et al. 1998). Wollert and colleagues showed that in vitro 
adenoviral overexpression of PKG-Iβ in neonatal rat cardiac myocytes enhanced the anti-
hypertrophic effect of NO in phenylephrine-stimulated cardiac myocytes (Fiedler et al. 
2002; Wollert et al. 2002).  However, the significance of the PKG pathway in modulating 
cardiac hypertrophy has been recently questioned. Lukowski and colleagues showed that, 
when compared to wild type mice, the degree of cardiac hypertrophy induced either by 
isoproterenol (ISO) infusion or by TAC was not changed in total PKG knock-out mice or 
in mice lacking PKG specifically in cardiomyocytes, indicating that the development of 
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cardiac hypertrophy is not amplified by the absence of endogenous PKG (Lukowski et al. 
2010).  
 
It has been reported that enhancement of the cGMP/ PKG pathway by inhibiting PDE 
mediated hydrolysis of cGMP reduces cardiac hypertrophy (Takimoto et al. 2005; Miller et 
al. 2009). Takimoto and colleagues showed that pharmacological inhibition of PDE5 with 
Sildenafil reverses hypertrophy, suppresses remodelling and improves cardiac function in 
mouse hearts subjected to thoracic aortic constriction (TAC). In addition, the authors 
suggested that the anti-hypertrophic effects of Sildenafil are mediated by the cGMP/PKG 
signalling pathway (Takimoto et al. 2005). Miller et al. published data which indicated that 
PDE1 inhibition with IC86340 is able to attenuate the hypertrophic response induced by 
chronic isoproterenol infusion in vivo (Miller et al. 2009). The authors also showed that 
expression levels of the dual-specific PDE1 are significantly up-regulated in various in 
vivo and in vitro models of hypertrophy. Results obtained with selective PKG or PKA 
inhibitors, indicated that PDE1 seems to regulate cardiac hypertrophy via modulation of 
cGMP/PKG signalling pathways (Miller et al. 2009). The role of PDE5 in regulating 
cardiac hypertrophy was also questioned by Lukowski and co-workers, as endogenous 
PDE5 could not be detected in cardiomyocytes from either wild type mice or mice lacking 
cardiac-specific PKG (Lukowski et al. 2010). Further studies are required to fully 
understand the role of cGMP/ PKG in cardiac hypertrophy. 
 
 
1.10.1.2 Calcineurin/ NFAT 
One of the most studied maladaptive pathways is the calcineurin pathway. Calcineurin is a 
calcium/calmodulin-regulated, serine/ threonine phosphatase that dephosphorylates 
members of the NFAT transcription factor family, causing their nuclear translocation and 
the activation of immune response genes such as interleukin-2 (Crabtree 1999). The 
physiological role of calcineurin was initially elucidated in T-cells where an increase in 
cytoplasmic calcium concentrations promoted the association of calmodulin with 
calcineurin and consequent activation of the enzyme (Olson and Williams 2000). 
 
Molkentin et al. have demonstrated the role of calcineurin in cardiac hypertrophy, 
generating transgenic mice that overexpressed activated forms of calcineurin or NFAT3 in 
the heart (Molkentin et al. 1998). These mice were shown to develop cardiac hypertrophy 
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and heart failure before two months of age. Pharmacological inhibition of calcineurin 
activity with the immunosuppressant drugs cyclosporin A (CsA) and FK 506, which 
inhibits calcineurin's ability to activate NFAT transcription factors, blocked the 
hypertrophic response of isolated cardiomyocytes to Ang II and PE. Furthermore, CsA 
treatment by subcutaneous injection prevented cardiac hypertrophy and associated 
pathology in calcineurin transgenic mice. (Molkentin et al. 1998). These results suggest the 
involvement of calcineurin in a ‘maladaptive’ type of hypertrophy as transition toward 
heart failure was accelerated. However, the role of calcineurin in the progression of cardiac 
hypertrophy is still controversial mainly due to conflicting results of in vivo experiments 
using the calcineurin inhibitors cyclosporine A (CsA) and FK506 to treat various rodent 
models of hypertrophy. However, interpretation of in vivo results is difficult as the doses of 
CsA required to inhibit calcineurin activity in the heart are about 10-fold higher than those 
required for immunosuppression and are associated with significant systemic toxicity. As 
well as this, calcineurin is not cardio-specific, therefore inhibition of its activity by CsA or 
FK506 may modify the cardiac effects via systemic influences (Frey and Olson 2003). The 
discovery of several endogenous calcineurin inhibitors, such as AKAP79, Cabin/Cain, and 
DSCR/MCIP has allowed for alternative methods of investigation. Overexpression of the 
calcineurin-binding domain of AKAP79 (see 1.7.1) in neonatal rat cardiomyocytes 
prevents PE-induced hypertrophy (Taigen et al. 2000). AKAP79 interacts with calcineurin 
as well as protein kinases A and C (see 1.5.1), creating yet another point of integration 
between hypertrophic signalling pathways. 
 
 
1.10.1.3 G-protein coupled receptors 
Another clear example of maladaptive mechanism is the signalling pathway associated to 
activation of the G-protein-coupled-receptor (GPCR). GPCR are crucial in normal 
cardiovascular function and in mediating the “fight or flight” response to endogenous 
catecholamines such as adrenaline, noradrenaline and angiotensin. The most important 
myocardial GPCRs include adrenergic (comprised of several subtypes of α- and β-
adrenergic receptors) and muscarinic receptors, which are coupled to three principal 
classes of heterotrimeric GTP-binding proteins, Gs, Gq/G11, and Gi. G proteins consist of 
the subunits Gα and Gβγ, which upon receptor activation dissociate and independently 
activate intracellular signalling pathways. Gq is the target of Ang II, ET-1, and α-
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adrenergic stimulation that have been demonstrated to determine hypertrophic responses in 
cardiomyocytes (Sadoshima et al. 1993; Nicol et al. 2000; Maruyama et al. 2002). 
 
Several studies have highlighted the involvement of Gq signalling in the development of 
hypertrophy and transition to heart failure. Sakata et al showed that transgenic mice 
overexpressing Gq develop a pronounced hypertrophy that rapidly progresses to heart 
failure in response to pressure-overload via aortic banding (Sakata et al. 1998) , suggesting 
that excessive activation of the Gq pathway is mainly deleterious. Transgenic mice with 
inhibited Gq signalling developed significantly less ventricular hypertrophy than control 
animals after pressure-overload was induced by aortic stenosis (Akhter et al. 1998). 
Furthermore, transgenic mice lacking both Gq and G11 in cardiomyocytes showed no 
hypertrophy in response to pressure-overload induced by TAC (Wettschureck et al. 2001). 
The lack of hypertrophic response in both of these studies proves that the Gq/ G11-mediated 
pathway is essential for cardiac hypertrophy induced by pressure overload. 
 
Milano et al. showed that overexpression of a constitutively active α1B-adrenergic receptor 
in the heart induced cardiac hypertrophy (Milano et al. 1994) while mice lacking this 
receptor failed to develop hypertrophy in response to chronic infusion of adrenergic 
agonists but still displayed a hypertrophic response to pressure overload (Vecchione et al. 
2002). 
 
 
1.10.1.4  cAMP/ PKA signalling in cardiac hypertrophy 
Stimulation of β-adrenergic receptors (β-ARs) activates adenylyl cyclase (AC), generating 
3’, 5’ cyclic adenosine monophosphate (cAMP), and results in positive chronotropic, 
inotropic, and lusitropic effects on the heart (Bers 2008) . Catecholamines released from 
the sympathetic nervous system in response to stress or exercise rapidly increase the 
cardiac output via this signalling pathway. As previously discussed (1.6), a number of 
publications have revealed that persistent stimulation by catecholamines leads to 
hypertrophic growth, ventricular dysfunction and, in the long term, to heart failure. In 
cardiac myocytes, both β1- and β2-ARs have been reported to mediate an increase in 
contractility via Gs-dependent coupling to adenylyl cyclase to generate cAMP (Xiao and 
Lakatta 1993). Chronic catecholamine treatment results in a significant downregulation of 
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β1-AR expression only, leading to desensitisation of the heart to inotropic β-adrenergic 
stimulation (Fowler et al. 1986; Engelhardt et al. 1999; Lohse et al. 2003; Barry et al. 
2008).  
 
The most abundant adrenergic receptor in the heart is the β1-AR which is coupled to Gs. 
Overexpression of β1-ARs in hearts of transgenic mice initially increases contractile 
function to isoproterenol, but eventually results in progressive cardiomyocyte hypertrophy 
and fibrosis leading to heart failure (Engelhardt et al. 1999). Likewise, transgenic mice 
overexpressing Gs also developed cardiac hypertrophy (Gaudin et al. 1995; Iwase et al. 
1996). Antos and colleagues demonstrated that transgenic mice overexpressing PKA 
develop dilated cardiomyopathy associated with cardiomyocyte hypertrophy and fibrosis, 
suggesting that PKA mediates the adverse effects of chronic β-adrenergic signalling (Antos 
et al. 2001). It has been suggested that AC may actually have cardioprotective effects. 
Elevated cardiac adenylyl cyclase activity was shown to result in long-term enhanced 
function, and in transgenic mouse models that suffer from cardiac failure (due to Gq 
overexpression).  
 
To investigate the hypothesis that increased AC6 would be cardioprotective, Roth and 
colleagues crossbred mice with Gq-associated cardiomyopathy and those with cardiac-
directed expression of AC6 (Roth et al. 2002). Survival was increased by cardiac-directed 
expression of AC6 and hypertrophic growth was abolished.  The overexpression of AC6 
was also found to improve contractility (Roth et al. 2002). Goa et al. also reported 
transgenic mice with cardiac-directed overexpression of AC6 demonstrate improved 
contractile function (Gao et al. 2002). Gao and colleagues later showed that AC6 
overexpression increases calcium cycling in cardiomyocytes and enhances cardiac function 
by down-regulating phospholamban, a sarcoplasmic reticulum Ca
2+
-ATPase inhibitor (Gao 
et al. 2004). Another study found that AC6, but not AC5, mRNA is decreased in rats with 
cardiac hypertrophy after myocardial infarction (Espinasse et al. 1999). Overexpression of 
AC5 was found to restore cyclic AMP signalling and contractile deficits in the Gαq-
hypertrophic mice, however cardiac hypertrophy still developed (Tepe and Liggett 1999). 
Okumura and colleagues demonstrated that decreasing AC5 expression may have a 
protective role in mice where hypertrophy was induced by aortic banding (Okumura et al. 
2003). The authors showed that, on comparison of AC5 knock out (AC5KO) mice and WT 
littermates, the number of apoptotic myocytes was increased significantly in WT (4-fold) 
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at both 1 and 3 weeks after TAC, and the number was significantly less in AC5KO (2-
fold). More importantly, cardiac apoptosis was induced prior to cardiac dysfunction in WT. 
The same group also demonstrated that the disruption of AC5 results in more effective 
desensitisation after chronic catecholamine stress and protects against the development of 
myocyte apoptosis and deterioration of cardiac function (Okumura et al. 2009). The 
findings suggest that, at least in adult myocytes, AC5 may lead to cardiac dysfunction and 
its disruption may have a cardioprotective effect. 
 
β2-adrenergic receptors couple to Gi, inhibiting AC and thus directly opposing Gs-
dependent signalling. In 1988, Neumann et al. published the first evidence of Gi up-
regulation occurring in patients with heart failure (Neumann et al. 1988). This was later 
confirmed by Bristow and colleagues who reported that in myocardial tissue from patients 
with heart failure the Gi content was increased by 30%, and basal AC activity was 
depressed by 70% (Hershberger et al. 1991). Gi is upregulated in hypertensive 
hypertrophy before the development of overt failure (Bohm et al. 1992), indicating that Gi 
up-regulation may precede decompensation. Mice genetically engineered to express a 
conditional Gi-coupled receptor demonstrated a profound decrease in heart rate upon 
stimulation resulting in cardiomyopathy and lethal arrhythmias (Redfern et al. 1999). 
 
Heart failure is accompanied by impaired β-AR function through both a decreased number 
of receptors and functional uncoupling. Inhibition of β-adrenergic receptor kinase (β-ARK 
or GRK), a kinase believed to mediate these processes, by overexpression of the inhibitory 
peptide β-ARKct attenuates cardiomyopathy secondary to deficiency of the sarcomeric 
protein MLP (Rockman et al. 1998). Moreover, β-ARKct overexpression significantly 
blunts the development of cardiac hypertrophy and delays development of systolic 
dysfunction in transgenic mice overexpressing the sarcoplasmic reticulum Ca
2+
-binding 
protein, calsequestrin (CSQ). These mice have a severe cardiomyopathy and markedly 
shortened survival (9 weeks), whereas CSQ/ β -ARKct mice exhibited a significant 
increase in survival age (15 weeks) and displayed less cardiac dilatation (Harding et al. 
2001). This data again demonstrates the beneficial effects of β-ARK inhibition of cardiac 
hypertrophy. 
These data suggest that components of the β-adrenergic signalling pathway may have 
different consequences on cardiac hypertrophy and failure. One explanation for the 
variation in effect of β-AR stimulation in animal models of cardiac hypertrophy is that in 
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cardiac myocytes cAMP/PKA signalling is compartmentalised (see 1.7). It is therefore 
possible that distinct and localised pools of cAMP mediate different downstream 
functional effects in cardiomyocytes.  
 
Current therapeutic treatment for dilated cardiomyopathy and heart failure are aimed at 
improving cardiac contractility by raising cAMP production through β-AR antagonists and 
phosphodiesterase inhibitors. Several PDE3 inhibitors – including, milrinone, amrinone, 
and enoximone – were developed as therapeutic agents for the treatment of ischaemic and 
dilated cardiomyopathy. The use of these inhibitors was shown to have short-term 
beneficial effects on cardiovascular function in treated patients in numerous studies, 
however long-term use of such drugs resulted in negative side effects such as arrhythmias 
and increased mortality (Movsesian and Alharethi 2002; Movsesian and Kukreja 2011). 
These detrimental consequences of long-term use of PDE3 inhibitors may be explained by 
the fact that non-selective inhibition of PDE3 would lead to a global activation of PKA, by 
increased intercellular cAMP.  This would result in generalised phosphorylation of all 
substrates of PKA, including those involved in mediating both beneficial and adverse 
effects. Based on this model, selective modulation of compartmentalised PDEs activity 
may result in a more effective treatment without the negative side effects. A more detailed 
description of the spatial organisation of the individual cAMP/PKA signalling sub-
compartments and of their specific regulation in cardiac myocytes would be required to 
develop novel therapeutics able to treat cardiovascular disease. Importantly, a better 
understanding of the regulation and function of individual PDE isoforms has in 
cardiomyocytes is essential as very little is known about the role of compartmentalised 
PDEs in regulating cAMP signalling in heart disease. In fact, few have published data on 
the role of PDEs in cardiac hypertrophy, and often results are conflicting  
 
Abi-Gerges and colleagues studied the expression of PDEs and their regulation in single 
hypertrophied cardiomyocytes isolated from Wistar rats exposed to pressure-overload by 
surgical thoracic aortic banding (TAC). Subsarcolemmal cAMP signals were detected by 
whole-cell patch-clamp recordings of the associated cyclic nucleotide-gated (CNG) current 
(ICNG) and PDE activity and protein levels were assessed. They reported a decrease in both 
PDE3 and PDE4 cAMP-hydrolyzing activity in TAC- animals, together with marked β-
adrenergic receptor desensitisation. Furthermore, western blot analysis revealed that 
PDE3A, PDE4A and PDE4B, but not PDE4D, expression levels were decreased in 
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hypertrophic myocytes (Abi-Gerges et al. 2009). In 2010, Mokni et al. investigated the 
activities of various PDE isoforms in Wistar rats where hypertrophy was induced by 
chronic infusion of angiotensin II (Ang II). It was reported that the cAMP hydrolysing 
activity of PDE4 is increased, whereas PDE1, PDE2 and PDE3 cAMP-degrading activities 
are unchanged. Utilising a real-time PCR approach, the same study shows a significant 
decrease in mRNA levels of PDE4D and no change in PDE2A, PDE3A, PDE3B, PDE4A, 
PDE4B or PDE4C which is somewhat in contradiction of the PDE activity assay results 
(Mokni et al. 2010). 
 
These studies show that, during cardiac hypertrophy, alterations in PDE expression and 
activity may occur. To fully understand compartmentalised cAMP signalling and PDE 
regulation in cardiac hypertrophy and whether selective modulation of PDEs activity may 
be exploited as a therapeutic treatment, further investigation is necessary. As previously 
mentioned (1.10.1.4), PDE inhibitors for several families have been used clinically or are 
currently being investigated in clinical trials for treatment for a number of different 
cardiovascular diseases. The PDE3 family have been used for a number of years to treat 
chronic heart failure, although their long-term use has generally been shown to increase 
mortality (Packer et al. 1991; Movsesian 2002; Movsesian and Alharethi 2002). More 
recently, PDE5 specific inhibitors have been used to treat pulmonary hypertension by 
reducing pulmonary vascular resistance (Galie et al. 2010). Some studies have also 
suggested that PDE5 inhibitors may be useful as a treatment for models of ischemia–
reperfusion, left and right ventricular hypertrophy, and congestive heart failure (Kumar et 
al. 2009). However there have been some suggestions that PDE5 inhibitors may have 
limited effects on vascular tone in humans, which indirectly contribute to the 
cardioprotective effects. 
Dual PDE inhibitors inducing synergic potencies with lesser undesirable side effects have 
been envisioned. Indeed, dual PDE3/4 inhibitors are now designed as therapeutic agents 
for chronic obstructive pulmonary disease (COPD). By combining both inhibitions, these 
compounds have additive and synergistic bronchodilatory and anti-inflammatory effects 
(Banner and Press 2009). 
 
Another approach to obtain efficient therapeutic effect, without the negative side effects, 
may be to specifically target the altered PDE family and in particular the altered isoform so 
that all other forms remain unaltered. For this to occur, it would be necessary to 
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characterise the all PDE isozymes present in the studied model and then identify which 
PDE isoforms are altered in the diseased state before selectively inhibiting the PDE of 
interest. The outcome of this type of treatment would be restoration of the altered PDEs 
and associated cellular function without changing the other non-altered PDEs. Selective 
pharmacological inhibition of individual PDE isoforms has proved difficult due to the fact 
that existing inhibitors target the catalytic site and this domain is highly conserved among 
isoforms, and thus, does not allow for discrimination between isoforms. One alternative 
approach is to displace the individual PDE isoform from its specific subcellular anchor 
site. This may be possible with the use of disruptor peptides (Christian et al. 2011; Sin et 
al. 2011) or overexpression of catalytically inactive PDE isoforms (dominant-negative 
approach see 7.2.2) (Houslay et al. 2007; Stangherlin et al. 2011), although further 
investigation is required to better develop these treatment strategies.  
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2 Thesis Aims 
 
 
In the heart, compartmentalised cAMP/PKA signals play a key role in the regulation of 
excitation contraction coupling (ECC). Recent studies have demonstrated that impairment 
of cAMP/ PKA compartmentalisation by altered PDE expression/ activity or AKAP 
binding, can lead to the development of heart disease. One such cardiovascular disease 
where altered PDE activity and expression levels have been described is cardiac 
hypertrophy. Understanding the fine control of cAMP and the regulation and function of 
individual PDE isoforms in normal and hypertrophied hearts, may provide new valuable 
insight for the development of novel therapeutics for the treatment of cardiac hypertrophy. 
 
Previous data (unpublished) in neonatal rat ventricular myocytes, transfected with Epac1-
camps FRET sensor, indicated PDE2 activity is significantly increased in hypertrophic 
cardiac myocytes and pharmacological inhibition of PDE2 with Bay 60-7550 counteracts 
NE-induced cardiomyocytes hypertrophy.  
Therefore the hypothesis that altered PDE2 activation induces hypertrophy, after excessive 
catecholamine stimulation, was tested in adult rat ventricular myocytes.  Utilising targeted 
FRET-based biosensors in an in vitro model of cardiomyocyte hypertrophy, the role of 
cAMP phosphodiesterases in the development of cardiac hypertrophy was investigated.
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3 Materials and Methods 
 
3.1  Materials 
The chemicals used in this study were of analytical grade. All chemicals were supplied by 
Sigma-Aldrich unless otherwise indicated. 
 
 
 
3.2  Cellular Biology 
All tissue culture was performed in sterile conditions using biological safety class II 
vertical laminar flow cabinets. Cells were grown in 37°C incubators maintained at 5% 
CO2. 
 
 
 
3.2.1 Primary Isolation Optimisation 
The goal of a cell isolation procedure is to maximise the yield of functionally viable, 
dissociated cells; however there are several parameters which may affect this outcome, 
such as: 
 
1. Type of tissue 
2. Species of origin 
3. Age of the animal 
4. Genetic modification(s) (knockouts, etc.) 
5. Dissociation medium  
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6. Enzyme(s)  
7. Impurities in any crude enzyme preparation  
8. Concentration(s) of enzyme(s)  
9. Incubation times 
 
From the literature it is clear the greatest variation in dissociation protocols is the enzyme 
used and the dissociation conditions (i.e. concentration of enzyme and incubation times).  
 
 
3.2.1.1 Collagenase 
Collagenases are endopeptidases that digest native collagen, the major fibrous component 
of animal extracellular connective tissue and are widely used in cell dissociation protocols.  
 
Due to the variation between batches of collagenase, Worthing Biochem offers a sampling 
service in order to pre-test a particular batch of enzyme. The customer is sent 3 batches of 
collagenase to test in their experiment and selects the most effective of the group to order 
in bulk.  
 
 
 
3.2.2 Adult Rat Ventricular Myocytes (ARVM) 
3.2.2.1 Isolation of ARVM 
Primary adult cardiac ventricular myocytes were isolated from the hearts of 200g-250g 
Wistar rats (Harlan Laboratories) with the following protocol. 
 
Male Wistar rats were stunned by a blow to the head and killed by cervical dislocation. 
The thoracic cavity was opened and the heart was quickly removed and placed in ice-cold 
Krebs solution (see 3.2.6 for all medias and buffer used for this protocol). The heart was 
mounted and tied via the aorta on to the cannula of a Langendorff perfusion system and 
perfused with Krebs solution at 37°C for approximately 5 minutes until all the blood had 
been washed out from the coronary vessels. Hearts were then perfused with an enzyme 
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solution containing 0.66mg/ml collagenase type I (Worthington) and 0.04mg/ml protease 
type XIV in warm Krebs. Enzyme solution was collected from the heart and re-circulated 
once the initial solution had passed through the heart. The heart was kept warm by heating 
the perfusate and using a heated jacket or lamp around the heart.  
 
 
 
Figure 3-1.The Langendorff perfusion system used to perform isolations.  
A. Buffer and enzyme are heated in a water bath and driven through the system by a 
peristaltic pump. The cannula was attached to a glass reservoir which kept the enzyme 
warm and also acted as a bubble trap. B. Image of a rat heart attached to the cannula during 
retrograde perfusion with enzyme.  
 
The heart was judged as being digested once the tissue felt soft to the touch and the colour 
had become pale and almost translucent (this took around 9-11 minutes depending on the 
size of heart). The perfusion was stopped, the heart was removed from the cannula and the 
ventricles were finely chopped in a Krebs solution containing 0.5% BSA. The tissue was 
gently triturated with a Pasteur pipette in order to dissociate the myocytes, and the 
supernatant transferred into a 15ml tube. The process was repeated until all the tissue was 
dissolved or there were no more living myocytes dissociating.  
 
This whole process was conducted in calcium free solution and therefore the calcium 
levels must be raised to physiological levels. The CaCl2 concentration in the cell solution 
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was gradually increased over time by adding 0.1 mM CaCl2 every 20 minutes until a final 
concentration of 1mM CaCl2 was obtained. Cells were then allowed to settle by gravity for 
20 minutes before removing supernatant and resuspending the pellet in supplemented 
M199 medium. Cells were counted using a haemocytometer. Only rod shaped quiescent 
cells were considered viable. Cells were seeded at 50,000 cells per 24mm laminin-coated 
glass microscope coverslips and incubated at 37°C for at least 2 hours before infection. 
 
 
 
Figure 3-2. Image of an adult rat ventricular myocyte (ARVM) isolation before counting and 
seeding the cells, showing both healthy (rod shaped) myocytes and dead (round) myocytes. 
 
 
 
3.2.2.2 Troubleshooting 
There are various possible results for tissue dissociation and being able to correctly 
recognise what these results are will help to identify the corrective actions to take next 
time. For example if the dissociation outcome is: 
 
Low yield and low viability of cells: This is an over/under digestion, cellular damage. 
Change to less digestive type enzyme and/or decrease working concentration. (e.g. from 
trypsin to collagenase/ from Type 2 collagenase to Type 1). 
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Low yield but high viability of cells: Suggests under dissociation.  
Increase enzyme concentration and/or incubation time and monitor both yield and viability 
response. If yield remains poor, evaluate a more digestive type enzyme and/or the addition 
of secondary enzyme(s). 
High yield but low viability of cells: Suggests this was a good dissociation but there is 
cellular damage. 
Enzyme is overly digestive and/or at too high a working concentration. Reduce 
concentration and/or incubation time and monitor yield and viability response. 
High yield and high viability: The ideal dissociation. 
 
 
3.2.2.3 Preparation of Laminin-coated coverslips 
Laminin (mouse purified, Millipore) was prepared to manufacturer’s specifications and 
stored at 4˚C. Laminin was diluted to 20 μg/ ml in supplemented M199 medium and 24 
mm cover glasses (VWR International) were sterilised with an ether ethanol solution (1:1) 
and set in a 6 well tissue culture (TC) plate to allow them to dry. Each coverslip was 
coated with 250 μl of laminin and incubated at 37°C for a minimum of 1 hour. Laminin 
was removed by aspiration before use. 
 
 
 
3.2.3 In-vitro hypertrophy protocol 
For hypertrophy induction, ARVM were seeded onto laminin coated coverslips at 50,000 
cells per slide and incubated at 37°C for 2 hours to allow living cells to attach to the glass. 
After this time the medium was aspirated and replaced. 1 μM norepinephrine (NE) in 
serum free medium was added to the hypertrophic myocytes and an equal amount of 
DMSO was added to control myocytes before viral infection (which occurs on same day as 
induction of hypertrophy). 
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3.2.4 Infection of ARVM with adenovirus vectors carrying 
FRET-based sensors 
Isolated ARVM were infected with the desired multiplicity of infection (MOI) using the 
following equation: 
 
 
 
 
After seeding the cells onto laminin coated coverslips and incubating for 2 hours as 
mentioned above, the medium was aspirated to remove dead cells and fresh supplemented 
M199 containing the calculated amount of virus was added. Cells were incubated at 37 ºC 
overnight (~18 hours) prior to use. 
 
 
 
3.2.5 CHO culture and transfection  
CHO-K1 cells from Hamster Chinese ovary cells were thawed in a water bath at 37°C and 
added drop wise to 5 ml of pre-warmed medium, centrifuged for 5 minutes at 300 x g, re-
suspended in fresh medium and seeded in a 75 cm
2
 flask containing 10 ml of the 
appropriate medium. Cells were fed every 2-3 days by changing medium, and split into 
new flasks when 80-90% confluent. 
 
CHO freezing  
Cells were trypsinised with trypsin-EDTA 0.05 % (Invitrogen), centrifuged for 5 minutes 
at 2,700 x g re-suspended in 3 volumes of FBS and 1 volume of freezing solution (3.2.6) 
added drop wise. Cells were then dispensed into 2 ml cryo vials and transferred to -80°C 
for 24h. Cells were then stored in liquid nitrogen tank. 
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3.2.6 Media, Buffers and compounds for Cellular Biology  
Kreb’s Solution 
* glucose added prior to use. 
Adjusted to pH 7.4, filter sterilised and stored at 4°C. 
 
 
Supplemented M199 medium (for ARVM) 
Filter sterilised and stored at 4°C 
 
 
Tyrode Solution  
NaCl 134 mM 
Glucose 11 mM 
KCl 4 mM 
MgSO4 1.2 mM 
NaH2PO4 1.2 mM 
HEPES 10 mM 
Adjusted to pH 7.34, filter sterilised and stored at 4°C. 
 
NaCl 120 mM 
Hepes 20 mM 
NaH2PO4 0.52 mM 
KCl 5.4 mM 
MgCl2 3.5 mM 
Taurine 20 mM 
Creatine 10 mM 
Glucose * 11.10 mM 
MEM199 (Invitrogen) 500 ml 
Taurine 5 mM 
L-Carnitine 2 mM 
Creatine 5 mM 
Pen/Strep 100 i.u. ml
−1
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Supplemented Hams F12 medium (for CHO-K1 cells) 
Ham’s F-12 (Invitrogen) 500 ml 
Glutamine (Invitrogen) 2 mM 
Penicillin 1 U/ ml 
Streptomycin 1 μg/ ml 
FBS (Invitrogen) 10 % 
 
 
Freezing Solution (for CHO-K1 cells) 
DMEM  
Glucose 12 % 
DMSO 40 % 
 
 
3.3 Molecular Biology 
3.3.1 Agar plates 
Agar plates were prepared by autoclaving LB agar broth (1 % tryptone, 0.5 % yeast 
extract, 170 mM NaCl and 1.5% agar), cooling the mixture ~45˚C, and then the 
appropriate antibiotic (ampicillin or kanamycin) for the plasmid antibiotic resistance gene 
was added, before pouring into 90 mm Petri dishes. Agar plates were stored sealed at 4°C 
for up to one month. 
 
 
 
3.3.2 Transformation of Chemically Competent Cells 
Chemically competent TOP10 cells (Invitrogen) were stored at -80˚C and thawed on ice 
for 10 minutes immediately prior to use. 2-2.5 ng of plasmid DNA was added per 50 μl 
aliquot of competent cells on ice, and mixed gently. Tubes were incubated for 15 minutes 
on ice, heat shocked at 42°C for 30 seconds, and returned to ice for a further 2 minutes. 
450 μl of pre-warmed SOC media (Invitrogen) was aseptically added to the cells, and tubes 
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were incubated at 37°C for 1 hour in a shaking incubator. 20-200 μl of the transformation 
mix was spread onto pre-warmed agar plates containing the appropriate antibiotic. Plates 
were incubated upside down at 37°C overnight. Colony growth indicated successful 
transformation of cells.  
 
 
 
3.3.3 DNA extraction and purification 
Single putative positive colonies were picked from agar plates using a sterile pipette tip, 
and grown for approx. 8 hours in 3 ml of LB containing the appropriate antibiotic at 37°C 
in an orbital shaker set at 180 rpm. 1 ml of the culture was used to check the plasmid 
isolated using a QIAprep Spin Miniprep Kit (Qiagen), following the manufacturer’s 
protocol for plasmid purification with a microcentrifuge. Plasmids were screened by 
restriction digest or sequencing. The remaining positive starter culture was added to 500 ml 
LB in a 2 L flask and incubated in an orbital shaker overnight at 37°C and 180 rpm. The 
bacterial cells were harvested by centrifugation at 6700 x g for 15 minutes at 4°C. 
 
The plasmid DNA was extracted from the bacteria using the HiSpeed Plasmid Maxi Kit 
(QIAGEN). Briefly, the bacterial pellet was re-suspended in 10 ml of the lysis Buffer P1. 
Buffer P1 contains Tris and EDTA. EDTA chelates divalent metals (primarily magnesium 
and calcium). Removal of these cations destabilises the cell membrane, producing lysis of 
the bacterial cells, and also inhibits DNases. 10 ml of Buffer P2 was added, the solution 
mixed thoroughly by inverting 4-6 times and incubated at room temperature for 5 minutes. 
Buffer P2 contains sodium hydroxide and SDS. SDS is a detergent which creates holes in 
the cell membranes and sodium hydroxide loosens the cell walls. This results in release of 
plasmid DNA and sheared cellular DNA from the cells. Sodium hydroxide also denatures 
the DNA, producing linearisation of cellular DNA and separation of the strands. 10 ml of 
Buffer P3 was added (chilled to 4°C), the solution mixed thoroughly by inverting 4-6 times 
and incubated on ice for 20 minutes. Buffer P3 was a neutralisation buffer containing 
potassium acetate and allows precipitation of genomic DNA, proteins, cell debris and KDS 
(combination of acetate and SDS). The solution was then poured into the QIAfilter 
cartridge and incubated for 10 minutes. During this time, HiSpeed Maxi tip was 
equilibrated by addition of 10 ml Buffer QBT and emptied by gravity flow. 
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The supernatant from the QIAfilter was applied to the anion-exchange HiSpeed tip by 
pressing on the plunger and allowed to enter the resin by gravity flow where the plasmid 
DNA selectively binds under low salt and pH conditions. The HiSpeed-tip was then 
washed with 60 ml Buffer QC, which was a medium-salt wash to remove RNA, proteins, 
metabolites and other low-molecular-weight impurities. The plasmid DNA was then eluted 
from the HiSpeed tip by addition of 15 ml Buffer QF, a high-salt buffer. As DNA is 
negatively charged, the addition of salt masks the charges and allows DNA to precipitate. 
10.5 ml of isopropanol was added to the plasmid DNA (concentrating the DNA and 
removing salt). The eluate/ isopropanol mixture was passed through the QIAprecipitator 
Maxi Module and washed with 2 ml 70% ethanol. The plasmid DNA was then eluted in 1 
ml H2O before quantification of yield and stored at -20˚C. 
 
 
 
3.3.4 Storage of plasmid DNA  
For long-term plasmid storage, 1 ml of overnight culture was mixed with 500 μl 
autoclaved glycerol in a sterile cryovial. The glycerol stock was then snap-frozen on dry 
ice and stored at -80˚C.  
 
Glycerol stocks could also be used to inoculate culture media by scraping the frozen stock 
with a sterile pipette tip and then transferred into 3 ml LB media containing the correct 
antibiotic. 
 
 
 
3.3.5 Quantification of nucleic acids  
The concentration of purified DNA was determined by Nanodrop 1000 spectrophotometer 
(Thermo Scientific). Absorbance wavelength was set at 260 nm and 280 nm. The 
A260:A280 ratio determines the purity of DNA where a value of 1.8 is indicative of highly 
purified DNA. The DNA concentration was calculated using the Beer-Lambert law, where 
an A260 reading of 1.0 optical density (OD) unit is equivalent to 50 μg/ml double-stranded 
DNA  
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3.3.6 DNA Sequencing 
DNA sequencing was performed by the University of Dundee Sequencing Service, 
http://www.dnaseq.co.uk/. DNA samples were supplied as per the web instructions, and 
sequencing carried out using either standard or custom primers. Analysis of DNA 
sequencing was performed using Genomics Workbench (CLC Bio). 
 
 
 
3.3.7 Restriction enzymes and Ligation  
All restriction enzyme were purchased by New England Biolabs, for ligation reactions, 
Rapid DNA Ligation Kit (Roche) was used. Plasmids were quantified by agarose gel 
electrophoresis. 
 
 
 
3.3.8 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was utilised to separate DNA molecules by size. This works 
by moving negatively charged DNA through an agarose matrix via the application of an 
electrical charge. The Bio-Rad Sub-Cell GT electrophoresis system was used. A 1 % 
agarose solution was prepared by dissolving agarose in 1x TAE buffer (40 mM Tris-Cl, 
20mM glacial acetic acid, 1 mM EDTA) by heating in a microwave oven. The solution 
was cooled to handling temperature, and 1:10 000 SYBR Safe DNA gel stain (Invitrogen) 
added. The solution was then poured into a gel mould and allowed to cool and set. DNA 
samples were prepared for loading using a 1:6 dilution of 6x DNA loading buffer (0.25% 
bromophenol blue, 0.25 % xylene cyanol FF and 40% sucrose). 1 kb DNA ladder 
(Promega) was used as a molecular size marker. The gel was run at 100 V for around 45 
minutes. The gel was then removed from the tank and visualised on an ultraviolet 
transilluminator. DNA bands can be cut directly from the gel and purified. 
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3.3.9 PCR and DNA purification  
PCR products and digested DNA were purified using QIAquick PCR Purification Kit and 
QIAquick Gel Extraction Kit (both from QIAgen) following manufacturer’s instructions. 
 
 
 
3.3.10 Generation of FRET-based constructs 
RI_epac and RII_epac 
The Epac1-camps sensor for cAMP (Nikolaev et al. 2004) was kindly provided by 
M.Lohse (Institute of Pharmacology and Toxicology, University of Wurzburg, Germany). 
RI_epac and RII_epac constructs were generated by fusion of the dimerisation and docking 
domains (D/D) of RIα (64 aa) or RIIβ (49 aa) to the N-terminus of the Epac1-camps A 27 
aa linker A (EAAAK)5A was inserted between the D/D and Epac1-camps to avoid 
inadequate interactions between the domains, allowing them to work independently (Di 
Benedetto et al. 2008). 
 
 
RI-Cygnet-2.1 and RII-Cygnet-2.1  
Cygnet-2.1 was generously supplied by Wolfgang Dostmann, (Departments of 
Pharmacology and Molecular Physiology and Biophysics, University of Vermont, 
Burlington). Targeted cygnet-2.1 constructs were created by inserting the D/D of RIα (64 
aa) or RIIβ (49 aa) between the NheI and XhoI restriction sites in pcDNA3 cygnet2.1. 
 
 
3.3.11 Generation of Ad5 recombinant vectors 
In order for these FRET-Based constructs to be used in adult ventricular myocytes, they 
first needed to be produced in an adenovirus. AdV5-PDE2A2wt-mCherry, AdV5-PDE2A2 
catalytically dead (D685A-D796A)-mCherry, RI-Cygnet and RII-Cygnet were produced 
by Vector Biolabs.  
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For RI_epac and RII_epac the AdEasy XL Adenoviral Vector Systems (Agilent 
Technologies, California) was employed. Briefly, the constructs were inserted into the 
MCS of pShuttle CMV and confirmed by restriction digest. DNA was purified and 
linearised by digesting the vector with Pme I and gel purifying. BJ5183-AD-1 cells were 
transformed with the linearised DNA by electroporation then grown overnight at 37˚C on 
LB-kanamycin agar plates. The smaller well isolated colonies were picked and grown in a 
3 ml LB-kanamycin broth. Colonies were screened for positive recombinants by digesting 
10 μl of miniprep DNA with PacI restriction enzyme and running the digestion product on 
a 0.8 % agarose TAE gel. PacI restriction of a recombinant pAdEasy-1 vector should 
appear as a large band at approximately 30 kb and a smaller band either at 3 kb or 4.5 kb 
depending on where the recombination took place. Recombinant pAdEasy plasmids were 
amplified in XL10-Gold ultracompetent cells following the manufacturer’s instructions. 
Purified recombinant adenovirus plasmid was digested with Pac I enzyme to confirm 
desired restriction pattern.  
 
 
3.3.11.1 Adenovirus production in AD-293 Cells 
Between 50 μg and 100 μg of viral plasmid DNA was digested overnight with 50 units of 
PacI enzyme. The next day the digested DNA was ethanol precipitated by adding 2 
volumes of ethanol and 0.3 volumes of sodium acetate and incubated at -20˚C for 1 hour. 
DNA was centrifuged at 22,000 x g for 30 minutes, supernatant discarded and the pellet 
washed in 70% ethanol and air dried for 5 minutes. The pellet was resuspended in 20 μl of 
sterile water. 
 
AD-293 cells were seeded in a 6 well plate to a density of 7x10
5 
cells per well and grown 
overnight. Two solutions containing the following were prepared: 
Solution 1: 450 μl of OptiMEM (Invitrogen) and 3-4 μg DNA per well 
Solution 2: 450 μl of OptiMEM and 2.5 μl LipofectaminTM 2000 (Invitrogen) per well. 
 
Solutions were left for 5 minutes at room temperature before mixing and incubating for a 
further 20 minutes at room temperature. 900 μl of the mixed solution was added drop wise 
to the wells. Cells were incubated at 37°C and 5% CO2 for 4 hours before replacing with 
fresh culture medium (see 3.3.11.4). Plaque formation normally occurred after 3-4 days 
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(but sometimes could take as long as 10 days). After the first plaques were seen the virus 
was left for a further 3-4 days to allow it to infect the rest of the cells before it was 
harvested.  
 
 
3.3.11.2 Harvest virus from AD293 cells 
After 3-4 days the cytopathic effect of the vector caused the cells to detach from the tissue 
culture dish or flask. In the initial transfection cells may be scraped from the well using a 
cell scraper. The media containing the cells was collected and the cells were harvested by 
centrifugation at 750 x g for 10 minutes at room temperature. The supernatant was 
discarded and the pellet resuspended in 8 ml of PBS. An equal volume of 
trichlorotrifluoroethane was added and after inversion of the falcon tube and gentle shaking 
the solution was centrifuged at 1,700 x g for 15 minutes at room temperature. The top 
aqueous layer was removed and used to infect more AD293 cells to amplify the virus or 
stored at -80°C until purification by CsCl gradient. 
 
 
3.3.11.3 Amplification of Virus 
AD293 cells were grown until 80-90% confluent in a T150 flask. To this 22 ml of fresh 
medium and 1 ml of virus was added. Cells took around 3-4 days to fully infect. Cells were 
harvested as previously mentioned and used to infect 4 T150 flasks. This procedure was 
repeated until 20-30 flasks were infected. The virus was then harvested and purified by 
CsCl gradient. 
 
 
3.3.11.4 Medium for AD293 cells 
Culture Medium 
DMEM – High glucose with sodium 
pyruvate and L-glutamine (Invitrogen) 
500 ml 
FBS (heat-inactive) (Invitrogen) 10 % 
 
Chapter 3 – Materials and Methods 
 
98 
Freezing Medium 
DMEM – High glucose with sodium 
pyruvate and L-glutamine (Invitrogen) 
50 ml 
FBS (heat-inactive) (Invitrogen) 40 % 
DMSO 10 % 
 
 
3.3.11.5 Adenovirus purification 
Centrifugation on CsCl density gradients was used to purify and concentrate crude 
adenoviral stocks. Ultra-clear centrifuge tubes 16 mm x 102 mm (Beckman Coulter Ltd, 
Buckinghamshire) were sterilised with 70% ethanol and then washed with sterile water. A 
CsCl gradient was produced by sequentially layering 2 ml of CsCl with a density of 1.45 
g/cm3, 3 ml of CsCl with a density of 1.32 g/cm
3
 and 2 ml 40% glycerol. The crude 
adenoviral supernatant was then added drop wise to the top of the gradient so not to disturb 
the layers and the remaining space was filled with PBS. The tube was loaded into a rotor 
and centrifuged at 112,400 x g for 1.5 hours at 4°C with maximum acceleration and zero 
deceleration. Following centrifugation, a band containing the complete adenovirus can be 
seen between the two CsCl layers. This was removed by piercing the tube below the virus 
band using a 21 gauge needle and removing the band in the minimum volume and taking 
care to prevent disruption of the other bands. Extracted virus was transferred to a Slide-A-
Lyzer Dialysis Cassette (molecular weight cut-off of 10000) (Perbio Science UK Ltd) for 
dialysis after hydration of the cassette for 1 minute in dialysis solution. The virus was 
dialysed in 5L of 0.01 M Tris pH 8 / 0.001 M EDTA for 6 hours, after which the buffer 
was changed and supplemented with 10 % glycerol and dialysis repeated overnight. The 
virus was then removed from the cassette, aliquoted and stored at -80°C. 
 
 
3.3.11.6 Titration by end-point dilution 
The Adenovirus titre was determined by performing an end-point dilution assay. Briefly, 
AD293 cells were plated in 80 wells of a 96-well plate at a 50 % confluence. Serial 
dilutions of the adenovirus of interest were prepared in a range of 1 x 10
-2
 to 1 x 10
-11
 in 
complete medium and 100 μl of each adenovirus dilution was added to 10 wells each row. 
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The first row was infected with the highest adenovirus dilution and in the last row 100 μl 
of adenovirus-free medium was added as a control. After 18 hours incubation in a 37˚C /5 
% CO2 incubator the medium containing the virus was replaced with 200 μl of fresh 
complete medium. Medium was then changed every 2-3 days. After 8 days of incubation 
the titre of the adenoviral stock was measured as Plaque Forming Unit/ ml (PFU/ ml) by 
counting the number of wells containing plaques and using the following formulas:  
 
 
  
 
For example if the titration gives 10/10 positive wells from 1 x 10
-2
 to 1 x 10
-8
 dilution, 
8/10 positive wells at 1 x 10
-9
, 3/10 positive wells at 1 x 10
-10
 dilution and 0/10 in all the 
remaining dilution rows, the proportionate distance would be:  
  
 
 
 
and  
 
 
 
in this case would be:  
 
 
ID50 = 10
-10.6 
 
The tissue culture infectivity dose 50 equals the reciprocal of ID50: 
 
 TCID50 / ml = 10
10.6
 = 3.98 x 10
10 
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According to the relation 1 TCID50 = 0.7 PFU/ ml. 
The final titre for this example expressed in PFU/ ml would be: 
  
Final Titre = 2.78 x 10
10
 
 
The PFU/ ml calculated for the viruses used are:  
 
RI_epac: 2.8 x 10
10 
RII_epac: 2.8 x 10
10 
Cygnet-2.1: 5.7 x 10
10
 
RI-Cygnet-2.1: 3.8 x 10
10
 
RII-Cygnet-2.1: 3.5 x 10
10
 
AdV5-PDE2A2wt-mcherry: 1.24 x 10
11
 
AdV5-PDE2A2cd (D685A-D796A)-mCherry: 1.24 x 10
11
  
 
 
3.4  Protein Analysis 
3.4.1 Preparation of lysates and protein quantification 
Adult rat cardiac myocytes were seeded in a 6 well tissue culture plate, treated as indicated 
and washed twice with ice cold PBS before adding 200-300 μl lysis buffer (see 3.4.4).  
 
To determine the protein concentration of cell lysates, a Bradford Assay was carried out, 
using bovine serum albumin (BSA) as the standard curve. In a clear, 96 well plate, known 
BSA concentrations between 0 and 10 μg were diluted to a final volume of 50 μl with 
distilled water. The protein samples were diluted in distilled water at a 1:10 ratio, to a final 
volume of 50 μl. Bradford reagent from Bio-Rad was diluted 1:5 with distilled water and 
200 μl added to each well. This reaction causes a colour change from brown to blue, the 
intensity of which is directly proportionate to the concentration of the protein. The 96 well 
plate was read at 560 nm using a microplate reader, which provided protein concentrations 
of each sample. 
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3.4.2 SDS-PAGE  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
to separate proteins according to their molecular weight. In brief, equal concentration of 
protein samples were denatured and reduced in 5x SDS-PAGE sample buffer followed by 
heating at 75˚C for 10 minutes. After centrifugation, protein samples were resolved on 
precast polyacrylamide gels (4-12% NuPAGE Novex Bis-Tris gel, Invitrogen) immersed 
in MOPS SDS running buffer according to nature of the samples and different protein 
separation range. Pre-stained protein marker (Bio-Rad) was loaded to the first well of the 
gel while the protein samples were loaded to the subsequent wells. The gel was run for 30 
minutes at 60 V then 1.5 hours at 160 V to allow adequate separation of the proteins. 
 
 
 
3.4.3 Western immunoblotting  
Proteins were electrotransferred onto nitrocellulose membranes (0.45 μm pore, Protran, 
Whatman GmbH) using X-Cell II blotting modular (Invitrogen) in Nu-PAGE transfer 
buffer containing 10 % methanol at room temperature for 2 hours at 30 V or overnight at 
4˚C. Successful transfer was indicated by full transfer of the molecular weight markers 
onto the nitrocellulose membrane. The membrane was then blocked in TBST with 5 % 
milk (Marvel) for 1 hour at room temperature with gentle agitation. Membranes were then 
probed with specific primary antibodies diluted in 1 % milk/TBST solution and incubated 
overnight at 4˚C. The membranes were washed 3 times for 10 minutes each in TBST 
before adding appropriate horseradish peroxidise (HRP) conjugated anti-immunoglobulin 
G (IgG) secondary antibody diluted again in 1 % milk/TBST solution. After secondary 
antibody incubation, membranes were washed and detected by enhanced 
chemiluminescence (ECL) Western Blotting Substrate (Thermo Scientific) and 
autoradiography. Chemiluminescent images of immunodetected bands were recorded on 
blue-light sensitive autoradiography X-ray films (Kodak BioMax MS) which were then 
developed using the Kodak® X-Omat Model 2000 processor.  
 
Immunoblot intensities were quantitatively analysed using ImageJ, Results, representing 
the mean of at least three independent experiments, were normalised to the amount of the 
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GAPDH. This ensures correction for the amount of total protein on the membrane in case 
of loading errors or incomplete protein transfers. 
 
 
 
Table 3-1. List of primary antibodies and dilutions used for each type of application. 
Antibody Host Supplier Catalogue 
No. 
Dilution Applications 
α-actinin 
(sarcomeric) 
Mouse  Sigma A7811 1:2000 IF 
PDE2A Rabbit FabGennix PD2A-
101AP 
1:500 – 
1:2000 
WB, IF 
PDE3A Rabbit FabGennix PD3-101AP 1:500 – 
1:1000 
WB, IF 
PDE4A Rabbit In-house  1:2000 WB,IP 
PDE4B Sheep In-house  1:1000 – 
1:5000 
WB, IP, IF 
PDE4D Sheep In-house  1:1000 – 
1:5000 
WB, IP, IF 
UCRI Rabbit In-house   WB 
PDE4B1 Rabbit In-house 12402 1:5000 WB 
PDE4B2 Rabbit In-house 12405 1:5000 WB 
PDE4D3 Rabbit In-house 12407 1:5000 WB 
PDE4D5 Rabbit In-house 12411 1:5000 WB 
WB, Western immunoblotting; IP, immunoprecipitation; IF, immunofluorescence 
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Table 3-2. List of secondary antibodies and dilutions used for each type of application. 
Antibody Host Supplier Catalogue 
No 
Dilution Application 
Anti-mouse 
IgG 
Goat Sigma A5278 1:5000 WB 
Anti-mouse 
IgG 
Rabbit Sigma A9044 1:5000 WB 
Anti-rabbit 
IgG 
Goat Sigma A8275 1:5000 WB 
Anti-goat 
IgG 
Rabbit Sigma A8919 1:5000 WB 
Goat anti-
mouse 
AlexaFluor® 
568 
Goat Invitrogen A11004 1:500  IF 
Goat anti-
rabbit 
AlexaFluor® 
568 
Goat Invitrogen A11011 1:500  IF 
Donkey anti-
goat 
AlexaFluor® 
488 
Donkey Invitrogen A11055 1:500  IF 
WB, Western immunoblotting; IP, immunoprecipitation; IF, immunofluorescence 
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3.4.4 Buffers and compounds for SDS-PAGE and Western 
immunoblotting 
Cell lysis buffer 
Hepes  25 mM 
EDTA  2.5 mM 
NaCl  50 mM 
Sodium pyrophosphate  30 mM 
Glycerol  10 % 
Triton X-100  1 % 
pH 7.5 and store at 4˚C  
On day of use add one Complete™ EDTA-free protease inhibitor cocktail tablet (Roche) in 
50 ml buffer. 
 
 
TBST  
Tris-Cl 20 mM 
NaCl 150 mM 
Tween 20 0.1 % 
pH 7.6 
 
 
Basic 5X Laemmli Buffer 
SDS 10 % 
Tris-Cl  300 mM 
pH 6.8  
Bromophenol Blue 0.05 % 
Glycerol 50 % 
β-Mercaptoethanol 10 % 
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3.4.5 Immunoprecipitation (IP) assay  
Immunoprecipitation (IP) is a technique that uses antibodies specific to a protein to remove 
those proteins from solution. The antibody-protein complexes are precipitated out of 
solution with the addition of an insoluble form of antibody binding proteins. It was decided 
that this method would be used as there was issues detecting changes in specific PDE4 
isoforms as many of these isoforms share similar molecular weights. Therefore 
immunoprecipitation was used to “pull down” a specific protein of interest which was used 
for western immunoblotting. 
 
 
Preparing Beads 
Firstly, a pre-clearing step was performed to reduce non-specific binding to the protein 
beads (protein A beads were used for rabbit polyclonal antibodies and protein G beads 
were used for goat or mouse antibodies). The total volume of beads for both the pre-clear 
and IP steps was calculated ( roughly 30 μl per pre-clear reaction and 500 μl per IP) and 
washed in cell lysis buffer (3.4.4) containing protease inhibitor before centrifuging for 1 
minute at 19,000 x g and removing the supernatant. This was repeated a further two times 
before resuspending the beads in total volume of lysis buffer required. 
 
 
IP Protocol 
For endogenous proteins 1 mg of lysate was used. 30 μl of prepared beads were added to 
lysates and rotated at 4˚C, end on end, for 30 – 60 minutes. Lysates were then centrifuged 
at 19,000 x g for 10 minutes at 4˚C. The supernatant was collected and 5-10 μg of chosen 
antibody was added (pan PDE4B and pan PDE4D was used at this stage). Beads were 
retained and washed with lysis buffer to be used as a negative control. Antibody and lysate 
reaction was rotated end on end at 4˚C for 30 minutes before adding 500 μl of prepared 
beads and rotating overnight. The immunocomplexes were then collected by centrifugation 
at 19,000 x g for 10 minutes and washed three times with lysis buffer. Supernatant was 
discarded and beads were boiled in Laemmli buffer before centrifuging at 19,000 x g for 5 
minutes. The supernatant was collected and proteins separated by SDS-PAGE and Western 
immunoblotting. 
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3.5  Cell based experiments 
3.5.1 Manual measurements of cell size  
Cardiomyocytes were seeded and maintained as previously described (3.2.2.3). 
Cardiomyocytes were either challenged for 24 hours with either 1 μM norepinephrine (NE) 
alone or NE and a specific PDE inhibitor. Control cells were maintained for the same 
length of time with DMSO added to the medium. Cells were chosen randomly and 
captured digitally with an ORCA AG (model C4742-80-12AG) camera on the stage of an 
inverted epifluorescence microscope (Olympus IX81, equipped with an Olympus 
PlanApoN, 60X, NA 1.42 oil objective) and analysed. Cell size was determined by the 
sectional area: length of cell x width of cell. Values are expressed as means ± S.EM. A 
Student’s t-test was performed to compare the two groups, and the P values are indicated.  
 
 
 
3.5.2 Real-time xCELLigence measurements  
The xCELLigence technology (Roche Applied Science) which allows a quantitative 
measurement of the cell size through real-time cell-electronic sensing (RT-CES) was used 
according to the manufacturer’s instruction. As cardiomyocytes are unable to divide, they 
tend to increase in cell volume in response to stress. This method allowed us to observe the 
change in impedance which is automatically converted to cell index and provides a 
quantitative measurement that reflects the nature of the cells, i.e. cell size.  
 
Cardiomyocytes were counted as before and seeded with 50,000 cardiomyocytes per 
laminin pre-coated well of the E-Plate 96 (Roche) in triplicates after background 
measurements were taken. Briefly after 2 hours of culture in supplemented M199 medium, 
cardiomyocytes were treated with either 1μM NE alone or NE following a 30 minutes or 2 
hours pre-treatment with PDE inhibitors. Controls with vehicle (DMSO alone) were also 
performed. The cultures were continuously monitored for up to 48 hours and the 
impedance as reflected by cell index (CI) values was set to record every 30 minutes. The 
xCELLigence data were then analysed using the RTCA software (Roche Applied Science). 
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The results were expressed by normalised CI, which are derived from the ratio of CIs 
before and after the addition of compounds. 
 
 
 
3.5.3 Phosphodiesterase Activity Assay 
Measurement of PDE activity was carried out using a radioactive cyclic AMP hydrolysis 
assay as previously described (Marchmont and Houslay 1980) and is a modification of a 
historical two-step procedure (Thompson and Appleman 1971). In the first step, samples 
are incubated with 8-[
3
H]-labelled cAMP substrate, and PDEs in the sample hydrolyse this 
to [
3
H]-5’-AMP. In the second step, addition of snake venom hydrolyses the 5’AMP to 
[
3
H]- adenosine, and incubation with an anion exchange resin binds any negatively 
charged, unhydrolysed cAMP, separating it from the adenosine. The amount of [
3
H]-
adenosine is then calculated by scintillation counting, to determine the rate of cAMP 
hydrolysis. 
 
 
3.5.3.1 Protein Sample Preparation 
Adult rat ventricular myocytes were plated overnight in a 6 well TC plate and seeded at 
100,000 cells per well in their normal growth medium. The cells plus medium were then 
collected by scrapping the cells from the well and then centrifuged for 1 minute at 19,000 x 
g to pellet the cells. The medium was removed and the samples were then homogenised in 
200 µL of KHEM Buffer (see 3.5.3.4) using a syringe. The samples were again centrifuged 
at 19,000 x g for a further minute to pellet the debris. The supernatant was transferred to a 
new 1.5ml Eppendorf tube. Protein sample concentrations were measured by Bradford 
Assay and stored at -20˚C. 
All steps were performed at 4°C unless indicated. Samples were measured in triplicate. 
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3.5.3.2 Assay procedure 
For this assay 20-25 µg of purified protein was diluted in KHEM buffer to a final volume 
of 50 µL. If an inhibitor of PDE activity was used the protein was diluted to a final volume 
of 40 µL of KEM buffer and 10 µL of selected inhibitor. 50 μl of substrate in 50μl of 
KHEM buffer was used as the blank control. 50μl of cAMP substrate was added to 50μl of 
the protein sample, mixed, and these were then incubated in a water bath at 30˚C for 10 
minutes. The samples were then placed in a boiling bath for 2minutes to inactivate the 
phosphodiesterase and stop the reaction. The tubes were then cooled on ice for 10 minutes. 
25 μl of 1 mg/ml snake venom from Ophiophagus Hannah was then added to the reaction 
tubes, the tubes were mixed thoroughly by flicking, and incubated for a further 10minutes 
at 30˚C. 400 μl of Dowex/ethanol solution was added to each reaction tube, vortexed and 
then incubated on ice for a further 15 minutes. Following incubation the tubes were then 
vortexed one final time and centrifuged at 19,000 x g for 2 minutes at 4˚C in a refrigerated 
bench-top centrifuge. 1 ml of Ecoscint scintillation fluid was added to fresh 1.5 ml 
Eppendorf tubes and 150 μl of supernatant from the reaction tubes was added. 50 μl of 
cAMP substrate solution was added to two of the tubes to determine total counts per 
minute for the assay. All tubes containing scintillant were vortexed thoroughly and counted 
for 1 minute in a beta scintillation counter calibrated for [
3
H].  
 
 
3.5.3.3 Determination of Phosphodiesterase Activity 
To determine specific PDE activity contained within any reaction tube the following 
formula was applied, 2.61 x (value – blank / average total) x 10-11 x 1012 x (1000/ μg 
protein) resulting in PDE activity in ρmoles/min/mg protein. To assess the effect of PDE 
inhibition, the activity of samples containing inhibitor was directly compared to an 
uninhibited control reaction and was expressed as the percentage of the control. 
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3.5.3.4 Buffers and compounds for PDE assay 
KHEM Buffer 
KCL 50 mM 
Hepes 50 mM 
MgCl2 1.94 mM 
EGTA 10 mM 
pH7.4 
Stored at 4˚C until required. 
 
Before use, 1 mM DTT and one protease inhibitor cocktail tablet (in 50 ml buffer) was 
added. 
 
 
 
 
 
PDE Assay Buffer 
Tris-Cl 20 mM 
MgCl2 10 mM 
pH7.4  
 
 
Dowex  
Stock is 1:1 mix of dowex: H20. Prior to use 2 parts of this mix was added to 1 part 
Ethanol (100 %).  
 
 
Snake venom 
10 mg/ ml stock in buffer A. Diluted to 1 mg/ ml (in buffer A) prior to use. 
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cAMP Substrate Mix 
2 μl of 'cold' + 3 μl of 'hot' 8-[3H]-labelled cAMP per 1ml of buffer B (i.e. 2 μl + 3 μl + 995 
μl buffer).  
'cold' unlabelled cAMP stock solution = 1 mM (will be 2 μM final)  
'hot' 8-[
3
H]- labelled cAMP = 1 μCi/ μl (will be 3 μCi/ ml final)  
 
Work out total volume(s) of cAMP mix, Snake venom, Dowex that will be required for 
whole assay (including pilot) and prepare in advance. 
 
 
Activation of Dowex Exchange Resin 
Dowex 1 x 8-400 was prepared and activated by dissolving 400 g of Dowex resin in 4 L of 
1 M NaOH. The solution was stirred for 15 minutes at room temperature and the resin 
allowed settling. The supernatant was removed and the Dowex resin was washed with 
distilled water until pH 9.0 (approx 30 times) and allowed to settle after each wash. 
The resin was then washed with 4 L of 1 M HCl for 15 minutes at room temperature and 
allowed to settle. The resin was washed a further 5 times with distilled water and stored at 
4˚C as 1:1 slurry with distilled water. This procedure generally produced approximately 1 
L of Dowex slurry. This Dowex slurry was utilised in the PDE assay as a 2:1 solution of 
Dowex slurry to 100 % ethanol. 
 
 
 
3.6  Quantitative Real-Time PCR 
Real-time polymerase chain reaction (PCR) is a technique widely used to determine 
relative gene expression.  
The technique of PCR uses in vitro enzyme-catalysed DNA synthesis to create millions of 
identical copies of DNA from a single or few fragments. PCR amplifies DNA in three 
steps: (1) Denaturation – separating the individual strands of DNA. (2) Annealing – 
primers bind to the single stranded DNA. (3) Extension – the thermostable DNA 
polymerase generates a complimentary DNA product. These steps are repeated for around 
40 cycles. The product from the first cycle can be used as a template for the primers in the 
second cycle and therefore successive cycles will generate and exponentially increasing 
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quantity of DNA (DNA produced = 2
n
, where n = number of cycles). The PCR product, or 
final number of DNA copies obtained, is related to the number of initial template copies. 
However, as the reaction progresses, some of the reagents are consumed as a result of 
amplification. This depletion will occur at different rates for each replicate.  The reactions 
start to slow down and the PCR product is no longer doubled at each cycle. Theoretically, 
there is a quantitative relationship between amount of starting target sample and amount of 
PCR product at any given cycle number. This makes the end point quantification of PCR 
products unreliable. In order to overcome this limitation, Real-Time PCR was developed 
(Higuchi et al. 1993). Real-Time PCR detects the emission of a fluorescent indicator 
during the reaction. The data is then measured at the exponential phase of the PCR reaction 
and not at the end as in traditional methods. 
 
One of the most common forms of this technique, and the one which was employed in this 
study, is TaqMan® real-time PCR. This type of probe is labelled with two fluorophores, a 
fluorescent reporter (i.e. 6-carboxyfluorescein, 6-FAM) at 5’ end and with a quencher (i.e. 
6-carboxy-tetrametil-rodamine, TAMRA) at 3’ end. TaqMan® probes are designed to 
specifically anneal to a target sequence localised between two PCR primers. When the 
fluorophores are in close proximity, the quencher absorbs the reported emission. During 
the final extension step in the PCR cycle the probe is cleaved, so upon excitation (494 nm) 
the reporter emits a fluorescent signal (518 nm) which can be detected. Therefore, the 
fluorescent signal detected is proportional to the number of DNA copies generated. 
 
 
 
3.6.1 RNA extraction  
Total RNA was extracted using TRIzol reagent (Invitrogen) which contained phenol and 
guanidine thiocyanate in a procedure based on the method of Chomczynski and Sacchi 
(Chomczynski and Sacchi 1987). Cells were seeded in 6 well plates (100,000 cells per 
well), medium was removed and cells were rinsed with PBS and subsequently lysed with 1 
ml of TRIzol® Reagent, directly added into the dish, collected with a scraper and 
homogenised by passing several times through a 1 ml syringe and a 26 gauge needle. 
Insoluble material was removed from the homogenate by centrifugation at 16,000 x g in a 
bench top centrifuge for 10 minutes at 4°C. RNA was separated from DNA and protein by 
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transferring the supernatant to a new tube and adding 200 μl of chloroform before shaking 
vigorously and incubating at room temperature for 5 minutes. The aqueous phase was then 
precipitated with ½ volume of isopropanol and centrifuged at 16,000 x g for 10 minutes at 
4˚C. The precipitate containing the RNA was then washed with 70% ethanol, centrifuged 
at 11,000 x g for 5 min, followed by air drying for 10 minutes at room temperature. Finally 
the RNA was briefly dried under vacuum and re-suspended in RNAse-free sterile water 
Total RNA was quantified using the Nanodrop 1000 spectrophotometer (Thermo 
Scientific).  
 
 
 
3.6.2 Reverse Transcription 
Real-time PCR can only amplify DNA, therefore it is crucial to convert RNA to cDNA. 
Reverse transcription of RNA samples was carried out by using QuantiTect® Reverse 
Transcription Kit (QIAGEN) according to manufacturer’s instructions. This kit provides an 
optimised mixture of Omniscript Reverse Transcriptase and Sensiscript Reverse 
Transcriptase, RNase inhibitor, optimised buffer containing dNTPs, and a mix of oligo-dT 
and random primers. 
Genomic DNA elimination:  
A genomic DNA elimination step is performed before starting retro-transcription using the 
gDNA Wipeout Buffer, 7x provided.  
 
Prepare the mix as follows: 
gDNA Wipeout Buffer, 7x  2 μl  
RNA template  from 10 pg up to 1 μg  
RNase-free water  up to 14 μl  
 
Reaction mix was incubated at 42˚C for 2 minutes and then placed on ice to cool before the 
reverse transcription step. 
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Quantiscript Reverse Transcriptase  1 μl  
Quantiscript RT buffer, 5x  4 μl  
RT primer mix  1 μl  
RNA template (from previous step)  14 μl  
Total Volume  20 μl  
Mix was incubated at 42˚C for 15 minutes, then 95˚C for 3 minutes to heat-inactivate the 
reverse transcriptase.  
The cDNA can be stored at -20˚C or used directly for Real-time PCR. 
 
 
 
3.6.3 TaqMan real-time PCR  
Gene-specific TaqMan probes and PCR primers sets (Eurofins MWG operon) were 
designed assisted by the Primer 3 software (http://frodo.wi.mit.edu/primer3/) If possible; 
the primers were designed to span an exon-intron-exon boundary to exclude amplification 
of genomic DNA. 18S rRNA was used as an internal control for normalising relative 
expression levels in the different samples. Real-time PCR was performed from reverse 
transcribed cDNA samples using the Platinum Quantitative PCR SuperMix-UDG with 
ROX (Invitrogen) following the manufacturer’s instructions. 
 
 Briefly, 25 ng of cDNA were added to a 96-well MicroAmp® Fast Optical Reaction Plate 
(applied Biosystems) with 7.5 μl of Platinum Quantitative PCR SuperMix-UDG with 
ROX, 2.2 μl of nuclease free water (Ambion) and 0.9 μl of TaqMan probe mix (containing 
0.3 μl each of the 10 μM primer pairs and 0.3 μl of 10 μM TaqMan probe. Thermal cycling 
and fluorescent monitoring were performed using the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems). For each target gene Real-time PCR was performed in three 
biological replicates each of which was done in a minimum of three technical replicates: 
 
 Initial denaturation at 95 °C for 2 min 
 Then 40 cycles of 15 sec at 95 °C for denaturation, 15 sec at 57 °C for annealing 
and 1 minute at 60 °C for extension.  
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 Fluorescence data were collected during the extension step of each cycle. Negative 
controls using RNA as template were also included in all runs to test for the 
presence of genomic DNA contamination.  
 
 
Table 3-3. Oligonucleotide sequence of primers and probes used for RT-PCR. 
Gene  Oligonucleotide sequence  
Atrial natriuretic 
peptide (ANP)  
Forward: 5’-GGATTGGAGCCCAGAGCGGAC-3’  
Reverse: 5’-CGCAAGGGCTTGGGATCTTTTGC-3’  
Probe: 5’-AGGCTGCAACAGCTTCCGGT-3’  
Brain natriuretic 
peptide (BNP)  
Forward: 5’-AGCCAGTCTCCAGAACAATCCACG-3’  
Reverse: 5’-AGGGCCTTGGTCCTTTGAGAGC-3’  
Probe: 5’-GCTGCTGGAGCTGATAAGAGAAAAGT-3’  
β-myosin heavy chain 
(β-MHC)  
Forward: 5’-CCAACACCAACCTGTCCAA-3’  
Reverse: 5’-CAGCTTGTTGACCTGGGACT-3’  
Probe: 5’-CTGGATGAGGCAGAGGAGAG-3’  
Rat PDE2A Probe: 5’- -3’ AGGTGGTGGAGGACAAACAG 
Rat PDE3A Forward: 5’- -3’  TCCTCTTTGCCACTCCTACG 
Reverse: 5’- -3’  GTGGTGTTTCAGCCTCTTCC 
Probe: 5’- -3’ AGACACTGATGACCCGGAAG 
Rat PDE4B Forward: 5’- ATGTGGCGTATCACAACAGC -3’  
Reverse: 5’- GTGAAGACAGCATCCAGTGC-3’  
Probe: 5’- -3’ ACGTTCTCCTCTCTACGCCA 
Rat 18S rRNA  Forward: 5’-CGCGGTTCTATTTTGTTGGT-3’  
Reverse: 5’-CGGTCCAAGAATTTCACCTC-3’  
Probe: 5’-TGAGGCCATGATTAAGAGGG-3’  
 
Rat PDE4D, α-actin primers and probes and rat PDE2A primers have been designed and 
kindly provided by Dr David Henderson (University of Glasgow). 
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3.7 Microscopy 
3.7.1 Immunostaining and Confocal Imaging 
Adult rat ventricular myocytes were prepared as previously described, seeded onto 
coverslips at 50,000 cells per well of a 6 well TC plate and, depending on experiment, 
were infected with virus of interest (usually RI_epac or RII_epac). In PDE localisation 
experiments, non-infected myocytes were stained. Cells were fixed with ice cold methanol 
and incubated for 5 minutes at -20˚C, washed 3 times with PBS to remove any methanol 
residue and permeabilised in PBS containing 0.1 % Triton®X-100 for 5 minutes at room 
temperature whilst shaking. The slides were then washed with PBS and incubated for 30 
minutes with blocking buffer (PBS containing 1 % BSA) at room temperature. One or two 
primary antibodies were diluted to the desired concentrations (Table 3-1) in blocking 
buffer, 100 µL of the solution applied to parafilm, and coverslips laid face down onto the 
antibody for 2 hours at room temperature or left overnight at 4˚C. For each coverslip 
treated with primary antibody, an IgG control was also prepared, using equal amounts of 
the appropriate normal IgG.  
 
Coverslips were then washed three times for 10 minutes in PBS, and incubated with the 
appropriate fluorescently labelled secondary antibody ( 
Table 3-2). This step took place for either 1 hour at room temperature, or overnight at 4°C. 
Coverslips were washed once more in PBS and then mounted on 76 x 26 mm microscopy 
slides using MOWIOL® 4-88 reagent and left to dry in a 37 ºC oven for 1 hour then stored 
at 4˚C in the dark. 
 
Confocal images were acquired using a 63x Zeiss oil immersion objective on a Zeiss 
Pascal LSM510 laser-scanning confocal microscope (Carl Zeiss). An argon laser was used 
to excite 488nm fluorescently labelled secondary antibodies. Helium/neon lasers were used 
to excite 568nm fluorescently labelled secondary antibodies. Zeiss Pascal software was 
used to gather image files. 
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3.7.2 FRET based imaging 
Fluorescence Resonance Energy Transfer (FRET) is a non-radiative process of energy 
transfer from an excited donor fluorophore to an acceptor fluorophore. This phenomenon 
can only occur when the two fluorophores are in close proximity to one another. This 
technique has been exploited to generate genetically-encoded sensors to visualise cyclic 
adenosine monophosphate (cAMP) dynamics in intact living cells (Zaccolo et al. 2000). A 
FRET-based indicator of cAMP is usually composed of a cAMP-binding domain and the 
cyan and yellow variants of the green fluorescent protein, CFP and YFP respectively. 
Excitation of CFP (430 nm) results in the transfer of the excited state energy to YFP 
(emitting a signal at 545 nm). Both emissions are collected for analysis. Binding of cAMP 
to the sensor induces a conformational change which alters the distance between the two 
fluorophores thereby affecting the energy transfer between them. When this occurs only 
the CFP emission (480nm) is detected. FRET changes can be expressed as changes in the 
ratio between CFP emission (480 nm)/ YFP emission (545 nm) upon illumination at a 
wavelength that excites selectively the donor CFP (430 nm). Changes in FRET can be used 
in real-time imaging experiments as variations in FRET efficiency correlates with changes 
in cyclic nucleotide intracellular concentration. 
 
 
3.7.2.1 Imaging set up 
The basic FRET imaging setup consists of an epifluorescence microscope, a light source 
for excitation of the donor fluorophore, a beam splitter to separate acceptor and donor 
emission signals, a digital camera to collect the signals and a computer to store and analyse 
the data. 
The FRET imaging system used throughout this project is as follows: 
 
Microscope: Olympus IX81 inverted microscope. 
 
Light Source: Xenon Mercury mixed gas arc burner (MT-ARC/HG LG2076, Ushio). 
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Excitation Filters: CFP: excitation filter ET436/20x, dichroic mirror T455LP, (Chroma 
Technology). YFP: excitation filter ET500/30x, dichroic mirror T515LP (Chroma 
Technology). 
 
Emission Filters: CFP: emission filter ET480/40m; YFP: emission filter ET535/30m 
(Chroma Technology).  
 
Beam Splitter: Dichroic mirror 505DCLP, YFP emission 545 nm, CFP emission 480 nm 
(Chroma Technology). 
Light emitted by the sample comprises both CFP and YFP emission wavelengths. The 
dichroic mirror splits the emitted light in two beams. Wavelengths below 505 nm, which 
include CFP emission at 480 nm, are reflected and directed through a series of mirrors 
towards to the CFP emission filter. Wavelengths over 505 nm, which include YFP 
emission at 545 nm, pass through the dichoric and are directed to the YFP filter. 
 
Objective: Olympus PlanApoN, 60X, NA 1.42 oil, 0.17/FN 26.5  
 
Immersion Oil: Immersion oil "IMMERSOL" 518F , Carl Zeiss  
 
Camera: ORCA AG (model C4742-80-12AG, Hamamatsu Photonics K.K., Japan) and 
HAMAMATSU camera controller. 
 
Computer: Dell DE6700, 2.66 GHz Intel Core 2 Duo CPU, 3.50 GB RAM, 400 GB hard 
drive, Windows XP Professional version 2002  
 
Image acquisition and analysis: All devices of this imaging system, such as the shutter, 
the motorised filter wheel and digital camera are controlled by Cell^R software (Olympus 
BioSystems). 
Offline image analysis was performed using ImageJ free software. 
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3.7.2.2 FRET experimental procedure and data analysis 
Cardiomyocytes and CHO cells expressing a FRET-based sensor were used to monitor 
basal intracellular cyclic nucleotide concentration and changes in cyclic nucleotide 
concentration upon the addition of chosen stimuli. 
 
The day before the experiment, cells are seeded onto a 24 mm laminin coated coverslip as 
previously described and infected with appropriate FRET-based sensor (for this example a 
typical experiment using a cAMP FRET-based sensor will be explained). Cells were 
images around 18 hours after infection. 
 
The coverslip was firstly placed into a metal slide holder which, when sealed, creates a 
bath where stimuli can be directly added. The bath is filled with 900 μl of saline solution 
and maintained at room temperature (for CHO cells D-PBS was used instead). 
 
Before starting the experiment a standard protocol for all experiments was designed 
(detailed explanation of this protocol can be found in (Gesellchen et al. 2011). Briefly, the 
following parameters must be set and remain the same throughout each set of experiments: 
 
Binning: Most of the camera detection systems used for FRET have the ability to combine 
the information in adjacent pixel and make them into one effective superpixel. The benefit 
of binning is that there is a reduced noise in the signal. A binning of 1x1 means that each 
individual pixel is used as such; a binning of 2x2 means that an area of 4 adjacent pixels is 
combined into one larger pixel, and so on. The drawback of binning is the loss of 
resolution. In the case of 2x2 binning; there is a fourfold increase in signal (the four single 
pixel contributions), a twofold loss in resolution but a twofold improvement in signal-to-
noise. 
All experiments in this thesis have been acquired with binning 2x2. 
Exposure Time: The exposure time determines the period of time cells are illuminated and 
photons are collected and converted into charges for each channel. Optimal exposure time 
depends on the expression levels of fluorophores as well as the characteristics of the lamp, 
the optics and the camera. Generally an exposure time of 50 – 300 ms should be used, 
depending on the brightness of the sample. Increasing the exposure time allows the 
photons coming from the sample to accumulate and enhance the intensity of the image. At 
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the same time this will increase the photobleaching of the fluorophores. There is also the 
risk of saturation of pixel charges and any further change in the signal cannot be detected. 
Experiments in this thesis have been acquired at an exposure time of 200 ms. 
 
Time course and Number of Acquisitions: The frequency of acquisition defines the 
interval between each data recording. This time between acquisitions depends on the 
characteristics of the sensor and the kinetics being investigated, but the normal range is 2 – 
60 seconds. A short interval between illuminations may again result in photo-damaging of 
the cells and photo-bleaching of the signal. 
All experiments have been acquired with a frequency of 5 seconds. 
 
After these parameters have been set, the experiment can be started. 
A small drop of oil is added to the objective lens before mounting the coverslip. A bright 
(well infected) cell, which is well attached and not contracting, is selected to perform the 
experiment. 
 
Cell^R software allows for a live display of the ratio between the mean fluorescence 
intensity of each channel, so it is possible to estimate when the signal has stabilised before 
adding the stimulus (usually after 25 acquisitions). Further stimuli can be carefully added 
after each plateau phase. Only once the signal has stabilised after the final stimulus should 
the experiment be concluded. 
 
The first step in analysing the experiment is to split and align the images taken by the CFP 
and YFP channels (this and the following steps is conducted offline using ImageJ) 
resulting in a perfectly superimposed image. A region of interest (ROI) is drawn on the 
background area and another around the cell of interest. Mean intensities for each 
acquisition is calculated and both CFP and YFP are subtracted from the background 
intensities, reducing any artefacts.  
cAMP changes are expressed as: 
 
% 
 
Where ΔR = Rt2 – Rt1 
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Rt1 is the average of at least 5 ratio (ICFP/IYFP) values calculated before the addition of the 
stimulus; Rt2 is the average of at least 5 ratio values at the plateau phase of reached after 
the addition of the correspondent stimulus. R0 corresponds to ICFP/IYFP at basal FRET level. 
 
 
3.7.2.3 Buffers and compounds for FRET 
Saline Buffer Cell Solution 
NaCl 125 mM 
Hepes 20 mM 
Na3PO4 1 mM 
KCl 5 mM 
MgSO4 1 mM 
Glucose 5.5 mM 
CaCl2 1 mM 
pH7.4, filter sterilised and stored at 4˚C.  
 
 
Stimuli:  
Isoproterenol, cilostamide, rolipram, IBMX, atrial natriuretic peptide (ANP) and forskolin 
were all purchased from Sigma-Aldrich. Bay 60-7550 and S-Nitroso-N-acetyl-DL-
penicillamine (SNAP) were bought from Cayman Chem.  
 
 
3.8 Statistical analysis 
In this thesis, all experiments were performed with an n of 3, unless otherwise specified in 
the figure legend. Statistical significance was calculated using either an unpaired two tailed 
t-test in Microsoft Excel or by analysis of variance (ANOVA) using Graph Pad Prism 
software, as stated in the figure legend. A p value < 0.05 was considered significant.  
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4 Intracellular cAMP signalling 
dynamics in adult cardiac myocytes. 
 
 
4.1  Introduction 
3’, 5’- cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger that 
regulates many cellular functions including excitation contraction coupling (ECC). 
Stimulation of β-adrenergic receptors (β-ARs) activates adenylyl cyclases (ACs) to 
generate cAMP, and consequently activates protein kinase A (PKA), its main effector, 
which in turn phosphorylates several proteins involved in the ECC process. It is now well 
established that the cAMP/PKA signalling pathway is compartmentalised which results in 
tight control of the specificity of signalling. One widely reported mechanism relies on PKA 
binding to A kinase-anchoring proteins (AKAPs). AKAPs are multiscaffolding proteins 
that anchor PKA to specific intracellular locations in close proximity to specific 
modulators and targets. PKA must then be selectively activated and this requires that 
cAMP is produced in discrete compartments. Phosphodiesterase-mediated degradation of 
cAMP is another well documented mechanism; PDEs represent the only means of 
degrading cAMP within the cell, and are integral to the compartmentalisation of cAMP. 
Interestingly, it has also been revealed that PDEs have different intracellular localisations 
(Mongillo et al. 2004; Mongillo et al. 2006) and displacement of endogenous PDEs from 
their intracellular anchor sites results in their loss of control over specific cAMP pools 
(Terrin et al. 2006), thus demonstrating the importance of PDE localisation for maintaining 
cAMP microdomains and specificity of signalling. There are 5 cAMP PDE families in the 
heart, and although particular PDE isoforms have been linked with regulating the PKA 
phosphorylation of certain cardiac proteins involved in ECC, to date most of the details 
about which PDEs are responsible for the control of cAMP signalling in many subcellular 
compartments remain to be established.  
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Our laboratory has previously published that two PKA isoforms, PKA-RI and PKA-RII, 
define distinct subcellular compartments by binding to specific endogenous AKAPs (Di 
Benedetto et al. 2008). It was demonstrated that the PKA-RI and PKA-RII compartments 
have equal access to cAMP, as forskolin treatment resulted in a comparable rise in [cAMP] 
in the two compartments. In addition, IBMX stimulation revealed comparable levels of 
PDE activity in both PKA-RI and PKA-RII compartments. Interestingly, selective 
inhibition of PDE families showed that at basal levels, PDE2 activity is prominent in the 
PKA-RI compartment but very low in the PKA-RII compartment, whereas PDE4 exerts its 
activity mainly in the PKA-RII domain. No difference was detected between PKA-RI and 
PKA-RII upon PDE3 inhibition. At these locations, cAMP is generated selectively by 
different hormonal stimuli. In neonatal rat cardiomyocytes ISO was found, using FRET 
and FRAP imaging approaches, to generate a pool of cAMP that selectively activates 
PKA-RII over PKA-RI and lead to the phosphorylation of TnI, PLB, and β2-AR. In 
contrast, prostaglandin 1 (PGE1) selectively activates PKA-RI and does not increase 
phosphorylation of these targets (Di Benedetto et al. 2008).  
 
More recently our laboratory generated cGMP FRET based sensors targeted to the PKA-RI 
and PKA-RII compartments in neonatal cardiomyocytes to study the interplay between 
cAMP and cGMP (Stangherlin et al. 2011). Activation of sGC by S-nitroso-N-
acetylpenicillamine (SNAP) generated a comparable rise in cGMP in the PKA-RI and 
PKA-RII compartments. Interestingly, activation of pGC by ANP resulted in a 
significantly larger cGMP signal detected in the PKA-RII compartment. Myocytes were 
then transfected with cAMP biosensors RI_epac and RII_epac Stangherlin et al. reported 
that cGMP can modulate cAMP signalling in these subcellular compartments by regulation 
of PDE2 and PDE3. Selective pharmacological inhibition of PDE2 and PDE3 found that 
PDE2 activity is preferentially coupled to the PKA-RII compartment, such that activation 
of PDE2 by cGMP leads to a selective reduction of cAMP content in this compartment. 
PDE3 was shown to be mainly coupled to the PKA-RI compartment. The authors showed, 
using FRET imaging and a catalytically inactive mutant of PDE2A (dnPDE2A), that 
displacing endogenous PDE2 by overexpressing the mutant PDE is able to reverse the 
effect of SNAP on the PKA-RII compartment. This data indicates that an active PDE2 
associated with the PKA-RII compartment is responsible for the cGMP-dependent 
reduction of the cAMP response in this locale (Stangherlin et al. 2011). 
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The above studies, investigating cAMP signalling dynamics in the PKA-RI and PKA-RII 
subcompartments, have been conducted in neonatal myocytes, but have never before been 
investigated in adult cardiomyocytes. Adult myocytes are a better model for cardiac 
function, as neonatal myocytes tend to de-differentiate in vitro and loose some of the 
characteristics that myocytes present in the intact organ in vivo. And thus it is important to 
confirm findings using a model of adult myocytes. In addition, the role of individual PDEs 
in shaping the cAMP response elicited by the β-adrenergic stimulation in the PKA-RI and 
PKA-RII compartments is yet to be determined.  
In this study, therefore, the role of phosphodiesterases (PDE) families in the control of 
cAMP levels in the PKA-RI and PKA-RII compartments within primary cultured adult rat 
ventricular myocytes (ARVM) was investigated. 
 
 
 
Aims 
 Measure and compare cAMP dynamics in response to β-adrenergic stimulation in 
the PKA-RI and PKA-RII compartments. 
 Study the role of different PDE families in the modulation of the cAMP response to 
catecholamines at these locations. 
 
 
4.2  Results 
4.2.1 Expression of a cAMP FRET-based sensor and its 
localisation to the PKA-RI and PKA-RII 
compartments 
In order to investigate the in vitro cAMP signalling dynamics in specific subcellular 
compartments in living adult cardiomyocytes, a real-time FRET-based imaging approach 
was employed. The targeted sensors used in this study (RI_epac and RII_epac) are based 
on the cystosolic FRET-based sensor Epac1-camps, a genetically encoded cAMP sensor 
consisting of YFP and CFP fluorophores linked to the cAMP binding domain of Epac1 
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(Nikolaev et al. 2004). RI_epac and RII_epac were generated by fusing the 
dimerisation/docking domain from either PKA-RIα (amino acids 1 to 64) or PKA-RIIβ 
(amino acids 1 to 49) to the N terminus of the soluble Epac-1 sensor (Di Benedetto et al. 
2008) (Figure 4-1). Therefore, these sensors, when expressed in intact cells, will localise 
where PKA-RI and PKA-RII are normally situated within the cell. 
 
 
 
 
Figure 4-1. Schematic representation of RI_epac and RI_epac FRET-based cAMP sensors. 
 
 
 
To verify if RI_epac and RII_epac are targeted to different subcellular compartments in 
adult cardiomyocytes, co-localisation studies using immunostaining of sarcomeric 
reference proteins were performed. Adult rat ventricular myocytes (ARVM) transduced 
with a viral vector carrying the sensors, fixed, and immunostained with antibodies against 
alpha actinin. Myocytes were then analysed by confocal microscopy. As illustrated in 
Figure 4-2, both sensors show striated pattern, however RI_epac appears to have greater 
co-localisation with alpha actin compared to cells transduced with RII_epac. These 
findings are in agreement with previous work in neonatal cardiomyocytes (Di Benedetto et 
al. 2008), which found that RI_epac shows a more widespread localisation with overlay on 
both the Z and M sarcomeric lines whereas RII_epac was found mainly on the M line in 
this cell type. This localisation pattern for RII_epac may seem to make little sense as many 
targets of PKA-RII are reported to be close to the Z-line, for example t-tubules and 
junctional SR. One explanation is that there are a number of AKAPs which specifically 
bind PKA_RII, as discussed in detail in 1.7.1, which are distributed in other areas of the 
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myocytes for example AKAP13 and Myospyrn. Co-localisation analysis confirms that 
although the confocal images show PKA-RII as having M-line distribution, there is co-
localisation of this sensor at the Z-line (Figure 4-3).  In addition and as previously shown 
in NRCM, RII_epac showed a clear localisation to the nuclear membrane. These results 
confirm that RI_epac and RII_epac have the expected localisation in ARVM and that the 
two reporters localise to different subcellular compartments in this cell type.  
 
 
 
Figure 4-2. Localisation of RI_epac and RII_epac FRET sensors in ARVM. 
(A) Cardiomyocytes were transduced with the FRET sensor (green) and then stained for α-
sarcomeric actinin (red), followed by laser scanning confocal microscopic visualisation at 
60x magnification. These representative images show the different localisation of the 
sensors in adult myocytes. (B) Representative line intensity profiles (as indicated by a white 
line on Fig A) of ARVM transduced with RI_epac or RII_epac (green) and stained with α- 
actinin (red). 
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To more rigorously assess whether the variation in sensor localisation is significantly 
different, and therefore confirm that RI_epac and RII_epac are targeted to different 
compartments within the adult cardiomyocyte, the Pearson correlation coefficient (PCC) 
was calculated (ImageJ with JACoP). The Pearson coefficient (r) quantifies the correlation 
between pixel intensity of the two channels measured. r values range between -1 and +1. A 
value of -1 indicates that when one channel signal increases, the other decreases 
accordingly (perfect negative correlation), and a value of +1 indicates that both channel 
signals increase in a similar ratio (perfect correlation) (Adler and Parmryd 2010).  
Figure 4-3, shows the PCC calculated using the fluorescence images acquired at the 
confocal microscope. The coefficient value was significantly higher in RI_epac than 
RII_epac (RI_epac: 0.789 ± 0.03; RII_epac: 0.596 ± 0.02, p <0.001), confirming a 
statistical difference in the localisation of these sensors in adult cardiomyocytes. These 
values also can be expressed as √PCC to give the percentage of correlation between sensor 
and α-actinin (RI_epac: ~89%; RII_epac: ~77%).  
 
 
 
 
Figure 4-3. Summary of colocalisation statistics.  
Pearson colocalisation coefficient was calculated using the JACOP plugin and Image J 
software for both sensors. RI_epac n = 15; RII_epac n = 13. Error bars represent SEM. Two 
tailed; paired t-test, *** p<0.001. 
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4.2.2 Characterisation and properties of RI_epac and 
RII_epac in adult myocytes. 
To explore cAMP levels in the subcellular compartments where PKA-RI and PKA-RII 
normally reside, a FRET-based imaging approach was utilised. FRET allows for high 
spatial resolution and real-time detection of cAMP signalling dynamics in intact living 
cells. 
 
ARVM were transduced with an adenovirus vector carrying RI_epac or RII_epac and 
imaged using an epifluorescent microscope the following day (Figure 4-4A). Cells were 
then challenged with cAMP raising stimuli in order to record the amplitude and kinetics of 
FRET change in the PKA-RI and PKA-RII subcellular compartments. Changes in 
intracellular concentrations of cAMP can be determined from changes in FRET. FRET can 
be expressed as the ratio (R) of CFP emission intensity over YFP emission intensity 
following excitation of the cell at 440 nm (R = ICFP/IYFP). Changes in this FRET ratio were 
expressed as the increase in CFP/YFP ratio over the CFP/YFP ratio at time zero (R0), as 
described in the Materials and Methods (3.7.2). An example of a typical FRET experiment 
utilising the RI_epac and RII_epac sensors is illustrated below (Figure 4-4B) and shows 
the differences in the FRET change obtained upon addition of number of stimuli resulting 
in elevated levels of cAMP in the two compartments.  
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Figure 4-4. An example of a FRET experiment in cardiomyocytes transduced with the 
targeted cAMP sensors. RI_epac and RII_epac. 
(A)Image of ARVM expressing RI_epac (left) or RII_epac (right). (B) Representative graph of 
kinetics of FRET change detected in response to 100 nM Isoproterenol, 10 μM IBMX and 25 
μM forskolin recorded in ARVM expressing RI_epac (blue) or RII_epac (red).  
 
 
In order to assess whether there was a difference in the basal levels of cAMP in the PKA-
RI compartment compared to the PKA-RII compartment, a number of FRET images of 
ARVM expressing each sensor were collected. The basal FRET values were calculated as 
ICFP/ IYFP upon excitation at 440 nm, where ICFP is the intensity of CFP emission and IYFP is 
the intensity of YFP emission. The results show (Figure 4-5) that the basal level of cAMP 
Chapter 4 – Results 
 
129 
in the PKA-RI and PKA-RII compartments is not statistically different, indicating there is 
no difference in intracellular cAMP levels in these two subcellular regions in unstimulated 
myocytes. 
 
 
 
 
Figure 4-5. Summary of the basal ICFP/IYFP ratio values detected in the ARVM transduced with 
RI_epac or RII_epac.  
RI_epac: R0 = 0.547 ± 0.007, n = 27; RII_epac: R0 = 0.566 ± 0.009, n = 25. Error bars represent 
SEM. Two tailed; paired t-test, ns. 
 
 
Next, the cAMP response generated in the two compartment by -adrenergic receptor 
stimulation was investigated (Figure 4-6). Activation of β-adrenergic signalling was 
achieved by the addition of the synthetic β-agonist ISO (100 nM) and resulted in an 
increase in cAMP in both compartments. Interestingly, the rise in cAMP observed in the 
PKA-RII compartment of the ARVM was significantly higher than that in the PKA-RI 
compartment. To explore whether there was a difference in phosphodiesterases activity in 
the two compartments after β receptor stimulation, myocytes were then challenged with 
100 μM 3-isobutyl-1-methylanxthine (IBMX), a non-selective PDE inhibitor. There was an 
increase of cAMP in both compartments, which resulted in similar intracellular levels after 
addition. In order to reach the maximal FRET change (ΔR/R0 max) in these sensors, a 
saturating concentration of 25 μM Forskolin (FRSK), an activator of adenylyl cyclase 
which stimulates cAMP production was administered to the myocytes. The magnitude of 
response detected was similar for both FRET reporters, indicating that the two probes give 
the same maximal FRET change at signal saturation. As the sensors have the same 
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dynamic range, any variations recorded between them can be assumed to reflect a 
difference in cAMP levels rather than a difference in probe performance. 
 
 
 
 
 
Figure 4-6. Summary of FRET measurements of cAMP levels in ARVM expressing RI_epac 
or RII_epac. 
All experiments were performed as following; 100 nM Isoproterenol to stimulate β-
adrenoceptors to produce cAMP, 100 μM IBMX to inhibit PDEs and finally 25 μM Forskolin to 
saturate the sensor. ISO: RI_epac: ΔR/R0 = 4.133 ± 0.221 %, n = 26; RII_epac: ΔR/R0 = 6.204 ± 
0.215 %, n = 31. IBMX: RI_epac: ΔR/R0 = 9.376 ± 0.311 %, n =26; RII_epac: ΔR/R0 = 10.112 ± 
0.252 %, n = 27. FRSK: RI_epac: ΔR/R0 = 10.727 ± 0.480 %, n =11; RII_epac: ΔR/R0 = 11.17 ± 
0.465 %, n = 8. Statistical significance calculated by two way ANOVA with Bonferroni’s post-
test, * p<0.05, *** p<0.001. 
 
 
From the summary of these experiments, there did appear to be some variation in cAMP 
generation between the PKA-RI and PKA-RII subunits which supported previous work 
done in the lab using neonatal myocytes (Di Benedetto et al. 2008). The kinetic data for 
RI_epac and RII_epac also indicated there may be dissimilarity in the way cAMP is 
Chapter 4 – Results 
 
131 
generated at these locations. The speed of FRET change after each stimulus was calculated 
by the formula speed = ΔFRET/Δt, where the FRET ratio detected at the first 5 time-points 
after the given stimulus was divided by the time in seconds (Figure 4-7). After the addition 
of ISO into the bath, the RII_epac sensor reacted significantly more quickly (1.3 ± 0.2 
/second) compared with RI_epac sensor (0.8 ± 0.1 /second; p < 0.05). However after the 
addition of IBMX, there was no difference in the speed of FRET change between RI_epac 
(1 ± 0.1 / second) and RII_epac (1 ± 0.2 / second). This indicates there is not only a greater 
level of cAMP production in the PKA-RII compartment after β-adrenergic stimulation, but 
the rate of cAMP level increase is quicker in this location. In addition, the above results 
suggest that such difference may at least in part depend on a different contribution of PDEs 
to the kinetics and amplitude of cAMP change in the two compartments. 
 
 
 
 
 
Figure 4-7. Summary of speed of FRET change (ΔFRET/ Δt) after each stimuli.  
ARVM expressing either RI_epac or RII_epac were stimulated with Isoproterenol (100 nM) 
and then IBMX (100 μM) and the rate of FRET change after each stimuli was calculated. ISO: 
RI_epac n = 26; RII_epac n = 31. ISO + IBMX: RI_epac n = 26; RII_epac n = 27.  Statistical 
significance calculated by two way ANOVA with Bonferroni’s post-test, * p<0.05. 
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4.2.3 Phosphodiesterase-mediated regulation of cAMP in 
subcellular compartments in cardiac myocytes. 
Although there was no significant difference in the cAMP levels after non selective PDE 
inhibition (ISO and IBMX treatment) seen in the summary of FRET experiments 
conducted (Figure 4-6), it was important to look closer at the contribution that PDEs may 
play in the control of cAMP level. This was done by taking the final response detected 
upon addition of ISO + IBMX treatment in these cells and by subtracting the ISO response 
(Figure 4-8A) to get a clearer idea of the PDEs contribution in determining cAMP levels in 
the PKA-RI and PKA-RII compartments. In the PKA-RI compartment there was a 
significantly greater increase in cAMP intensity compared with the PKA-RII compartment, 
indicating there was a significantly greater contribution of PDEs acting in the PKA-RI 
compartment compared with the PKA-RII compartment. To explore whether or not this 
was due to a higher basal level of PDEs activity in the PKA-RI compartment, ARVM 
transduced with the targeted sensors were challenged with 100 μM IBMX alone (Figure 
4-8B). This treatment was found to induce a cAMP increase which was comparable in the 
two locations. These results suggest that it is only after β-adrenoceptor stimulation and 
cAMP generation that this disparity in the PDE activity in the two compartments can be 
identified. One possible explanation for this is that a number of PDE, including PDE3 and 
PDE4, have PKA phosphorylation sites (Omori and Kotera 2007) and therefore activation 
of PKA by ISO stimulation leads to the modification of PDE activity in a compartment 
specific manner. 
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Figure 4-8. The contribution of phosphodiesterases (PDEs) in ARVM transduced with 
RI_epac or RII_epac. 
(A) Myocytes are stimulated first with 100 nM Isoproterenol, then IBMX (100 μM). The 
contribution of the IBMX response alone is shown here. (B) Myocytes are treated with IBMX 
without Isoproterenol. IBMX after ISO: RI_epac n =26; RII_epac n = 27. IBMX alone: RI_epac: 
n =5; RII_epac n = 6. Error bars represent SEM. Two tailed; paired t-test, *** p<0.001. 
 
 
In order to identify which family of phosphodiesterases may be controlling each 
subcellular location which could possibly account for the higher PDE activity in the PKA-
RI compartment; myocytes were first pre-treated with a selective PDE inhibitor before 
stimulation of cAMP production with 100 nM ISO. Among the cAMP-hydrolysing PDEs 
expressed in the heart, selective inhibitors for PDE2, PDE3 and PDE4 but not for PDE1 
and PDE8 are commercially available, so the analysis focused on the former. In the 
experiments investigating the effect of PDE2, ARVM were incubated for 10 minutes with 
50 nM of the PDE2 inhibitor Bay 60 7550 at 37˚C before imaging. Cells were then 
challenged as before with ISO, IBMX and then finally with Forskolin to achieve the 
maximal response. Under basal conditions (Figure 4-9A), there was a comparable level of 
cAMP in each condition. Upon ISO stimulation (Figure 4-9B), there was a greater cAMP 
increase in PKA-RII compartment than the PKA-RI compartment in control myocytes. 
Pre-treatment of the myocytes with Bay 60-7550 resulted in a significantly greater increase 
in cAMP in both compartments compared to controls. There was a 2 fold increase in the 
amount of cAMP generated in the PKA-RI compartment and a 1.3 fold increase in the 
PKA-RII compartment upon PDE2 inhibition. In addition, PDE2 inhibition abolished the 
difference between the PKA-RI and PKA-RII compartments. Maximal FRET responses 
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were achieved by saturating the sensors with 100 μM IBMX and 25 μM forskolin (RI_epac 
control: ΔR/R0 max =11.042 ±0.413, n =9; RII_epac control: ΔR/R0 max = 11.170 ± 0.465 
n = 8; RI_epac + Bay 60-7550: ΔR/R0 max =10.287 ±0.285, n =8; RII_epac + Bay 60-
7550: ΔR/R0 max = 10.118± 0.433 n = 5). These results indicate that although PDE2 is 
present in both the PKA-RI and PKA-RII compartments in the adult myocytes, after β-AR 
stimulation PDE2 activity appears to higher in the PKA-RI compartment compared to the 
PKA-RII compartment. 
 
 
 
 
Figure 4-9. Summary of FRET change upon the selective inhibition of PDE2.  
(A)Summary of basal cAMP levels in ARVM in the presence or absence of PDE2 inhibitor 
Bay 60-7550 (50 nM). RI_epac control n =9; RII_epac control n = 9; RI_epac + Bay 60-7550 n 
=18; RII_epac + Bay 60-7550 n = 12. (B) Summary of FRET change induced by 100 nM 
isoproterenol in the presence or absence of Bay 60-7550. RI_epac control: ΔR/R0 =3.47 ± 
0.152 %, n =8; RII_epac control: ΔR/R0 = 5.871 ± 0.405 %, n = 16; RI_epac + Bay 60-7550: 
ΔR/R0 =7.616 ± 0.528 %, n =10; RII_epac + Bay 60-7550: ΔR/R0 = 7.633 ± 0.427 %, n = 9 
Statistical significance calculated by two way ANOVA with Bonferroni’s post-test, *** 
p<0.001.  
 
 
To explore the local contribution on the control of cAMP levels of the PDE3 family of 
phosphodiesterases, adult myocytes were pre-incubated with 10 μM cilostamide, a 
selective PDE3 inhibitor. Results similar to PDE2 inhibition at basal levels of cAMP were 
obtained with cilostamide, and there was no significant differences between the groups 
measured (Figure 4-10A). As a control again the amount of cAMP generated in the two 
compartments upon β-adrenergic stimulation was measured, before comparing these 
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results with ARVM which had been pre treated with cilostamide and stimulated with ISO 
(Figure 4-10B). It was found that PDE3 inhibition only had an effect on the level of cAMP 
generated in the PKA-RI compartment, with a 1.4 fold increase in cAMP production. The 
maximal FRET response was measured again in the presence of this selective inhibitor 
(figure not shown) and it was found that PDE3 inhibition had no effect on the maximal 
FRET change at saturation (RI_epac control: ΔR/R0 max =10.281 ±0.536, n =7; RII_epac 
control: ΔR/R0 max = 10.264 ± 0.363 n = 10; RI_epac + cilostamide: ΔR/R0 max =9.051 
±0.449, n =10; RII_epac + cilostamide: ΔR/R0 max = 9.198± 0.550 n = 7). These results 
indicate that PDE3 controls a pool of cAMP which is functionally coupled to the PKA-RI 
compartment alone. 
 
 
 
 
Figure 4-10. Summary of FRET change upon the selective inhibition of PDE3. 
(A) Summary of basal cAMP levels in ARVM in the presence or absence of PDE3 inhibitor 
cilostamide (10 μM). RI_epac control n =7; RII_epac control n = 10; RI_epac + cilostamide n 
=9; RII_epac + cilostamide n = 7. (B) Summary of FRET change induced by 100 nM 
isoproterenol in the presence or absence of cilostamide. RI_epac control: ΔR/R0 =4.402 ± 
0.276 %, n =8; RII_epac control: ΔR/R0 = 5.634 ± 0.276 %, n = 11; RI_epac + cilostamide: 
ΔR/R0 =6.23 ± 0.541 %, n =11; RII_epac + cilostamide: ΔR/R0 = 5.884 ± 0.834 %, n = 8. 
Statistical significance calculated by two way ANOVA with Bonferroni’s post-test, *p<0.05, ** 
p<0.01. 
 
 
The PDE4 family is expressed at high levels in the heart (Mongillo et al. 2004) and 
therefore it is important to investigate the role of this family in compartmentalised cAMP 
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signalling. This was achieved by selectively inhibiting all PDE4 isoforms by pre treating 
the cells for 10 minutes with 10 μM rolipram. As with the other selective inhibitors, 
rolipram incubation had no effect on basal cAMP levels in adult myocytes (Figure 4-11A). 
Upon addition of 100 nM ISO in control myocytes (Figure 4-11B) there was a higher 
generation of cAMP in the PKA-RII compartment compared to the PKA-RI compartment. 
In myocytes which had been treated with rolipram before imaging there was an increased 
level of cAMP in both compartments compared with control cells. Results were similar to 
those found in PDE2 with a larger increase in the PKA-RI compartment (1.8 fold increase) 
than recorded in the PKA-RII compartment (1.3 fold increase). Again this indicates that 
although PDE4 isoforms are found in both locations, their effect is predominant in the 
PKA-RI compartment. The maximal FRET response was measured in the presence of 
rolipram (figure not shown) and it was found that PDE4 inhibition which had no 
significant effect on the maximal FRET change at saturation (RI_epac control: ΔR/R0 max 
=10.281 ±0.536, n =7; RII_epac control: ΔR/R0 max = 10.264 ± 0.363 n = 10; RI_epac + 
rolipram: ΔR/R0 max = 8.697 ± 0.753, n =7; RII_epac + rolipram: ΔR/R0 max = 10.522 ± 
0.801 n = 7).  
However, on comparison of the ISO stimulated ARVM pre-treated with rolipram and the 
saturating response or ARVM pre-treated with rolipram, it was found that there was no 
significant difference in the PKA-RI compartment. This suggests that the ISO + rolipram 
response saturated the response in this sensor. No valid conclusions can be drawn for the 
PDE4 activity in the PKA-RI compartment of ARVM.   
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Figure 4-11. Summary of FRET change upon the selective inhibition of PDE4. 
(A) Summary of basal cAMP levels in ARVM in the presence or absence of PDE4 inhibitor 
rolipram (10 μM). RI_epac control n =7; RII_epac control n = 10; RI_epac rolipram n =9; 
RII_epac rolipram n = 7. (B) Summary of FRET change induced by 100 nM isoproterenol in 
the presence or absence of rolipram. RI_epac control: ΔR/R0 =4.152 ± 0.239 %, n =10; 
RII_epac control: ΔR/R0 = 5.838 ± 0.299 %, n = 13; RI_epac rolipram: ΔR/R0 =7.512 ± 0.68 %, n 
=7; RII_epac rolipram: ΔR/R0 = 7.733 ± 0.643 %, n = 7. Statistical significance calculated by 
two way ANOVA with Bonferroni’s post-test, *p<0.05, **p<0.01; *** p<0.001. 
 
The above figures show that selective inhibition of each family has no effect on basal 
cAMP, nor does IBMX treatment at basal level. This could be due to compensation by 
other PDE families controlling the compartment which have not been inhibited (i.e PDE8 
which is IBMX insensitive). It is only after β-AR stimulation that any differences in PDE 
activity are observed. However, Mika and colleagues have shown that in ARVM selective 
inhibition of PDE2, 3 and 4 under basal conditions does have an effect on cAMP and ECC. 
The authors show that selective inhibition of PDEs results in an increase in sarcomere 
shortening and the calcium transient at basal levels as well as after the addition of 1 nM 
ISO (Mika et al. 2013). Measurements were recorded in isolated myocytes loaded with 5 
µM Fura-2 AM at stimulated at a frequency of 0.5 Hz before determining changes in 
sarcomere length and Fura-2 ratio at 512 nm using an IonOptix system. Although this 
study and Mika et al. investigate the impact of selective PDE inhibition in ARVM and 
utilise the same inhibitors at similar concentrations, this thesis studies the impact of PDEs 
in specific compartments deep within the cardiomyocyte whereas Mika and co-workers 
focus on the functional effects these inhibitors have on ECC and do not record the levels of 
cAMP.  It is possible that there may be an effect on global cAMP which could impact ECC 
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in the cell, however no changes recorded by FRET in either compartment. It has been 
shown that more than one PDE family controls the PKA-RI and PKA-RII compartments, 
therefore it is possible that one family may try to compensate for another when its activity 
is impaired to maintain the correct level of cAMP required for normal function.   
 
 
Figure 4-12 provides a summary of the above 3 experiments investigating the PDEs that 
are responsible for controlling the cAMP signalling in the PKA-RI and PKA-RII 
subcellular compartments.  At the PKA-RI location, PDE2, PDE3 and PDE4 all seem to 
play a role in the control of cAMP signalling. PDE3 appears to have no effect in the PKA-
RII compartment where control of cAMP hydrolysis appears to be mediated solely by 
PDE2 and PDE4. 
 
 
 
 
Figure 4-12. Summary of experiments recording effect of selective PDE inhibition on ISO 
stimulation. 
ARVM were transduced with adenovirus containing a targeted FRET-based sensor and 
preincubated for 10 minutes with the selective PDE inhibitor. A. Effect of selective PDE 
inhibition upon ISO stimulation (100 nM) in the PKA-RI compartment. B. Effect of selective 
PDE inhibition upon ISO stimulation (100 nM) in the PKA-RII compartment. Statistical 
significance calculated by one way ANOVA with Dunnett’s post-test, * p<0.05, *** p<0.001. 
Chapter 4 – Results 
 
139 
4.3  Conclusions 
In this study, the cAMP signalling dynamics within distinct subcellular compartments in 
adult myocytes was investigated. The involvement of PDEs in regulating the specificity of 
signalling at these locations was also explored. In order to investigate cAMP signalling in 
microdomains of the adult myocytes, the genetically encoded FRET-based sensors targeted 
to the PKA-RI and PKA-RII compartments (RI_epac and RII_epac respectively) were 
cloned into adenoviral vectors allowing them to be expressed in ARVMs. 
Immunofluorescence revealed that, as previously shown in neonatal myocytes, when 
expressed in ARVM RI_epac and RII_epac present diverse subcellular localisations. 
RI_epac had a broad striated pattern overlaying with both the M and Z sarcomeric lines, 
whereas RII_epac shows tighter striated localisation with a very strong signals in 
correspondence of the M line and a much weaker localization overlaying the Z line, 
confirming previous findings in NRVMs (Di Benedetto et al. 2008).  
A real time FRET based imaging approach with these targeted cAMP sensors was then 
utilised to study the cAMP signalling dynamics in adult myocytes upon β-AR activation. 
The results obtained showed that cAMP production upon addition of 100 nM ISO, a β-AR 
agonist, was significantly higher in the PKA-RII compartment compared with the PKA-RI 
compartment. No change was detected in the basal cAMP-hydrolytic activity but the 
contribution of PDEs activity after β-AR stimulation was significantly higher in the PKA-
RI compartment. It was hypothesised that the reason for the lower cAMP generation in the 
PKA-RI compartment may be due to there being a higher activity of endogenous PDEs 
upon β-AR stimulation. 
 
To explore these findings, selective inhibitors for a number of cardiac PDEs families were 
employed to try to identify the PDE isoforms responsible for the regulation of cAMP 
signalling at each subcellular compartment. Interestingly it was found that in the PKA-RI 
compartment PDE2 and PDE4 families were the main modulators of signalling with a 
smaller but significant contribution from the PDE3 family, whereas cAMP in the PKA-RII 
compartment was hydrolysed by PDE2 and PDE4, but not PDE3. This data supports work 
conducted in rat neonatal myocytes showing that PDE2 and PDE4 play a key role in 
modulating the cAMP response to β-AR stimulation, whereas PDE3 seems to exert only a 
marginal effect(Mongillo et al. 2004; Mongillo et al. 2006). Forskolin treatment revealed 
that PDE3 and PDE4 provide a similar contribution to determining intracellular cAMP 
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concentration in myocytes (Mongillo et al. 2004). The findings in this thesis further 
support the hypothesis of a compartmentalisation of cAMP signalling in adult myocytes, as 
well as the importance of PDE2 and PDE4 in the regulation of cAMP, generated in 
response to β-AR stimulation, in areas where different subsets of PKA are located. These 
data illustrate that local pools of cAMP generated in different subcellular compartments of 
the cardiomyocyte are individually regulated by different PDE isoforms.
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5 cAMP signalling dynamics in an in 
vitro model of cardiac hypertrophy. 
 
 
5.1  Introduction 
Cardiac hypertrophy is an adaptive response to an increase in biomechanical stress 
resulting in an increase in the size of individual myocytes while the number of cells 
remains unchanged. Hypertrophy is also associated with increased risk of sudden death and 
progression to heart failure. Cardiomyocytes hypertrophy is defined by a significant 
increase in myocyte size, enhanced protein synthesis, a higher organisation of the 
sarcomere and reactivation of the fetal gene programme. These fetal genes include 
natriuretic peptides (Atrial, Brain and C-type natriuretic peptide), α-skeletal actin and β-
myosin heavy chain (β-MHC), which are commonly used as molecular markers for cardiac 
hypertrophy (Chien et al. 1991; Yazaki et al. 1993). 
 
One of the most prominent characteristics in hypertrophic hearts is a marked 
desensitisation and downregulation of β-ARs which can be attributed to sustained 
catecholamine stimulation which leads to heart failure (Bristow 1998). Under normal 
conditions catecholamines released from the sympathetic nervous system stimulate the β-
adrenergic receptors (β-ARs) which activate adenylyl cyclases (ACs) to generate cAMP. 
cAMP is a ubiquitous second messenger essential for the regulation of a vast array of 
intracellular processes including excitation-contraction coupling (ECC) by managing the 
force, frequency and duration of contraction. In ventricular myocytes cAMP produced in 
response to catecholamine stimulation of β-ARs consequently activates protein kinase A 
(PKA), which in turn phosphorylates several proteins involved in the ECC process, thereby 
increasing contractility (inotropy) and accelerating relaxation (lusitropy) (Bers 2008). 
However in cardiomyocyte hypertrophy there is impairment of the β-AR/ cAMP/ PKA 
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signalling resulting in reduced contractile function (Tse et al. 1978; Tse et al. 1979; 
Engelhardt et al. 1999; Zhang et al. 2005; Osadchii 2007; Abi-Gerges et al. 2009). 
Cyclic nucleotide phosphodiesterases (PDEs) are the only known enzymes to regulate 
intracellular concentrations of cAMP by continuously hydrolysing the molecule (Osadchii 
2007). Therefore PDEs can regulate contractility in response to different stimuli, for 
example β-ARs and natriuretic peptide receptors stimulation (Muller et al. 1990; Nishikimi 
et al. 2006). PDEs have also been reported to participate in cardiac remodelling, where 
modifications in cardiac and aortic PDE specific activity occur during the onset of heart 
disease (Lugnier and Stoclet 1979). 
 
For these reasons, PDE inhibitors have been widely used for a number of years as 
treatment for patients with heart failure. The action of some PDE inhibitors, such as the 
selective PDE 3 inhibitor milrinone, have been found to be initially beneficial to patients, 
however long term use of the drug is detrimental to the heart (Jaski et al. 1985; Movsesian 
and Alharethi 2002). This contradictory effect of cAMP enhancement by PDE inhibition 
can be explained by the fact that cAMP signalling is compartmentalised. This means that 
multiple spatiotemporally distinct pools of cAMP can modulate specific cellular functions 
and it has been reported that each individual pool of cAMP generated is regulated by 
different PDE families (Movsesian and Bristow 2005). In the context of heart disease, 
raising cAMP levels in one branch of the signalling pathway may be beneficial, but raising 
levels throughout the cell and activating a multitude of different pathways may have 
negatives effects. 
 
Until now only a few studies have investigated the role of cAMP signalling and PDE 
activity in cardiac hypertrophy, and the results have been contradictory. Abi-Gerges and 
colleagues investigated β-adrenergic regulation of cardiac contractility and cAMP PDE 
expression in single cardiomyocytes following induction of cardiac hypertrophy (Abi-
Gerges et al. 2009). In this study myocytes were isolated from Wistar rats where 
hypertrophy had been induced by surgical thoracic aortic banding (TAC). Cyclic 
nucleotide-gated channels (CNG) were over expressed in sham and hypertrophic 
cardiomyocytes and, using patch clamp recordings of the associated current, a 
measurement of subsarcolemmal cAMP was produced. The authors reported a loss in total 
cAMP hydrolytic activity due to a reduction in PDE3 and PDE4 activities in hypertrophied 
myocytes. Western blot analysis showed a decrease in the expression of PDE3A, PDE4A 
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and PDE4B whereas PDE4D remained unchanged in hypertrophic cells (Abi-Gerges et al. 
2009). More recently, Mokni et al. published their work investigating the activities of 
different PDE families where hypertrophy had been induced in Wistar rats by chronic 
infusion of angiotensin II. Utilising a cAMP-PDE activity assay (Thompson and Appleman 
1971), Mokni and colleagues described a marked increase in PDE4 hydrolysing activity in 
hypertrophic myocytes, whereas PDE1, PDE2 and PDE3 activities were unaffected. 
However another PDE assay investigating cGMP hydrolysing activity found an increase in 
PDE1, PDE2 and PDE5 activities in the same type of cells. Real time PCR revealed, 
somewhat in contradiction to the PDE activity assay results, that there was a decrease in 
mRNA levels of PDE4D and no change in PDE2A, PDE3A, PDE3B, PDE4A, PDE4B or 
PDE4C. Increases were recorded in PDE1A, PDE1C and PDE5A mRNA levels, 
supporting the cGMP PDE activity assay results (Mokni et al. 2010). 
 
Although these studies have contrasting results, it should be noted that even though both 
investigated PDE activity in hypertrophic myocytes, different animal models of 
hypertrophy were used. Mokni et al. also used cell lysates to conduct the PDE activity 
assays, whereas Abi-Gerges and co-workers used intact cardiomyocytes; however the 
experimental set up in the latter case would only allow monitoring of the PDE activity of 
subsarcolemmal cAMP. As yet there are no studies investigating PDE activity of cAMP 
compartmentalised signalling in hypertrophic adult cardiomyocytes that investigate 
subcellular compartments that are deeper than the subsarcolemmal space.  
 
In this study an in vitro model of cardiac hypertrophy was set up in a primary culture of 
isolated adult ventricular myocytes (ARVM) from Wistar rats. cAMP signalling dynamics 
were studied at defined macromolecular complexes organised by AKAPs within the 
cardiomyocyte using a real time imaging approach and genetically encoded FRET-based 
sensors (RI_epac and RII_epac) targeted to the locations where PKA-RI and PKA-RII 
normally reside via their interaction with AKAPs. 
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Aims 
 Establish an in vitro model of norepinephrine (NE)-induced cardiac hypertrophy in 
adult rat ventricular myocytes (ARVM).  
 Measure and compare cAMP dynamics in response to β-adrenergic stimulation in 
the PKA-RI and PKA-RII compartments in hypertrophic myocytes and establish 
whether there are differences in local cAMP signalling compared to control 
myocytes. 
 Study the role of different PDE families in the modulation of the cAMP response to 
catecholamines at these locations in hypertrophic ARVM compared to control cells. 
 
 
 
 
5.2  Results 
5.2.1 Norepinephrine induced hypertrophy in an adult 
myocyte in vitro model of cardiac hypertrophy. 
It has been previously reported that norepinephrine (NE) plays a key role in the 
development of some in vivo models of cardiac hypertrophy (Gans and Cater 1970; Marino 
et al. 1991; Tsoporis et al. 1998). Simpson et al. showed that primary cultured neonatal 
cardiomyocytes maintained in serum-free media and treated with NE undergo hypertrophic 
growth (Simpson et al. 1982). The development of the hypertrophic phenotype upon NE 
stimulation was assessed by measuring changes in myocyte size, total cell protein content, 
myocyte surface area and cell volume. Biochemical studies in spontaneously hypertensive 
rats (SHR) have revealed increased NE levels in the blood as well as an accelerated NE 
turnover in the heart (Nagatsu 1974; Nagaoka and Lovenberg 1976). More recently NE 
stimulation has been shown to induce cardiac hypertrophy in adult rat ventricular myocytes 
(ARVM) (Ikeda et al. 1991; Amin et al. 2001; Xiao et al. 2001; Kuster et al. 2005; 
Thandapilly et al. 2011). Ikeda et al. demonstrated that exposure of ARVM to NE caused a 
significant increase in [
3
H] leucine incorporation and total protein content (Ikeda et al. 
1991). 
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This model of cardiac hypertrophy was chosen as the use of cultured myocytes allows for 
the analysis of specific variables at a cellular level without interactions from other cell 
types, as would normally occur in an in vivo or ex vivo model. NE-treatment of ARVM is 
also an easy and highly reproducible method to induce cardiac myocyte hypertrophy in 
vitro. Hypertrophic growth is also quick (6-8 hours) using this method which is important 
as isolated adult myocytes do not undergo division and only survive a few days in culture 
medium, without the addition of drugs to inhibit contraction. Butanedione monoxime 
(BDM) is one example of a stimulus which inhibits myosin ATPase and protects the 
myocardium from damage. BDM has been extensively used in the isolation and culture of 
mouse myocytes (Kivisto et al. 1995). However, it acts as a non-specific phosphatase in 
the culture medium and this may lead to significantly altered cellular electrical properties 
(Verrecchia and Herve 1997; Watanabe et al. 2001). 
 
In the first part of this study a protocol to induce hypertrophic growth of adult 
cardiomyocytes in culture was developed. Isolated ARVM were treated overnight with 1 
μM NE in serum free M199 medium. 
To assess whether this method induced cardiac hypertrophy in cultured ARVM, several 
parameters were measured: 
 
Cell size: transmitted light images of hypertrophied and control cardiac myocytes from 
different culture preparations were randomly acquired and the average cell length and 
longitudinal section area (length x width) of ARVM were calculated using Image J 
software (Beltrami et al. 2003; Gupta et al. 2005; Banyasz et al. 2008; Miller et al. 2009; 
Thandapilly et al. 2011). At the imaging set up used for these experiments, one pixel 
corresponds to 0.07 µm when images are acquired using a 40X objective. 
 
Cell growth (Cell Index): The xCELLigence technology allows a quantitative 
measurement of the cell size through real-time cell-electronic sensing (RT-CES) 
(Vistejnova et al. 2009; Sin et al. 2011). Cardiomyocytes increase in cell volume in 
response to stress. This method allowed us to observe the change in impedance which is 
automatically converted to cell index and provides quantitative measurements of cell size. 
Fetal cardiac gene program: Reactivation of the fetal gene program is a characteristic 
feature of hypertrophied and failing hearts. Fetal cardiac genes Atrial Natriuretic Peptide 
(ANP), Brain Natriuretic Peptide (BNP) and skeletal α-actin mRNA levels were measured 
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by performing real-time PCR and values were normalised to an invariant endogenous 
control (in this study 18S rRNA was used as the control) to correct for sample variations in 
RT-PCR efficiency and errors in sample quantification. Real-time PCR was performed in 
three biological replicates and an average was taken. n = number of technical replicates 
(minimum of 3). 
 
As illustrated below (Figure 5-1), myocytes treated overnight with 1 μM NE showed a 
significant increase in cell size. Longitudinal section area was significantly greater (1.54 
fold) in NE treated cells. The degree of hypertrophy detected is comparable to values that 
have previously been reported by a number of authors (Amin et al. 2001; Miller et al. 
2009; Thandapilly et al. 2011).  
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Figure 5-1. Norepinephrine treatment induces hypertrophic growth in ARVM. 
(A) Representative images of ARVM untreated and treated with 1μM norepinephrine (NE) 
overnight. (B) Representative images of control and NE treated ARVM stained with α-actinin. 
(C) Summary of longitudinal section area calculated for control and NE treated myocytes. 
Control: 38003.85 ± 997.63 pixels (2660.27 ± 69.83 µm
2
), n = 101; NE: 58542.48 ± 1621.56 
(4097.97 ± 113.51 µm
2
), n = 90. Error bars represent SEM. Two tailed; paired t-test, *** 
p<0.001. 
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Another measurement of the change in cell size after overnight NE treatment was 
conducted by measuring the increase in cell index. Importantly, the reproducibility of the 
manual measurement was verified by the results obtained from this RT-CES method. NE 
treated cells showed a significant 1.58 fold increase in cardiomyocyte size compared to 
controls after 24 hours of constant monitoring (Figure 5-2).  
 
 
 
 
 
Figure 5-2. Comparison of growth in control and NE treated ARVM.  
Summary of cell index calculated in control and NE-treated myocytes. Error bars represent 
SEM. Two tailed; paired t-test,* p<0.05. 
 
 
Finally, there was significant increase in ANP and α-actin mRNA levels tested in NE 
treated ARVM compared to control (Figure 5-3) and a trend of increased BNP mRNA 
levels.  
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Figure 5-3. Reactivation of the fetal gene program in NE treated ARVM. 
Summary of RT-PCR results showing increased ANP and α-actin expression level in NE-
treated cardiac myocytes. Control = 1 ± 0.4, n = 29; NE treated ARVM ANP mRNA: 2.46 ± 
0.41, n=29; NE treated ARVM BNP mRNA: 1.98 ± 0.36, n = 17; NE treated ARVM α-actin 
mRNA: 2.96 ± 0.45, n = 19. Error bars represent one way ANOVA with Dunnetts post test, * 
p<0.05, ** p<0.01. 
 
 
These data confirm that overnight treatment with 1 μM NE, as previously demonstrated 
(Ikeda et al. 1991; Xiao et al. 2001; Thandapilly et al. 2011), induces modification of the 
cellular phenotype that recapitulate a number of changes observed in hypertrophic hearts in 
vivo. 
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5.2.2 Expression and localisation of cAMP FRET-based 
sensors to the PKA-RI and PKA-RII compartments in 
hypertrophic myocytes 
In order to investigate whether the targeted cAMP sensor localisation is altered in 
hypertrophic myocytes, ARVM that had been treated overnight with 1 μM NE, were also 
transduced with adenoviral vector carrying the cAMP FRET sensors RI_epac and RII_epac 
(ie cells were treated with NE and sensor on the same day maintained in culture for the 
same length of time as control myocytes), fixed and immunostained with antibodies 
against alpha actinin and imaged at the confocal microscope. As demonstrated in Figure 
5-4, the difference in the subcellular localisation of RI_epac and RII_epac appears to be 
attenuated in ARVM. In addition, another main difference in the case of RI_epac is its 
increased localisation to the perinuclear region. Thus, it appears that in hypertrophic 
myocytes the distinction between PKA-RI and PKA-RII compartments is reduced. It 
should also be noted that hypertrophic myocytes tend to express both sensors at a brighter 
level than in control cells perhaps due to increased protein synthesis and nuclear 
transportation. 
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Figure 5-4. Localisation of RI_epac and RII_epac FRET sensors in hypertrophic ARVM. 
(A) Hypertrophic cardiomyocytes were transduced with the FRET sensor (green) and then 
stained for α-sarcomeric actinin (red), followed by laser scanning confocal microscopic 
visualisation at 60x magnification. These representative images show the different 
localisation of the sensors in adult myocytes. Representative line intensity profiles (as 
indicated by the white line). (B) Representative images of non-hypertrophic myocytes 
stained for the same markers as previously shown (Figure 4-2). 
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To verify if the localisation of the two sensors are significantly different in hypertrophic 
myocytes, as well as to compare the localisation of the sensors to control myocytes, the 
Pearson correlation coefficient (PCC) value was calculated using ImageJ with JACoP as 
previously described. Figure 5-5 illustrates the PCC calculated using the fluorescence 
images acquired at the confocal microscope in control and hypertrophic myocytes. In 
control myocytes, as shown in Figure 4-3, the coefficient value is significantly higher in 
RI_epac than RII_epac, confirming that there is a difference in the localisation of these 
sensors in adult cardiomyocytes. However, in hypertrophic myocytes there is no significant 
difference between the two compartments. When comparing control myocytes with 
hypertrophic myocytes, there is reduced RI_epac co-localisation with α-actinin in the 
hypertrophic cells and increased RII_epac co-localisation with α-actinin in hypertrophic 
cells compared to control. This data would suggest that there is a redistribution of AKAPs, 
reflected by the different localisation for RI_epac and RII_epac and any further 
experiments should take into account these changes. Therefore any differences in the 
response to cAMP raising agents in hypertrophic ARVM, may be the consequence of the 
fact that the reporters are localised to different subcellular compartments compared to the 
non-hypertrophic counterparts.  
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Figure 5-5. Summary of sensor localisation analysis. 
Pearson colocalisation coefficient calculated using the JACOP plugin for Image J software 
for both sensors. RI_epac control: 0.789 ± 0.03, n = 15; RII_epac control: 0.596 ± 0.02, n = 13; 
RI_epac hypertrophic: 0.634 ± 0.03, n = 9; RII_epac hypertrophic: 0.685 ± 0.02, n = 7. ANOVA 
with Bonferroni’s post test, *** p<0.001. 
 
These values also can be expressed as √PCC to give the percentage of correlation between 
sensor and α-actinin (RI_epac hypertrophic: ~80%; RII_epac hypertrophic: ~83%). 
 
To assess the impact that chronic catecholamine stimulation has on compartmentalised 
cAMP signalling in ARVM, a FRET-based imaging approach was implemented, as in the 
previous chapter. ARVM were treated with NE to induce hypertrophy in vitro and were 
subsequently transduced with an adenovirus carrying the targeted FRET-based sensors 
RI_epac and RII_epac (on the same day as NE treatment). Cells were then imaged the 
following day on an epifluorescent microscope. cAMP production was stimulated by 
challenging the myocytes with cAMP raising stimuli and the effect of each stimulus was 
determined in the PKA-RI and PKA-RII subcellular locations. Below (Figure 5-6) is an 
example of a FRET experiment employing RI_epac and RII_epac in hypertrophic ARVM 
demonstrating the distinct responses obtained in the two compartments upon addition of 
various stimuli which increase cAMP generation.  
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Figure 5-6. . Representative example of a FRET experiment in hypertrophic cardiomyocytes 
transduced with the targeted cAMP sensors. 
(A)Image of hypertrophic ARVM expressing RI_epac (left) or RII_epac (right). (B) 
Representative kinetics of FRET change detected in response to 100 nM Isoproterenol, 10 
μM IBMX then 25 μM forskolin recorded in hypertrophic ARVM expressing RI_epac (red) or 
RII_epac (blue).  
 
 
To investigate the normal basal cAMP levels in the PKA-RI and PKA-RII compartments 
in hypertrophic ARVM, FRET images of myocytes expressing either RI_epac or RII_epac 
were acquired in the absence of any stimulus. The basal FRET values were calculated as 
ICFP/ IYFP upon excitation at 440 nm, where ICFP is the intensity of CFP emission and IYFP is 
Chapter 5 – Results 
 
155 
the intensity of YFP emission. These data show (Figure 5-7) that the basal levels of cAMP 
in the PKA-RI and PKA-RII compartments are not statistically different in hypertrophic 
myocytes. These results were compared to the same experiment in control cells and it was 
found there was no difference in the basal cAMP levels in any of the groups, indicating 
there is no difference in intracellular cAMP levels in these two subcellular regions in 
hypertrophic myocytes compared with control cells. 
 
 
 
 
 
Figure 5-7. Summary of the analysis of basal ICFP/IYFP ratio value in control and hypertrophic 
ARVM expressing RI_epac or RII_epac. 
RI_epac control n = 10; RII_epac control n = 17; RI_epac hypertrophic ARVM n = 13; 
RII_epac hypertrophic ARVM n = 14. Two way ANOVA with Bonferroni’s post test, no 
significance. 
 
 
With the aim of assessing the cAMP signalling dynamics in these two subcellular locales, 
hypertrophic ARVM, which had been previously transduced with adenoviral vector 
carrying RI_epac or RII_epac, were challenged with stimuli to elevate cAMP levels and 
thus revealing any disparities between the compartments. Cells were stimulated with β-
adrenoreceptor agonist ISO (100 nM) which resulted in a similar increase in both the PKA-
RI and PKA-RII compartments (Figure 5-8). 
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The phosphodiesterases activity in the two compartments, after β receptor stimulation, in 
hypertrophic myocytes was then explored. 100 μM 3-isobutyl-1- methylanxthine (IBMX), 
a non-selective PDE inhibitor was added to the cells, this allowed for the investigation of 
PDE activity at the two sensor sites. Again there was an increase of cAMP in both 
compartments (Figure 5-8), which resulted in similar intracellular levels after addition of 
the stimuli.  
 
In order to achieve the maximum FRET response (ΔR/R0 max) of these sensors in this cell 
type, the myocytes were challenged with a saturating concentration of 25 μM Forskolin 
(FRSK), an activator of adenylyl cyclase which stimulates cAMP production. The degree 
of FRET change detected was comparable for both the PKA-RI and PKA-RII 
compartments (Figure 5-8), indicating that the two probes still give the same maximal 
FRET change at signal saturation in hypertrophic ARVM. This means that these probes 
have the same dynamic range and therefore any disparities recorded between them can be 
believed to reflect a variation in cAMP levels rather than a difference in sensor 
performance. 
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Figure 5-8. Summary of FRET measurements of cAMP signals in hypertrophic ARVM 
expressing RI_epac or RII_epac. 
(A) Experiment carried out in control ARVM. (B) ARVM were pre-treated overnight with 1 μM 
norepinephrine then 100 nM Isoproterenol, 100 μM IBMX and finally 25 μM Forskolin. ISO: 
RI_epac hypertrophic ARVM: ΔR/R0 = 2.137 ± 0.215 %, n = 28; RII_epac hypertrophic ARVM: 
ΔR/R0 = 1.774 ± 0.146 %. IBMX: RI_epac hypertrophic ARVM: ΔR/R0 = 7.162 ± 0.316 %, n 
=26; RII_epac hypertrophic ARVM: ΔR/R0 = 8.023 ± 0.301 %, n = 15. FRSK: RI_epac 
hypertrophic ARVM: ΔR/R0 = 8.505 ± 0.371 %, n = 16; RII_epac hypertrophic ARVM: ΔR/R0 = 
9.481 ± 0.420 %, n = 14. Statistical significance calculated by two way ANOVA with 
Bonferroni’s post test, * p<0.05, ** p<0.01, *** p<0.001. 
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Although these results do not appear to unveil any differences between RI_epac and 
RII_epac in the hypertrophic ARVM, the kinetic data indicate that there may be disparities 
in the kinetics of cAMP levels increase in the PKA-RI and PKA-RII compartments. The 
rate of FRET change after each stimulus was calculated by the formula rate = ΔFRET/Δt, 
where the FRET ratio detected at the first 5 time points after the addition of the stimulus 
was divided by the time in seconds. The rate of FRET change detected in hypertrophic 
myocytes after ISO stimulation was similar for both the RI_epac and RII_epac sensors 
(Figure 5-9) (RI_epac hypertrophic ARVM: 0.30 ± 0.06 /second; RII_epac hypertrophic 
ARVM: 0.28 ± 0.06
 
/second; ns). However after the addition of IBMX, the FRET response 
was significantly faster in the PKA-RII compartment compared to the PKA-RI 
compartment (RI_epac hypertrophic ARVM: 0.4 ± 0.08 /second; RII_epac hypertrophic 
ARVM: 0.7 ± 0.1
 
/second, p < 0.05). 
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Figure 5-9. Summary of rate of FRET change (ΔFRET/ Δt) after each stimuli.  
Rate of FRET change in control (A) or hypertrophic (B) ARVM expressing either RI_epac or 
RII_epac when stimulated with Isoproterenol (100 nM) and then IBMX (100 μM). Statistical 
significance calculated by two way ANOVA with Bonferroni’s post test, * p<0.05. 
 
 
On comparison with control ARVM, as shown in the previous chapter (Figure 4-7), when 
ISO was added to the bath, there was a quicker response in RII_epac compared to RI_epac 
(RI_epac: 0.8 ± 0.1/ second; RII_epac: 1.3 ± 0.2/ second) and no difference was 
documented after IBMX stimulation (RI_epac: 1 ± 0.1/ second; RII_epac 1 ± 0.2/ second). 
From these data, the calculated rate of FRET change is smaller in hypertrophic myocytes 
in both compartments. After the addition of ISO, control cells respond to the stimulus 
significantly faster than in hypertrophic myocytes (RI_epac control vs. RI_epac 
hypertrophic: p < 0.001; RII_epac control vs. RII_epac hypertrophic:  p < 0.001). The 
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same can also be said after addition of IBMX (RI_epac control vs. RI_epac hypertrophic: p 
< 0.001; RII_epac control vs. RII_epac hypertrophic: p < 0.05). 
 
 
 
5.2.3 Comparison of compartmentalised cAMP signalling 
in control and hypertrophic adult cardiomyocytes. 
The literature shows that cyclic nucleotide signalling is regulated in discrete subcellular 
compartments to maintain homeostasis and control diverse cellular functions. The 
compartmentalisation of cAMP was first described in studies conducted in perfused rat 
hearts stimulated with ISO and prostaglandin (PGE1), where different effects on PKA 
activation and its downstream targets were reported (Hayes et al. 1979). Further studies 
have supported this hypothesis that cAMP signalling works in a compartment specific way 
and that compartmentalisation is regulated by PDEs. Alterations in the cAMP/PKA 
signalling pathway and changes in PDE activity contributes to the progression of 
cardiovascular diseases. Thus it was interesting to investigate whether there were any 
changes in compartmentalised cAMP signalling between control and hypertrophic ARVM. 
 
In control myocytes, activation of β-adrenergic signalling by the addition of the β-agonist 
ISO (100 nM) induced a larger increase in cAMP in the PKA-RII compartment compared 
to the PKA-RI compartment. Conversely, ISO stimulation in hypertrophic ARVM resulted 
in much smaller increase in cAMP in both compartments under investigation with no 
significant difference between the two locations. 
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Figure 5-10. Summary of FRET measurements of cAMP signals in control and hypertrophic 
ARVM expressing RI_epac or RII_epac upon addition of isoproterenol. 
Cardiomyocytes were stimulated with 100 nM isoproterenol – a β-adrenoceptors agonist.  
RI_epac control: ΔR/R0 = 4.133 ± 0.221 %, n = 26; RII_epac control: ΔR/R0 = 6.204 ± 0.215 %, 
n = 31; RI_epac hypertrophic: ΔR/R0 = 2.137 ± 0.215 %, n = 28; RII_epac hypertrophic: ΔR/R0 
= 1.774 ± 0.146 %, n = 34.  Statistical significance calculated by two way ANOVA with 
Bonferroni’s post test, *** p<0.001. 
 
 
This data illustrates that in hypertrophic ARVM there is a significantly lower cAMP 
response upon ISO stimulation compared to non-hypertrophic myocytes, which suggests 
either desensitisation of β-adrenergic receptors upon chronic treatment with NE and/ or 
increased phosphodiesterase (PDE) activity in hypertrophic myocytes. 
 
After ISO stimulation, cells were then treated with non-selective PDE inhibitor IBMX to 
assess the PDE activity in the PKA-RI and PKA-RII compartments. Results obtained 
showed no difference in the two compartments in control myocytes nor was there a 
difference between the PKA-RI and PKA-RII compartments in hypertrophic myocytes. 
However when comparing the control and hypertrophic ARVM, control cells generated a 
significantly greater cAMP rise in both compartments compared to the hypertrophic 
myocytes. 
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Figure 5-11. Summary of FRET measurements of cAMP production in control and 
hypertrophic ARVM expressing RI_epac or RII_epac upon addition of isoproterenol and 
IBMX.  
RI_epac control: ΔR/R0 = 9.376 ± 0.311 %, n =26; RII_epac control: ΔR/R0 = 10.112 ± 0.252 %, 
n = 27; RI_epac hypertrophic: ΔR/R0 = 7.162 ± 0.316 %, n =26; RII_epac hypertrophic: ΔR/R0 
= 8.023 ± 0.301 %, n = 15. Statistical significance calculated by two way ANOVA with 
Bonferroni’s post test, *** p<0.001. 
 
 
In order to compare the maximal FRET change (ΔR/R0 max) in these control and 
hypertrophic ARVM, a saturating concentration of 25 μM Forskolin (FRSK), an activator 
of adenylyl cyclase was administered after ISO and IBMX stimulation (Figure 5-12). 
Again results illustrated no difference in the two compartments in control myocytes nor 
was there a difference between the PKA-RI and PKA-RII compartments in hypertrophic 
myocytes. However when comparing the control and hypertrophic ARVM, control cells 
generated a significantly larger cAMP response in both compartments compared to the 
hypertrophic myocytes. A number of studies have suggested that adenylyl cyclase function 
is down-regulated in hypertrophy and heart failure (Chen et al. 1991; Bohm et al. 1992; 
Bohm 1995; Fung et al. 2002), which could explain why there is a lower cAMP response 
in hypertrophic myocytes compared to non-hypertrophic ARVM upon forskolin treatment.  
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Figure 5-12. Summary of FRET measurements of cAMP production in control and 
hypertrophic ARVM expressing RI_epac or RII_epac upon addition of isoproterenol, IBMX 
and forskolin. 
RI_epac control: ΔR/R0 = 10.727 ± 0.480 %, n =11; RII_epac control: ΔR/R0 = 11.17 ± 0.465 %, 
n = 8; RI_epac hypertrophic ARVM: ΔR/R0 = 8.505 ± 0.371 %, n =16; RII_epac hypertrophic 
ARVM: ΔR/R0 = 9.481 ± 0.420 %, n = 14. Statistical significance calculated by two way 
ANOVA with Bonferroni’s post test, ** p<0.01. 
 
 
The data described in Figure 5-11, does not give a clear indication of the PDE activity 
alone as the response detected is a combination of the responses to ISO and IBMX. To 
obtain a clearer indication of the PDEs contribution in determining cAMP levels in the 
PKA-RI and PKA-RII compartments, the PDE contribution in determining the cAMP 
response was calculated by taking the final response detected upon addition of ISO + 
IBMX treatment in both control and hypertrophic cells and by subtracting the ISO 
response for each subcellular compartment (Figure 5-13A). As shown in the previous 
chapter, in control myocytes a significantly higher cAMP response in the PKA-RI 
compartment was detected compared to the PKA-RII compartment, indicating there is a 
greater contribution of PDEs acting in the PKA-RI compartment compared to the PKA-RII 
compartment. In hypertrophic ARVM the opposite is seen: here the PKA-RII compartment 
showed a significantly larger FRET change compared to the PKA-RI. To investigate the 
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impact hypertrophy has on PDE activity; control and hypertrophic ARVM transduced with 
either RI_epac or RII_epac were compared. In the PKA-RI compartment, there was no 
difference in cAMP response upon IBMX stimulation, however in the PKA-RII 
compartment there was a significantly greater cAMP response in the hypertrophic 
myocytes compared with the control ARVM. These data indicate that in hypertrophic adult 
cardiomyocytes, there is an increase in PDE activity selectively associated with the PKA-
RII compartment. 
 
To investigate whether an increase in the basal activity of PDEs occurs in hypertrophic 
myocytes, the response stimulation with IBMX (100 μM) alone in normal and 
hypertrophic cardiac myocytes was assessed (Figure 5-13B). In control myocytes, no 
difference was detected between the PKA-RI and PKA-RII compartments upon non-
selective PDE inhibition. Nor was there a difference in basal PDE activity in the two 
compartments in hypertrophic myocytes when IBMX was given as a first stimulus. These 
results indicate an increased PDE activity selectively in the PKA-RII locale of 
hypertrophic myocytes after catecholamine stimulation compared to non-hypertrophic 
ARVM. 
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Figure 5-13. The contribution of phosphodiesterases (PDEs) in control and hypertrophic 
ARVM transduced with RI_epac or RII_epac. 
(A) Myocytes are stimulated first with 100 nM Isoproterenol, then IBMX. The contribution of 
the IBMX response alone was calculated showing the basal PDE activity. RI_epac control: 
ΔR/R0 =5.267 ± 0.344 %, n =26; RII_epac control: ΔR/R0 = 3.683 ± 0.318 %, n = 27; RI_epac 
hypertrophic: ΔR/R0 = 4.968 ± 0.405 %, n =26; RII_epac hypertrophic: ΔR/R0 = 6.275 ± 0.280 
%, n = 15. (B) Myocytes are treated with IBMX without Isoproterenol. RI_epac control: ΔR/R0 
=5.425 ± 0.539 %, n =5; RII_epac control: ΔR/R0 = 5.432 ± 0.287 % n = 6; RI_epac 
hypertrophic: ΔR/R0 =6.308 ± 0.262 %, n =6; RII_epac hypertrophic: ΔR/R0 = 6.272 ± 0.218 % 
n = 6. Statistical significance calculated by two way ANOVA with Bonferroni’s post test, * 
p<0.05, ** p<0.01, *** p<0.001. 
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5.2.4 Contribution of individual PDEs to the control of the 
cAMP response to catecholamines in the PKA-RI 
and type II compartments in hypertrophic myocytes. 
In order to explore which of the phosphodiesterase families are responsible for the 
increased basal cAMP hydrolytic activity in the PKA-RII compartment and for the altered 
cAMP response to catecholamine stimulation in hypertrophic ARVM, myocytes 
expressing RI_epac and RII_epac were treated with a selective PDE inhibitor before 
stimulation with 100 nM ISO to induce cAMP synthesis. 
For experiments investigating the role of PDE2, both control and hypertrophic myocytes 
expressing either RI_epac or RII_epac were pre-treated with the selective PDE2 inhibitor 
Bay 60-7550 (50 nM) for 10 minutes at 37˚C before imaging. In most cases such treatment 
did not affect the basal cAMP levels in the myocytes (Figure 5-14) as the level of cAMP 
detected was comparable in all conditions.  
 
 
 
 
Figure 5-14. Summary of basal cAMP levels in ARVM in the presence or absence of PDE2 
inhibitor Bay 60-7550 (Bay) in the control and hypertrophic myocytes (NE).  
RI_epac control: n = 9; RII_epac control: n = 9; RI_epac + Bay 60-7550: n =18; RII_epac + 
Bay 60-7550: n = 12; RI_epac hypertrophic: n =19; RII_epac hypertrophic: n = 11; RI_epac 
hypertrophic + Bay 60-7550: n =16; RII_epac hypertrophic + Bay 60-7550: n = 14. Statistical 
significance calculated by two way ANOVA with Bonferroni’s post test, ns. 
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As shown in the previous chapter (Figure 4-6), ISO stimulation results in a significantly 
higher FRET change in the PKA-RII compartment compared to the PKA-RI compartment 
in control myocyte. Pre-treatment of the myocytes with Bay 60-7550 resulted in a 
significantly greater increase in the cAMP response to ISO stimulation in both 
compartments compared to controls (Figure 5-15). As a larger FRET change was detected 
in the PKA-RI compartment after PDE2 was inhibited with Bay 60-7550 (2 fold increase 
of cAMP compared to a 1.3 fold increase in the PKA-RII compartment), these results 
suggest that there is a larger contribution of PDE2 to the control of cAMP levels in the 
PKA-RI compartment than the in PKA-RII compartment. 
 
In hypertrophic myocytes (Figure 5-15), ISO stimulation caused a similar cAMP rise in 
both compartments. Pre-treatment of ARVM with PDE2 inhibitor Bay 60-7550 produced a 
cAMP increase in response to ISO which was significantly higher in the PKA-RII 
compartment compared to the PKA-RI compartment. Again, there was a 2 fold increase in 
the amount of cAMP generated in the PKA-RI compartment, the same generated in control 
myocytes, but a 3.2 fold increase in the PKA-RII compartment when PDE2 inhibitors 
where present. These results indicate that although PDE2 is present in both the PKA-RI 
and PKA-RII compartments in hypertrophic ARVM PDE2 appears to contribute more to 
the control of the cAMP response to ISO in the PKA-RII compartment whereas the 
contribution of PDE2 in the PKA-RI compartment appears to be unchanged. 
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Figure 5-15. Summary of FRET change upon the selective inhibition of PDE2 in control and 
hypertrophic (NE treated) ARVM. 
Summary of FRET change induced by 100 nM isoproterenol in the presence or absence of 
PDE2 inhibitor Bay 60-7550. RI_epac control: ΔR/R0 = 3.47 ± 0.152 %, n = 8; RII_epac control: 
ΔR/R0 = 5.871 ± 0.405 %, n = 16; RI_epac + Bay 60-7550: ΔR/R0 = 7.616 ± 0.528 %, n =10; 
RII_epac + Bay 60-7550: ΔR/R0 = 7.633 ± 0.427 %, n = 9; RI_epac hypertrophic: ΔR/R0 = 1.798 
± 0.116 %, n = 7; RII_epac hypertrophic: ΔR/R0 = 1.609 ± 0.179 %, n = 18; RI_epac 
hypertrophic + Bay 60-7550: ΔR/R0 = 4.224 ± 0.121 %, n = 9; RII_epac hypertrophic + Bay 60-
7550: ΔR/R0 = 5.427 ± 0.289 %, n = 10. Statistical significance calculated by two way ANOVA 
with Bonferroni’s post test, * p<0.05, ** p<0.01, *** p<0.001. 
 
 
For experiments investigating PDE3, both control and hypertrophic myocytes were 
transduced overnight with adenovirus carrying the coding sequence for RI_epac or 
RII_epac before pre-treatment with the selective PDE3 inhibitor cilostamide (10 μM) for 
10 minutes at 37˚C prior to imaging. Under basal conditions there was a comparable level 
of cAMP in each condition (Figure 5-16). 
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Figure 5-16. Summary of basal cAMP levels in ARVM in the presence or absence of PDE3 
inhibitor cilostamide (Cilo) in the control and hypertrophic (NE treated) ARVM.  
RI_epac control: n =8; RII_epac control: n = 11; RI_epac + cilostamide: n =11; RII_epac + 
cilostamide: n = 8; RI_epac hypertrophic: n =8; RII_epac hypertrophic: n = 4; RI_epac 
hypertrophic + cilostamide: n =11; RII_epac hypertrophic + cilostamide: n = 13. Statistical 
significance calculated by two way ANOVA with Bonferroni’s post test. 
 
 
In control cells stimulated with ISO (Figure 5-17) there was again a higher cAMP response 
in the PKA-RII compartment in ARVM. Upon pre-treatment with cilostamide, it was 
found that PDE3 inhibition only had an effect on the cAMP level detected in the PKA-RI 
compartment, with a 1.4 fold increase in cAMP production. 
 
Hypertrophic myocytes challenged with ISO alone generated a small comparable increase 
in cAMP in the PKA-RI and PKA-RII compartment (Figure 5-17). When hypertrophic 
myocytes were preincubated with the PDE3 inhibitor, there was no significant change in 
either compartment after ISO stimulation. These results indicate that in control myocytes 
PDE3 appears to be predominantly active in the subcellular location where PKA-RI 
normally resides, however in hypertrophic myocytes, there appears to be a loss of PDE3 
activity in this compartment. 
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Figure 5-17. Summary of FRET change upon the selective inhibition of PDE3 in control and 
hypertrophic (NE treated) ARVM. 
Summary of FRET change induced by 100 nM isoproterenol (ISO) in the presence or 
absence of PDE3 inhibitor cilostamide. RI_epac control: ΔR/R0 =4.402 ± 0.276 %, n =8; 
RII_epac control: ΔR/R0 = 5.634 ± 0.276 %, n = 11; RI_epac + cilostamide: ΔR/R0 =6.23 ± 
0.541 %, n =11; RII_epac + cilostamide: ΔR/R0 = 5.884 ± 0.834 %, n = 8; RI_epac 
hypertrophic: ΔR/R0 =2.025 ± 0.341 %, n =16; RII_epac hypertrophic: ΔR/R0 = 2.030 ± 0.239 
%, n = 15; RI_epac hypertrophic + cilostamide: ΔR/R0 =3.075 ± 0.655 %, n =10; RII_epac 
hypertrophic + cilostamide: ΔR/R0 = 2.769 ± 0.495 %, n = 11. Statistical significance 
calculated by two way ANOVA with Bonferroni’s post test, * p<0.05, ** p<0.01, *** p<0.001. 
 
 
The effect of PDE4 activity on cAMP signalling in hypertrophic myocytes was studied by 
transducing both control and hypertrophic myocytes with an adenovirus carrying the 
RI_epac or RII_epac reporters overnight before pre-treating the cells for 10 minutes with 
selective PDE4 inhibitor rolipram (10 μM) and incubation at 37˚C before experiments 
began. Under basal conditions there was a comparable level of cAMP in each condition 
(Figure 5-18). The only exception was the case of hypertrophic myocytes in which PDE4 
had been inhibited, where there was a significantly larger basal level of cAMP in the PKA-
RII compartment compared to the PKA-RI compartment (p < 0.05). 
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Figure 5-18. Summary of basal cAMP levels in ARVM in the presence or absence of PDE4 
inhibitor rolipram (Rol) in the control and hypertrophic (NE treated) ARVM.  
RI_epac control: n =11; RII_epac control: n = 6; RI_epac + rolipram: n =9; RII_epac + 
rolipram: n = 9; RI_epac hypertrophic: n =9; RII_epac hypertrophic: n = 8; RI_epac 
hypertrophic + rolipram: n =12; RII_epac hypertrophic + rolipram: n = 12. Statistical 
significance calculated by two way ANOVA with Bonferroni’s post test, ** p<0.01. 
 
 
In control myocytes stimulated with ISO there was a higher generation of cAMP in the 
PKA-RII compartment (Figure 5-19). Myocytes treated with PDE4 inhibitor rolipram 
before imaging produced an increased level of cAMP in both compartments compared with 
control cells. This resulted in a 1.8 fold increase in cAMP in the PKA-RI compartment and 
a 1.3 fold increase in the PKA-RII compartment. 
 
In hypertrophic myocytes the effect of ISO stimulations was again a similar rise in cAMP 
in both locations (Figure 5-19). When treated with rolipram before β-AR stimulation, the 
outcome was a rise in cAMP specifically in the PKA-RII compartment. These findings, 
when compared to control myocytes, suggest a loss of PDE4 activity in the PKA-RI 
compartment and a gain of PDE4 activity in the PKA-RII compartment in hypertrophic 
ARVM. 
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Figure 5-19. Summary of FRET change upon the selective inhibition of PDE4 in control and 
hypertrophic (NE treated) ARVM. 
Summary of FRET change induced by 100 nM isoproterenol (ISO) in the presence or 
absence of PDE4 inhibitor rolipram. RI_epac control: ΔR/R0 =4.152 ± 0.239 %, n =10; 
RII_epac control: ΔR/R0 = 5.838 ± 0.299 %, n = 13; RI_epac + rolipram: ΔR/R0 =7.512 ± 0.68 %, 
n =7; RII_epac + rolipram: ΔR/R0 = 7.733 ± 0.643 %, n = 7; RI_epac hypertrophic: ΔR/R0 
=2.181 ± 0.353 %, n =12; RII_epac hypertrophic: ΔR/R0 = 2.145 ± 0.354 %, n = 9; RI_epac 
hypertrophic + rolipram: ΔR/R0 =2.764 ± 0.457 %, n =10; RII_epac hypertrophic + rolipram: 
ΔR/R0 = 4.907 ± 0.669 %, n = 10. Statistical significance calculated by two way ANOVA with 
Bonferroni’s post test, * p<0.05, ** p<0.01, *** p<0.001. 
 
 
PDE 1, 2, 3, 4, 5, 7, 8 and 9 are known to be expressed in the heart to different extents 
(Omori and Kotera 2007); however their individual contribution to cAMP hydrolysis in 
hypertrophic ARVM has not been assessed for all of them. The FRET data above suggests 
an increase in PDE2 activity in the PKA-RII compartment, a reduction of PDE3 in the 
PKA-RI and a possibly a partial relocalisation of PDE4 from the PKA-RI to the PKA-RII 
compartment. To test this hypothesis PDE activity assays were performed on cell lysates to 
establish whether total activity of individual PDEs was affected in hypertrophic vs. control 
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ARVM (Figure 5-20). Lysates were treated with PDE inhibitors and the amount of cAMP 
hydrolysis was calculated using a phosphodiesterase activity assay (materials and methods 
3.5.3 (Marchmont and Houslay 1980). In this two step procedure, protein from control or 
hypertrophic ARVM are first incubated with 1 μM 8[3H]-labelled cAMP. In the second 
step the product of cAMP hydrolysis (5’AMP) is incubated with snake venom which 
dephosphorylates 5’AMP to adenosine. The non-hydrolysed cAMP (negatively charged) is 
separated from the neutral charged adenosine with Dowex ion-exchange resin and the 
amount of adenosine is measured by scintillation counting. 
 
As expected, treatment with the non-selective PDE inhibitor IBMX resulted in a dramatic 
decrease in cAMP hydrolysing activity. IBMX inhibits all PDE families, with the 
exception of PDE8 (Wang et al. 2008). No difference was detected between control and 
hypertrophic myocytes, indicating that there is no difference in the overall PDE activity in 
the two conditions. Treatment with Rolipram (10 μM), which inhibits all members of the 
PDE4 family, revealed the highest hydrolysing activity among all the selective PDE 
inhibitors, indicating that PDE4 is responsible for the majority of cAMP hydrolysing 
activity in ARVM. This is in agreement with previous data from Mongillo and co-workers 
(Mongillo et al. 2004). Again there was no difference recorded in PDE4 activity in control 
and hypertrophic myocytes. Inhibition of PDE3 with cilostamide (10 μM) also 
significantly reduced cAMP hydrolysis in both cell types to a similar level. Inhibition of 
PDE2 with Bay 60-7550 (50 nM) had the smallest effect of all the PDE inhibitors tested, 
but still significantly reduced cAMP in both control and hypertrophic adult myocytes to a 
similar level.  
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Figure 5-20. cAMP hydrolysing activities of different PDE families in control and 
hypertrophic ARVM. 
ANOVA with Bonferroni’s post test, no significance between control and hypertrophic 
myocytes. 
 
 
There appears to be no difference in the total activity of individual PDEs in control vs. 
hypertrophic cells. As the FRET data which showed differences in PDE control over the 
two subcellular compartments occurred after β-AR stimulation, it would have been 
interesting to repeat the PDE activity assay in lysates which are pre treated with ISO as 
well as PDE inhibitors. It is interesting to note that both PDE3 and PDE4 are activated by 
PKA (Omori and Kotera 2007); therefore ISO treatment could increase the activity of these 
PDE families in selected compartments of the myocyte. However due to time constraints 
and difficulty in extracting a sufficient amount of protein from this cell type, these 
experiments could not be completed. 
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5.2.5 Changes in individual PDE families expression as 
assessed by protein and mRNA level in hypertrophic 
ARVM 
To explore whether the observed deranged PDE-mediated control of compartmentalised 
cAMP signals seen in hypertrophic myocytes is due to altered expression levels of the 
individual PDEs involved, analysis of both PDE protein levels by Western blot and PDE 
mRNA levels by real-time PCR were performed using antibodies specific to the known 
PDE isoforms present in ARVM.  
Western blot analysis of the expression level of all PDE were performed in triplicates in 
control and hypertrophic ARVM; GAPDH was utilised as internal standard to correct for 
sample to sample variation and loading errors and results were normalised to control 
ARVM. Similarly, RT-PCR was performed in 3 biological replicates and an average was 
taken before 18S rRNA was utilised as internal reference and data were then normalised to 
control myocyte samples. n = number of technical replicates (minimum of 3). At least 3 
different animal preparations were used. 
 
For PDE2 (Figure 5-21), the results obtained show that, despite the increase in PDE2 
activity detected with FRET imaging in hypertrophic myocytes, no significant difference in 
PDE2 gene expression or protein levels was found between control and hypertrophic 
ARVM. These findings suggest that the increased PDE2 activity observed in hypertrophic 
myocytes selectively in the PKA-RII compartment may be due to activation of PDE2 
rather than to a change in the amount of PDE2. 
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Figure 5-21. PDE2 mRNA and protein levels in control and hypertrophic ARVM.  
(A) Western blot of PDE2A and GAPDH in control and hypertrophied ARVM. (B) Western blot 
quantification: n = 3 (C) Representative RT-PCR showing no significant changes in PDE2A 
expression level in hypertrophic myocytes as compared to control cells. Control: n = 10; 
hypertrophic ARVM: n = 10. Error bars represent SEM. Two tailed; paired t-test.  
 
 
For PDE3 (Figure 5-22), the results of the expression level analysis show that, despite the 
apparent decrease in PDE3 activity detected with the FRET imaging approach in 
hypertrophic myocytes, there was a significant increase in PDE3 gene expression and 
protein levels in hypertrophic vs. control ARVM. 
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Figure 5-22. PDE3A mRNA and protein levels in control and hypertrophic ARVM.  
(A) Western blot of PDE3A and GAPDH in control and hypertrophied ARVM. (B) Western blot 
quantification: n = 3. (C) Representative RT-PCR showing a small increase in PDE3A 
expression level in hypertrophic myocytes compared to control cells. Control: n = 15; 
hypertrophic ARVM: n = 15. Error bars represent SEM. Two tailed; paired t-test, * p<0.05. 
 
 
PDE4 gene expression and protein levels were more challenging to investigate as there is 
more than one PDE4 gene expressed in the heart. The PDE4 family is highly evolutionarily 
conserved and it is encoded by four genes, namely PDE4A, PDE4B, PDE4C and PDE4D 
(Houslay and Adams 2003). These four PDE4 genes further encode 25 different isoforms 
all with unique N-terminal regions. It has been reported the PDE4C is not present in heart 
tissue (Kostic et al. 1997) and more recently it was reported that in cardiomyocytes the 
majority of PDE4 cAMP hydrolytic activity is provided by the PDE4D subfamily, with a 
small contribution from PDE4B, and virtually no contribution from PDE4A or PDE4C 
(Mongillo et al. 2004). Based on the above information, this study focused on the analysis 
of the expression of PDE4B and PDE4D in hypertrophic myocytes. 
 
There are 4 known isoforms of PDE4B (PDE4B1, PDE4B2, PDE4B3 and PDE4B5 which 
have calculated molecular weights of 83 kDa, 64 kDa, 82 kDa and 57 kDa respectively) 
and so it was decided that immunoprecipitation (IP), using an antibody that recognises all 
known PDE4B isoforms, would be the best way to assess PDE4B protein expression. An 
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IP was performed with an IgG control and probed for an antibody against PDE4B 
isoforms. After IP only PDE4B1/ PDE4B3 could be detected. No statistical comparison 
was performed as n = 2. Neither protein nor mRNA expression levels of PDE4B were 
significantly altered in hypertrophic myocytes, although the mRNA level showed a small 
but not significant higher level in hypertrophic myocytes compared to control cells.  
 
 
 
 
Figure 5-23. PDE4B mRNA and protein levels in control and hypertrophic ARVM.  
 (A) Immunoprecipitation (IP) was performed using PDE4B antibody before running Western 
Blot. Band at ~80 kDa represents PDE4B1 or PDE4B3. (B) Representative RT-PCR showing 
no change in PDE4B expression level in hypertrophic myocytes compared to control cells. 
Control: n = 12; hypertrophic ARVM: n = 12. Error bars represent SEM. Two tailed; paired t-
test. 
 
 
There are 11 published isoforms of PDE4D with recorded molecular weights ranging 
between 58 – 91 kDa and therefore it was difficult to detect any clear changes in band 
intensities when comparing control and hypertrophic myocytes. Immunoprecipitation was 
performed using IgG as a control, and an immunoblot was then probed with an antibody 
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raised against all PDE4D isoforms (pan PDE4D). No statistical comparison was performed 
as n = 2. No statistically significant changes could be detected in the mRNA or protein 
expression levels of PDE4D, although the PDE4D mRNA levels showed a small but not 
significant increase in hypertrophic myocytes. 
 
 
 
 
Figure 5-24. PDE4D mRNA and protein levels in control and hypertrophic ARVM.  
(A) Immunoprecipitation (IP) was performed using PDE4D antibody before Western Blotting. 
Band at ~ 85 kDa represents PDE4D5 or PDE4D7. (B) Representative RT-PCR showing no 
change in PDE4D expression level in hypertrophic myocytes compared to control cells. 
Control: n = 13; hypertrophic ARVM: n = 13. Error bars represent SEM. Two tailed; paired t-
test. 
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The above results suggest that any alterations in PDE2 and PDE4 activity in hypertrophic 
myocytes may be due to changes in the activation state of the enzyme rather than protein or 
mRNA expression levels. The PDE3 FRET results appear to be contradicted by the protein 
and mRNA levels obtained. This may be explained by a concomitant inhibition of the 
overexpressed PDE3 in hypertrophic myocytes. 
  
 
 
5.2.6 Alteration in phosphodiesterase localisation in 
hypertrophic myocytes 
It has been previously published that cardiac phosphodiesterases (PDEs) have distinct 
subcellular localisations which can be detected by immunostaining and confocal 
microscopy (Mongillo et al. 2004). Together with this study and the FRET data obtained in 
this investigation which showed increase PDE2 activity specifically in the PKA-RII 
compartment and PDE4 shifting from the PKA-RI compartment to the PKA-RII 
compartment, immunostaining of cardiomyocytes to further explore alterations in PDE 
localisation was performed. 
Control and hypertrophic ARVM were co-stained with anti-PDE (PDE2A, PDE3A, 
PDE4B or PDE4D) and anti-α-actinin antibodies and cells were imaged using confocal 
microscopy. The Pearson correlation coefficient (PCC) value was calculated using ImageJ 
with JACoP plug-in.  
 
Interestingly PDE4B and PDE4D localisation were altered in hypertrophic myocytes where 
a higher correlation with α-actinin is detected (expressed as of correlation between PDE 
isoform and α-actinin). This data is in line with earlier FRET data in this study (Figure 
4-11) suggesting a shift in PDE4 localisation from the PKA-RI to PKA-RII compartment. 
Immunofluorescence experiments for RI_epac and RII_epac with α-actinin revealed that 
RII_epac localises significantly more with α-actinin in hypertrophic myocytes compared to 
controls (Figure 5-5). In the heart, PDE4 has been shown to bind to some AKAPs (see 
1.7.1). Therefore it is possible to hypothesise that the altered PDE4 localisation may be due 
to relocalisation of AKAPs which occurs after chronic catecholamine stimulation in 
ARVM. No change in PDE localisation was detected for either PDE2A or PDE3A. 
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Figure 5-25. Localisation of PDE families in control and hypertrophic ARVM. 
Control and hypertrophic cardiomyocytes stained for PDE of interest (green) and then 
stained for α-sarcomeric actinin (red), followed by laser scanning confocal microscopy.  
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(A) Confocal image of ARVM labelled with anti-PDE2A (green) and anti α-actinin (red) 
antibodies. (B) Summary of colocalisation statistics for PDE2A. Control: n = 6; hypertrophy: 
n = 11. (C) Confocal image of ARVM labelled with anti-PDE3A (green) and anti α-actinin (red) 
antibodies.(D) Summary of colocalisation statistics for PDE3A. Control: n = 11; hypertrophy: 
n = 3. (E) Confocal image of ARVM labelled with anti-PDE4B (green) and anti α-actinin (red) 
antibodies. (F) Summary of colocalisation statistics for PDE4B. Control: n = 20; 
hypertrophy: n = 12. (G) Confocal image of ARVM labelled with anti-PDE4D (green) and anti 
α-actinin (red) antibodies. (H) Summary of colocalisation statistics for PDE4D. Control: n = 
12; hypertrophy: n = 7. Error bars represent SEM. Two tailed; paired t-test,* p<0.05, *** 
p<0.001. 
 
As earlier FRET data (Figure 4-10) indicated a complete loss of PDE3A activity in the 
PKA-RI compartment in hypertrophic ARVM, immunostaining was expected to show 
noticeable alterations in PDE3A localisation. One possible reason that no change in 
PDE3A localisation was detected is that the cell population tested was low for PDE3A 
hypertrophic ARVM (n=3) compared to all other groups with large variability between 
cells. Unfortunately due to time constraints the staining could not be repeated and the 
population tested could not be increased. Another possible explanation is that PDE3 is 
inhibited in the PKA-RI compartment of hypertrophic myocytes and therefore a decrease 
in activity is recorded yet the PDE3 localisation remains unchanged. Further investigation 
would be required to determine the mechanisms involved. As cGMP can inhibit PDE3 and 
activate PDE2, it would be interesting to explore whether this mechanism is involved. 
 
 
 
5.3  Conclusions 
In order to assess alterations in cAMP/PKA signalling dynamics and phosphodiesterase 
regulation in cardiac hypertrophy, an in vitro model of hypertrophy was established in 
adult rat ventricular myocytes (ARVM). Chronic catecholamine stimulation induces 
cardiac hypertrophy; therefore a model of hypertrophy was set up by treating primary 
cultured ARVM overnight with norepinephrine (NE). To assess if treatment of ARVM 
with NE resulted in a hypertrophic phenotype, several markers were considered and 
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compared between control and NE treated myocytes. These included cell size (both length 
and longitudinal sectional area), cell index, organisation of sarcomeric units and fetal gene 
expression. All parameters investigated indicated that overnight treatment of ARVM with 
NE resulted in the appearance of the expected markers of hypertrophy, indicating that this 
is an acceptable in vitro model of cardiomyocyte hypertrophy. 
 
To study cAMP signalling at different subcellular compartments within the hypertrophic 
cell, a FRET based imaging approach and cAMP FRET sensors targeted to the PKA-RI 
and PKA-RII domains were employed. The results showed that after β-AR stimulation 
with ISO, the level of cAMP produced in both compartments was significantly lower in 
hypertrophic myocytes compared to control ARVM. Investigation of the contribution of 
PDE in determining the level of cAMP revealed that there was higher PDE activity in the 
PKA-RII compartment of hypertrophic ARVM compared to control, whereas the PDE 
activity in the PKA-RI compartment remained unaltered. 
 
To try to better understand which PDE families are responsible for the increased hydrolytic 
activity in the PKA-RII compartment of hypertrophic myocytes, selective PDE inhibitors 
were utilised. The results obtained demonstrate that in hypertrophic myocytes there are 
variations in all the PDE families studied compared to controls. In control ARVM, PDE2 
and PDE4 are mainly associated with the PKA-RI compartment, but some PDE2 activity is 
also present in the PKA-RII compartment; however in hypertrophic ARVM PDE2 activity 
was found to be predominantly associated to the PKA-RII compartment and PDE4 activity 
resulted to be exclusively associated to the PKA-RII compartment, with a complete loss of 
activity in the PKA-RI compartment. PDE3 activity was found to be coupled only to the 
PKA-RI compartment in control myocytes, whereas in hypertrophic ARVM, a loss of 
PDE3 in the PKA-RI locale and no change in the PKA-RII was detected. Immunostaining 
of PDE localisation in ARVM also showed a change in PDE4B and PDE4D localisation in 
hypertrophic myocytes supporting the dramatic alterations gathered with the FRET-based 
imaging technique. 
 
The results of this study show some similarities with data previously published by Abi-
Gerges and colleagues, where a decrease in PDE3 activity was found in cardiomyocytes 
isolated from Wistar rats where hypertrophy had been induced by surgical thoracic aortic 
banding (TAC) (Abi-Gerges et al. 2009). The same paper also reported a decrease in PDE4 
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activity, while the results in this thesis show a loss of PDE4 activity selectively in the 
PKA-RI compartment but an increase in the PKA-RII compartment. Abi-Gerges et al. were 
also able to show decreasing protein expression of PDE3A, PDE4A and PDE4B which is 
in contrast to the results obtained here. There are several possible reasons as to why the 
results in this study differ from the already published data, such as the models of 
hypertrophy used and the animal models used to investigate hypertrophy. This study 
explored cAMP dynamics in an in vitro model of catecholamine induced hypertrophy in 
primary cultured adult rat ventricular myocytes, whereas Abi-Gerges et al. used thoracic 
aortic constriction (TAC) to provoke hypertrophy. Also the techniques used to monitor 
cAMP signalling could be accountable for the differences reported. Abi-Gerges et al. 
studied the cAMP signal exclusively in the subsarcolemmal region using whole cell patch 
clamp and CNG ion channels as a cAMP sensor. This study uses FRET-based imaging and 
fluorescent Epac sensors targeted to the subcellular compartments where PKA-RI and 
PKA-RII normally reside. It is plausible that the PDE 3 and PDE 4 activities differ at the 
cell membrane in hypertrophic ARVM compared with the PKA-RI and PKA-RII 
compartments as cAMP signalling and PDE localisation is known to be 
compartmentalised.  
 
One of the key areas of interest for our laboratory is PDE2 control of cAMP signalling in 
cardiomyocytes. In this study, overall PDE2 activity was shown to increase in hypertrophic 
myocytes, although PDE2 mRNA and protein expression levels showed no difference from 
control myocytes. One possible explanation for this result is that PDE2 may undergo 
activation, resulting in increased activity of this enzyme. Such activation may result from 
increased cGMP levels and consequent cGMP binding to the GAF domain of PDE2. 
However, in order to confirm this hypothesis further investigation of cAMP/cGMP 
interplay in hypertrophic myocytes is required as well as exploring the role of PDEs in the 
development of cardiac hypertrophy. 
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6 The interplay between cAMP and 
cGMP and its impact on cardiac 
hypertrophy. 
 
 
6.1  Introduction 
The second messenger 3’ -5’ cyclic guanosine monophosphate (cGMP) is also an 
important mediator of cardiac function. cGMP reduces cardiac contractility and induces 
vasorelaxation via protein kinase G (PKG)(Archer et al. 1994). cGMP is synthesised by 
two isoforms of guanylyl cyclase: the soluble GC (sGC) which is cytosolic and stimulated 
by nitric oxide (NO) and the particulate GC (pGC), a membrane bound enzyme activated 
by natriuretic peptides (ANP, BNP and CNP). The two forms of GC have been shown to 
mediate different functional effects and it has been suggested that, similar to cAMP, cGMP 
signalling may also be compartmentalised. A study conducted by Gisbert & Fischmeister 
in 1988 showed that in frog ventricular myocytes, sGC activation causes definite inhibition 
of the L-type Ca
2+
 current (ICaL) induced by isoprenaline, whereas pGC activation has little 
effect (Gisbert and Fischmeister 1988). Castro et al. demonstrated that in adult rat 
cardiomyocytes the pGC, but not the sGC activates the cGMP-gated current ICNG. The 
same group also reported that PDE5 controls cGMP generated by the sGC but not by the 
pGC, whereas PDE2 exclusively controls the cGMP generated by the pGC. (Castro et al. 
2006). It should be noted that the technique used in the Castro et al. study relies on the rat 
olfactory cyclic nucleotide–gated (CNG) channel α-subunit and the Ca2+ current ICNG as a 
readout of cGMP levels, which limits the analysis to subsarcolemmal cGMP. 
 
Phosphodiesterases (PDEs), the only cyclic nucleotide degrading enzymes, play a role not 
only in the spatiotemporal regulation of cGMP signals but also in the cross-regulation of 
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the cAMP signal by cGMP. In cardiac cells, the potentiation of Ca
2+
 currents and the 
reduction of the responsiveness to β-adrenergic receptor agonists, have been suggested to 
result from the effects of cGMP on PDE mediated cAMP hydrolysis (Vila-Petroff et al. 
1999; Layland et al. 2002). Cardiac myocytes express several PDE isoforms: PDEs 1, 2, 3, 
4, 5, 8 and 9. Of these isoforms, there are three families of cGMP‐regulated PDEs that 
hydrolyse cAMP, PDE1, PDE2 and PDE3. These PDE families differ with respect to, 
affinity and specificity for cAMP and cGMP as well as their subcellular localisation 
(Martins et al. 1982; Zaccolo and Movsesian 2007). cGMP-mediated inhibition of the 
cAMP-hydrolyzing activity of PDE1 has been demonstrated only in vitro, whereas cGMP 
regulation of PDE2 and PDE3 has been shown to occur both in vitro and in vivo (Zaccolo 
and Movsesian 2007). PDE1 is activated by Ca
2+
 and calmodulin, and hydrolyses cAMP 
and cGMP in a mutually competitive manner. Three PDE1 genes encoding for the proteins 
PDE1A, PDE1B and PDE1C have been identified to date, all with similar affinity for 
cGMP (Km=1 to 5 μmol/L), but which differ greatly on their affinity for cAMP (Kakkar et 
al. 1999). PDE1A and PDE1B, show a preference for cGMP, whereas PDE1C hydrolyses 
the two cyclic nucleotides with equally high affinity (Bender and Beavo 2006). It is still 
unclear whether PDE1 plays a role in cGMP-mediated cAMP hydrolysis in vivo, the major 
limiting factor for these experiments is a lack of specific PDE1 inhibitors. 
 
cGMP regulation of cAMP hydrolysis occurs by cGMP binding to the GAF-B domain of 
PDE2, increasing its ability to degrade cAMP by approximately 10 fold (Rosman et al. 
1997; Martinez et al. 2002). In the case of PDE3, cGMP acts as a competitive inhibitor of 
cAMP hydrolysis (Shakur et al. 2001). PDE3 has similar affinities for both cAMP and 
cGMP, but due to the higher catalytic rate for cAMP,PDE3 is inhibited by cGMP 
(Degerman et al. 1997). Given the described properties of PDE1, PDE2 and PDE3, 
modulation of cAMP PDE activity by cGMP can therefore shape intracellular cAMP 
gradients and the functional effect of cAMP signalling. 
 
More recently the cAMP-cGMP interplay has been explored at a subcellular compartment-
specific level within cardiac myocytes. As previously mentioned, Stangherlin et al. 
performed experiments using FRET based sensors for cAMP and cGMP targeted to the 
subcellular domains where PKA-RI and PKA-RII normally reside and found that cGMP 
can strongly modulate cAMP pools in these locations. This study found that in neonatal rat 
myocytes, PDE2 activity is mainly associated with the PKA-RII subcellular compartment, 
Chapter 6 – Results 
 
188 
whereas PDE3 activity is mainly coupled to the PKA-RI compartment. Stimulation of sGC 
with S-Nitroso-N-acetyl-D, L-penicillamine (SNAP) increases the cAMP response to ISO 
selectively in the PKA-RI compartment via inhibition of PDE3, whereas the cAMP 
response is reduced in PKA-RII compartment via cGMP-mediated activation of PDE2. 
Stimulation of pGC with atrial natriuretic peptide (ANP) reduced cAMP levels in the 
PKA-RII compartment via activation of PDE2 but had no effect on the PKA-RI 
compartment, thus indicating that cGMP signals are also compartmentalised. 
 
These findings are clinically relevant as they may impact on the treatment of pathological 
conditions such as heart failure. Current treatments of heart failure, depending on the 
severity and stage of the disease, rely on raising cAMP levels via inotropes and the use of 
vasodilators and nitrates to increase cGMP levels. Inotropic therapy, via treatment with 
PDE3 inhibitors, has been shown to significantly improve hemodynamic measurements in 
patients with heart failure with short term use (Cuffe et al. 2002), yet it is well established 
that this type of treatment has negative long-term effects on the patient’s outcome. For 
example the Prospective Randomized Milrinone Survival Evaluation (PROMISE) study, 
which randomised patients with class III/IV heart failure to PDE3 inhibitor milrinone 
versus placebo, found a 28% increase in risk of death in the treated group and during the 
Vesnarinone Trial (VEST) found an 11% increase in mortality of treated patients (Packer 
et al. 1991; Feldman et al. 1993). It has been hypothesised that these negative effects may 
be due to the fact that cAMP signalling is compartmentalised. GPCRs, ACs, PDEs and 
cAMP effectors are spatially organised in macromolecular complexes within the 
cardiomyocyte, to allow selective phosphorylation of targets in response to specific 
stimuli. The functional outcome of cAMP signalling depends on the location of the 
subcellular compartment within which cAMP is generated. A global increase of cAMP is 
not the best approach to treating heart failure as this may result in off target effects.  
 
As cGMP is known to regulate cAMP by modulation of PDE2 and PDE3 in discrete 
compartments in cardiomyocytes (Stangherlin et al. 2011), this too could have an effect on 
the use of cAMP PDE inhibitors as a therapeutic treatment in heart disease . Altered levels 
of cGMP can affect PDE activity and in the case of PDE3 may inhibit the enzymatic 
hydrolysis of cAMP. It is therefore crucial to have a better understanding of cyclic 
nucleotide signalling interplay at a subcellular level as this may lead to the development of 
novel therapeutics for heart disease. In addition to this, numerous studies have indicated 
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that cGMP and PKG are anti-hypertrophic (1.10.1.1) and thus it is of interest to investigate 
cGMP signalling in the NE-induced in vitro model of cardiac hypertrophy. 
 
 
Aims 
 Investigate whether unique cAMP/cGMP crosstalk at specific subcellular 
compartments occurs in adult rat ventricular cardiac myocytes  
 Determine how changes in cGMP affect cAMP levels at subcellular sites 
 Explore if cGMP and cAMP interplay is altered in an in vitro model of cardiac 
hypertrophy. 
 
 
 
 
6.2  Results 
6.2.1 cGMP-mediated modulation of cAMP levels in the 
PKA-RI and PKA-RII subcellular compartments. 
The question of whether the generation of cGMP could affect the isoproterenol (ISO)-
induced cAMP response at a subcellular level in ARVM was first investigated. Previous 
studies in the laboratory had shown that PKA-RI and PKA-RII isoforms, due to their 
ability to preferentially anchor to different AKAPs, define distinct subcellular 
compartments in which cAMP is uniquely regulated. To study cAMP signalling in these 
two distinct subcellular compartments two FRET reporters for cAMP were designed 
(RI_epac and RII_epac) that are targeted to the intracellular sites where endogenous PKA-
RI and PKA-RII normally reside (see 4.2.1). 
 
Cardiomyocytes were transduced with adenovirus carrying either RI_epac (the cAMP 
reporter targeted to the PKA-RI compartment) or RII_epac (targeted to the PKA-RII 
compartment) and then stimulated with 100 nM ISO. The cAMP response detected at those 
sites was compared with the response detected in ARVM which had been pre-treated for 
10 minutes with either the NO donor S-Nitroso-N-Acetyl-D, L-Penicillamine (SNAP) or 
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atrial natriuretic peptide (ANP). SNAP, via generation of NO, stimulates the production of 
cGMP by the cytosolic soluble GC (sGC) whereas ANP activates the particulate GC (pGC) 
with consequent generation of cGMP by this enzyme localised at the sarcolemma.  
 
The cAMP response to ISO alone was found to be higher in the PKA-RII compartment as 
compared to the PKA-RI compartment (Figure 6-1) confirming previous results (Di 
Benedetto et al. 2008). Pre-treatment of cells with the NO donor SNAP (100 μM) 
dramatically affected this response, inducing a significant reduction of the FRET change in 
the PKA-RII compartment and shows a trend of a higher FRET change in the PKA-RI 
compartment (Figure 6-1).  
 
In the following set of experiment the effect of ANP treatment was investigated. The 
cAMP FRET response in control cells treated with ISO alone was again higher in the 
PKA-RII compartment compared to the PKA-RI compartment (Figure 6-1B), however pre-
treatment of the myocytes with ANP exclusively affected the response in the PKA-RI 
compartment. The FRET change in PKA-RI was greater compared to its control (Figure 
6-1B).  
 
 
 
Figure 6-1. Summary of the effect of cGMP on the cAMP response to isoproterenol in PKA-
RI and PKA-RII subcellular compartments. 
 Myocytes were preincubated for 10 minutes with (A) SNAP or (B) ANP before stimulating 
with 100 nM Isoproterenol. (A) RI_epac: ΔR/R0 = 2.756± 0.422 %, n = 7; RII_epac: ΔR/R0 = 
4.294 ± 0.418 %, n = 8; RI_epac + SNAP: ΔR/R0 = 4.476± 0.624 %, n = 7; RII_epac + SNAP: 
ΔR/R0 = 2.561 ± 0.524 %, n = 8. (B) RI_epac: ΔR/R0 = 3.521± 0.29 %, n = 15; RII_epac: ΔR/R0 = 
4.9 ± 0.25 %, n = 21; RI_epac + ANP: ΔR/R0 = 5.45± 0.341 %, n = 25; RII_epac + ANP: ΔR/R0 = 
5.02 ± 0.30 %, n = 33. Statistical significance calculated by two way ANOVA with 
Bonferroni’s post test, *p<0.05, *** p<0.001. 
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Together these data indicate that cGMP can affect the response to ISO in a compartment 
specific manner. Previously it has been shown that SNAP produces a uniform increase in 
cGMP throughout the cell so that differences observed are unlikely to be ascribed to an 
uneven generation of cGMP but are instead due the specific localisation of PDEs that are 
differently modulated by cGMP (Stangherlin et al. 2011). The experiments performed in 
the presence of SNAP, suggest that PDE3 (which is inhibited by cGMP) is found mainly in 
the PKA-RI compartment, as increased levels of cGMP lead to the inhibition of PDE3 and 
therefore an increased concentration of cAMP in the response to ISO. PDE2 (which is 
activated by cGMP) was found to be mainly associated to the PKA-RII compartment as 
indicated by the decreased level of cAMP recorded in this compartment (Stangherlin et al. 
2011). 
 
The data obtained in ARVM pre-treated with ANP would again suggest that PDE3 is 
mainly associated with the PKA-RI compartment in the ARVM. However, in the PKA-RII 
compartment there is no effect suggesting that PDE2 is not activated as seen in the 
experiments using SNAP. One possible explanation is that cGMP generated by ANP via 
the pGC does not reach and effectively activate PDE2 (due to a different 
compartmentalisation of the sGC and pGC and limited diffusion of cGMP). An alternative 
explanation is that the amount of cGMP generated by pGC is sufficient to inhibit PDE3 
(Km of cGMP for PDE3 =20 nmol/L) but not sufficient to activate PDE2 (Km for cGMP 
binding to GAF domain of PDE2 =10 μmol/L). 
To confirm the hypothesis that the effect of SNAP and ANP on the cAMP response to ISO 
relies on PDE2 and PDE3, additional experiments in which ARVM are stimulated with 
ISO in the presence of increased cGMP levels plus pharmacological inhibitors of PDE2 
and PDE3 were completed. 
 
 
 
6.2.1.1 The effect of cGMP on the local ISO-induced cAMP 
response in the presence of selective inhibitors. 
Firstly it was important to assess whether, after cGMP raising agents or the addition of 
PDE 2 and 3 inhibitors, there was a difference in the cAMP levels in the two compartments 
that is independent of ISO stimulation, as this may alter the interpretation of the 
experiments performed in the presence of ISO. Previous work conducted in neonatal 
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myocytes found that ANP treatment generated a larger pool of cGMP in the PKA-RII 
compartment and that amount of cGMP produced in the PKA-RI compartment was unable 
to inhibit PDE3 activity (Stangherlin et al. 2011), therefore SNAP was chosen as the 
cGMP raising agent. Myocytes infected with RI_epac or RII_epac FRET based sensors 
were either untreated, preincubated with SNAP alone or with the selective inhibitors for 10 
minutes before imaging. Basal levels of cAMP were obtained by capturing a number of 
FRET images of ARVM expressing the cAMP reporter and calculated as previously 
described (4.2.2). These results confirmed that the basal level of cAMP in the PKA-RI and 
PKA-RII compartments is not altered upon addition of cGMP raising agents and PDE 
inhibitors specific for families 2 and 3 as shown in Figure 6-2A. 
 
In control experiments, as previously shown (Figure 4-6), cardiomyocytes treated with ISO 
(100 nM) alone showed a trend of a higher cAMP response in the PKA-RII compartment 
than the PKA-RI compartment and ARVM pre-incubated with SNAP (100 μM) then 
stimulated with ISO resulted in a trend of a higher cAMP response in the PKA-RI 
compartment than the PKA-RII compartment although these results were not always 
significant due to the increasing number of multiple comparisons made (Figure 6-2B +C). 
These experiments seemed to confirm previous results (6.2.1) where SNAP treatment 
created an inversion of the cAMP gradients typically observed in PKA-RI and PKA-RII 
compartments in response to catecholamine stimulation. 
 
In cardiomyocytes pre-treated with SNAP and the PDE2 inhibitor Bay 60-7550 (50 nM), 
ISO stimulation generated a comparable FRET change in the PKA-RI and PKA-RII 
compartments. On comparison with SNAP treatment alone, SNAP treatment in the 
presence of PDE2 inhibitor results in a significantly greater cAMP response to ISO in the 
PKA-RII compartment only, whereas there is no further increase in the PKA-RI 
compartment. 
 
In ARVM pre-treated with SNAP and the PDE3 inhibitor cilostamide (cilo) (10 μM), ISO 
stimulation resulted in a comparable cAMP level generated in both compartments which 
was not significantly different from ARVM treated with SNAP alone (Figure 6-2C). 
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Figure 6-2. Summary of the effect of cGMP on the cAMP response to ISO in PKA-RI and 
PKA-RII subcellular compartments after selective PDE inhibition. 
(A)Summary of basal cAMP levels in ARVM treated with SNAP and selective PDE inhibitors. 
RI_epac control: n = 13; RII_epac control: n = 12; RI_epac + SNAP: n = 9; RII_epac + SNAP: n 
= 9; RI_epac + SNAP + Bay 60-7550 n = 5; RII_epac + SNAP + Bay 60-7550: n = 6; RI_epac + 
SNAP + Cilo: n = 6; RII_epac + SNAP + Cilo: n = 7. (B) Myocytes were preincubated for 10 
minutes with SNAP (100 μM) and PDE2 selective inhibitor Bay 60-7550 (50 nM) before 
stimulating with 100 nM Isoproterenol.  (C) Myocytes were preincubated for 10 minutes with 
SNAP (100 μM) and PDE3 selective inhibitor Cilo (10 mM) then 100 nM Isoproterenol. 
Statistical significance calculated by two way ANOVA with Bonferroni’s post test, *p<0.05, 
**p<0.01. 
 
 
In line with previous findings (Figure 5-15), these results indicated that PDE2 activity is 
mainly associated with the PKA-RII compartment when there is higher than basal cGMP 
levels, as inhibition of PDE2 with Bay 60-7550 resulted in an increase in cAMP generated 
in response to ISO stimulation specifically in this compartment. Pre-treated with SNAP 
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and PDE3 inhibitor Cilo had no effect on the ISO response in either compartment of 
ARVM, as expected if PDE3 is selectively coupled to the PKA-RI compartment and is 
already inhibited by cGMP induced by SNAP treatment.  
 
 
 
6.2.2 cGMP-mediated local modulation of cAMP levels in 
the PKA-RI and PKA-RII compartments in 
hypertrophic myocytes. 
In the following set of experiments, the observed cGMP-mediated modulation of cAMP 
signalling at subcellular locations was investigated in hypertrophic myocytes to establish 
whether this signalling pathway is altered during cardiac hypertrophy. Isolated ARVM 
were treated overnight in medium containing 1 μM NE to induce an in vitro model of 
cardiomyocyte hypertrophy. Experiments were then conducted in the same way as above, 
by pre-treating the cells with 100 μM SNAP for 10 minutes before imaging.  
The results showed that the cAMP response to ISO in untreated hypertrophic myocytes 
was similar in both the PKA-RI compartment and the PKA-RII compartment (Figure 
6-3A).  
 
Pre-treatment of the cells with SNAP (100 μM) had a no effect on either compartment 
(Figure 6-3A).  
 
On comparison of SNAP pre-treated control cells with SNAP treated hypertrophic cells; 
the cAMP generated was significantly less in the PKA-RI compartment only in 
hypertrophic cells while the PKA-RII compartment remained unchanged (Figure 6-3B). 
 
These data sets are consistent with the information shown in the previous chapter where 
PDE2 activity is present in both the PKA-RI and PKA-RII compartments of hypertrophic 
myocytes (Figure 5-15), but importantly that there is a significant loss of PDE3 activity in 
the PKA-RI compartment in hypertrophic myocytes (Figure 5-17). In hypertrophic cells, 
SNAP treatment does not reduce cAMP in the PKA-RII compartment as one would expect 
given the activation of PDE2. This may be due to the fact that in hypertrophic cells PDE2 
is already activated. 
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Figure 6-3. Summary of the effect of cGMP on the cAMP response to ISO in PKA-RI and 
PKA-RII subcellular compartments in hypertrophic ARVM. 
(A) Myocytes were preincubated for 10 minutes with SNAP or before stimulating with 100 
nM Isoproterenol. RI_epac hypertrophic: ΔR/R0 = 2.026± 0.491 %, n = 8; RII_epac 
hypertrophic: ΔR/R0 = 1.926 ± 0.364 %, n = 6; RI_epac hypertrophic + SNAP: ΔR/R0 = 1.447± 
0.184 %, n = 8; RII_epac hypertrophic + SNAP: ΔR/R0 = 2.675 ± 0.449 %, n = 11. (B) Summary 
of experiments comparing control and hypertrophic ARVMs after SNAP pre-treatment. 
RI_epac + SNAP: n = 7; RII_epac + SNAP: n = 8. Statistical significance calculated by two 
way ANOVA with Bonferroni’s post test, *p<0.05, *** p<0.001. 
 
 
 
6.2.3 Investigation of cGMP levels at the PKA-type I and 
PKA-type II locations using targeted cGMP FRET 
based sensors. 
One possible explanation for the observed differences in cAMP signalling and PDE 
contribution in hypertrophic myocytes in the PKA-RI and PKA-RII subcellular 
compartments in ARVM is that these may rely on variations in the pools of cGMP. To 
investigate if this is the mechanism involved, cGMP changes were monitored selectively in 
the two compartments defined by PKA-RI and PKA-RII using modified versions of the 
cGMP sensor Cygnet-2.1. This had been previously adapted in our laboratory in the same 
way as the targeted cAMP sensors, by fusing the dimerisation/docking domain from either 
RIα (amino acids 1 to 64) or RIIβ (amino acids 1 to 49) to the N-terminus of Cygnet-2.1 
(Figure 6-4). In order to achieve expression of these reporters in adult myocytes, these 
probes had to be cloned into adenoviral vectors. Due to time constraints this stage was 
Chapter 6 – Results 
 
196 
completed by Vector Biolabs. Briefly, Cygnet-2.1was XhoI/EcoRI cut out from pcDNA3.1 
and the dimerisation docking domain for RIα and RIIβ were NheI cut from another 
pcDNA3.1 vector “filled in” using Klenow fragment and subcloned EcoRI into the 
multiple cloning site region of pDual-CCM vector. Positive vectors were checked using 
PacI/BglII digestion. The adenoviral vector was then packaged as previously described 
(3.3.11). 
 
 
 
 
Figure 6-4. Schematic representation of the FRET-based cGMP sensors used in this study. 
 
 
 
To explore whether changes in PDE activity between control and hypertrophic myocytes 
are due to different levels of cGMP in the PKA-RI and PKA-RII compartments, the basal 
level of cGMP was compared at the two locations. For these experiments ARVMs were 
infected with either RI-Cygnet-2.1 or RII-Cygnet-2.1 and a number of images were taken 
for each sensor to calculate the basal ratio. Interestingly the basal level of cGMP was found 
to be higher in the PKA-RI compartment compared to the PKA-RII compartment in 
cardiac myocytes (Figure 6-5A). As a control to exclude that fusion of the targeting 
domains to the Cygnet sensor may affect the efficiency of energy transfer and therefore 
may account for the difference in FRET value detected with the two reporters, the 
adenovirus containing the two targeted cGMP sensors was used to infect Chinese hamster 
ovarian (CHO) cells. In this cell type, there was no difference recorded between the two 
compartments as expected (Figure 6-5B). These data show than in ARVMs the level of 
cGMP is higher in the PKA-RI compartment under normal conditions.  
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Figure 6-5. Summary of the basal ICFP/ IYFP ration values detected with the targeted cGMP 
sensors RI-Cygmet-2.1 and RII-Cygnet-2.1. 
(A) Summary of basal cGMP levels in ARVM. RI-Cygnet-2.1: n = 54; RII-Cygnet-2.1: n = 66. 
(B) Summary of cGMP levels in CHO cells. RI-Cygnet-2.1: n = 35; RII-Cygnet-2.1: n = 26. 
Error bars represent SEM. Two tailed; paired t-test, **p<0.01. 
 
 
In order to investigate whether an increased intracellular cGMP level may be responsible 
for the increased PDE2 activation detected from the FRET data in hypertrophic myocytes, 
the global cystosolic cGMP basal levels were calculated and compared to control ARVMs. 
As illustrated in Figure 6-6A, the basal level of cGMP was significantly higher in the NE 
treated hypertrophic myocytes compared to control cells. This data suggests that, in 
hypertrophic myocytes, the increased PDE2 activity is due to higher levels of intracellular 
cGMP selectively in the PKA-RII compartment. Thus it appears that in hypertrophic 
myocytes, the basal cGMP levels are increased leading to activation of PDE2 and 
increased cAMP hydrolysis. As PDE2 is already activated the addition of SNAP would be 
expected to have little effect on PDE2 activity and cAMP concentration, as observed 
(Figure 6-3). 
 
To further test this hypothesis, the cGMP levels at the PKA-RI and PKA-RII subcellular 
locations in hypertrophic myocytes were explored, to observe if there was an alteration 
which would explain the differences seen in PDE2 and PDE3 activities in this model of 
disease. In control myocytes (Figure 6-6B), there was a higher basal level of cGMP in the 
PKA-RI compartment compared to the PKA-RII compartment.  
However, in hypertrophic myocytes, there was an increased basal level of cGMP in both 
compartments compared with control cells, but a greater fold change was detected in the 
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PKA-RII compartment. The difference in cGMP concentrations between the two 
compartments in this cell type was abolished. 
 
 
 
 
Figure 6-6. Comparison of cGMP intracellular levels between control and hypertrophic 
ARVMs.  
(A) Summary of all the experiments performed in controls and hypertrophic myocytes 
transduced with Cygnet-2.1. Cygnet-2.1 control:  n = 55; Cygnet-2.1 hypertrophic: n = 45. 
Error bars represent SEM. Two tailed; paired t-test, *** p<0.001. (B) Summary of all the 
experiments performed in controls and hypertrophic myocytes transduced with the targeted 
cGMP sensors. RI-Cygnet-2.1 control: n =54; RI-Cygnet-2.1 control: n = 66; RI-Cygnet-2.1 
hypertrophic: n =51; RII-Cygnet-2.1 hypertrophic: n = 53. Statistical significance calculated 
by two way ANOVA with Bonferroni’s post test, *p<0.05, **p<0.001. 
 
 
 
The higher basal level of cGMP in both compartments of hypertrophic ARVM would 
means that in hypertrophic myocytes PDE3 is inhibited more than in control cells while 
PDE2 activity increases. Although cGMP levels are higher in both PKA-RI and PKA-RII 
compartments of the hypertrophic ARVM, the greatest increase is in the PKA-RII 
compartment, and this could explain why the FRET reporters detected a higher PDE2 
activation in this compartment (Figure 5-15), but no altered PDE2 protein and mRNA 
expression was found (Figure 5-21). On the other hand, the increased cGMP level in the 
PKA-RI compartment of hypertrophic myocytes could explain the observation that PDE3 
activity is unchanged in face of an increased level of PDE3 expression (see Figure 5-17 
and Figure 5-22). 
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6.2.4 β3-adrenergic receptor signalling in the PKA-RI and 
PKA-RII compartments of hypertrophic 
cardiomyocytes 
In the heart, under normal conditions, β-adrenergic stimulation results in increased force 
and frequency of myocardial contraction and the rate of relaxation. Three types of β-
adrenergic receptors (β-ARs) are expressed in cardiac myocytes, β1, β2 and β3-ARs, 
although the effect of catecholamines in the human heart is generally attributed to β1 and 
β2-ARs. These receptors are coupled to Gs proteins and lead to the activation of the 
cAMP/PKA pathway. 
 
Gauthier and colleagues were the first to demonstrate that β3-ARs are expressed in the 
human heart. Stimulation of β3-ARs with agonist, BRL-37344 (BRL), caused dose-
dependent negative inotropic effects. This β3-AR–mediated negative inotropic effect is not 
linked to Gs proteins but is coupled to Gi (Gauthier et al. 1996). These inhibitory effects 
have been more recently found to involve the production of nitric oxide (NO) via 
activation of endothelial type-3 NO synthase (eNOS), which, in turn, stimulates sGC to 
produce cGMP (Vaziri and Wang 1999). 
 
Mongillo and colleagues previously reported that NE stimulation of neonatal rat myocytes 
leads not only to the activation of β1 and β2 adrenoceptors but also to the activation of β3-
adrenergic receptors which are functionally coupled to an endothelial nitric oxide synthase 
(eNOS). In this study the authors showed that β3-ARs are involved in NE-induced NO 
generation, leading to sGC activation, synthesis of cGMP, and activation of PDE2 
(Mongillo et al. 2006). 
In the failing heart, it is well established that downregulation of β1 and desensitisation of 
β2-ARs occurs, however the amount of β3-AR protein has been shown to increase up to 3 
fold in different models of heart failure (Cheng et al. 2001; Moniotte et al. 2001). β3-ARs 
are activated at higher catecholamine concentrations than β1- and β2-ARs and are relatively 
resistant to desensitisation (Lafontan 1994). In one study, catecholamine stimulation of a 
neonatal culture of myocytes from mice with both β1-AR and β 2-AR knocked out 
(ADRB1-/-/ADRB2-/-) was found to decrease the frequency of contraction. The β3-AR 
agonist CL316243 was able to replicate this effect (Devic et al. 2001). On the other hand, 
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some investigations have found that β3-AR produce cardioprotective effects in pressure 
overload hypertrophy and heart failure via NOS (Niu et al. 2012).  
 
On the basis of the above evidence, it was decided to then investigate the impact of  β3 
receptor on cAMP levels  in the PKA type I and PKA type II subcellular compartments in 
the ARVM, in order to assess whether the coupling of this receptor to the compartments is 
altered in hypertrophy. This information may help to explain the altered cGMP 
concentration in hypertrophic myocytes since β3-AR stimulation can raise cGMP levels via 
activated NOS. 
 
In order to explore β3 receptor function, isolated ARVM were transduced overnight with 
adenovirus containing the targeted cGMP FRET based sensors (RI-Cygnet-2.1 or RII-
Cygent-2.1) to record cGMP changes in the PKA-RI and PKA-RII subcellular 
compartments. Ten minutes prior to imaging, cells were treated with 100 nM β3-AR 
antagonist (SR59230A) and basal cGMP levels were measured. In control myocytes, as 
shown in Figure 6-5, there was a greater concentration of cGMP in the PKA-RI 
compartment compared to the PKA-RII compartment under normal conditions. In 
myocytes pre-treated with 100 nM β3-AR inhibitor (SR59230A), Figure 6-7A, there was a 
decrease in the basal cGMP in the PKA-RI compartment only, abolishing the difference 
between the two locales. These data suggest that β3-ARs are mainly coupled to the PKA-RI 
compartment in ARVMs as inhibition of β3-ARs caused a decrease in cGMP levels 
specifically in this compartment. This data also shows that in the PKA-RI compartment 
there is constitutive activation of β3-ARs. This is surprising as the literature indicates that 
this type of receptor is activated by high levels of catecholamines (Lafontan 1994). 
Nothing else could be found in the literature to support β3-AR activation in unstimulated 
cardiomyocytes without high circulating levels of catecholamines and so further 
investigation would be necessary to identify the mechanism involved here.  
To investigate the β-AR activity in hypertrophic myocytes, the above experiment was 
conducted in ARVM which had been stimulated overnight with 1 μM NE to induce an in 
vitro model of the disease. In hypertrophic myocytes, Figure 6-7B, there was no difference 
in cGMP basal levels between the two compartments. With the addition of the β3-AR 
inhibitor, there was a trend for a decrease in cGMP in the PKA-RII compartment, although 
this was not significantly different from the untreated myocytes, this resulted in a lower 
level of cGMP in the PKA-RII compartment compared to the PKA-RI compartment. These 
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results indicate that in hypertrophic myocytes the β3-ARs are mainly located in the PKA-
RII compartment, as inhibition of β3-ARs resulted in a smaller cGMP response in this 
compartment. 
 
 
 
 
Figure 6-7. Summary of the investigation of β3-AR signalling in PKA-RI and PKA-RII 
compartments in control and hypertrophic ARVM. 
(A) Summary of FRET experiments in control myocytes transduced with cGMP FRET based 
sensors RI-Cygnet-2.1 and RII-Cygent-2.1 then treated with 100 nM β3-AR inhibitor 
(SR59230A) 10 minutes prior to imaging. RI-Cygnet-2.1 control: n =54; RII-Cygnet-2.1 
control: n = 66; RI-Cygnet-2.1 + β3-AR inhibitor: n =56; RII-Cygnet-2.1 + β3-AR inhibitor: n = 
55. (B) Summary of FRET experiments in myocytes treated overnight with 1 μM NE and 
transduced with the targeted cGMP sensors. Cells were preincubated for 10 minutes with 
100 nM β3-AR inhibitor (SR59230A). RI-Cygnet-2.1 hypertrophic: n =51; RII-Cygnet-2.1 
hypertrophic: n = 53; RI-Cygnet-2.1 hypertrophic+ β3-AR inhibitor: n =59; RII-Cygnet-2.1 
hypertrophic + β3-AR inhibitor: n = 33. Statistical significance calculated by two way 
ANOVA with Bonferroni’s post test, *p<0.05, **p<0.001. 
 
 
Comparison of control vs. NE-induced hypertrophic myocytes transduced with the targeted 
cGMP FRET based-biosensors RI-Cygent-2.1 and RII-Cygnet-2.1 in ARVM treated with 
100 nM β3-AR inhibitor (SR59230A) reveals that there is a significantly greater basal level 
of cGMP in NE treated myocytes. β3-ARs are inhibited in both conditions, yet there is still 
a significant increase in both compartments of hypertrophic myocytes, which indicates that 
cGMP is generated by another route in addition to soluble GC (sGC) activation by β3-ARs. 
Perhaps in hypertrophic myocytes there is a higher activation of particulate GC (pGC) 
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which produces cGMP. This is plausible as there is an increase in ANP expression (fetal 
gene switch on) in hypertrophic myocytes, which may result in activation of pGC (see 6.1). 
 
 
 
 
6.3  Conclusion 
cGMP is a ubiquitous second messenger that, along with cAMP, modulates cardiac 
function. cGMP is generated by both the soluble and the particulate guanylyl cyclases 
(GCs) in response to nitric oxide and natriuretic peptides, respectively, and activation of 
the pGC or the sGC produce distinctive downstream effects suggesting that cGMP 
signalling is also compartmentalised. 
It has previously been published that cGMP can alter PDE2 and PDE3 activity and 
therefore can potentially affect cAMP concentrations. In order to assess if an interplay 
between cGMP and cAMP signalling occurs in adult rat cardiomyocytes in the PKA-RI 
and PKA-RII compartments, cells were first treated with GC activators to raise cGMP 
levels, then the cAMP response to β-AR stimulation was measured and compared to cells 
with basal levels of cGMP. Myocytes stimulated with 100 nM ISO generated a cAMP 
response that was significantly higher in the PKA-RII compartment than in the PKA-RI 
compartment. To measure the effect of cGMP on the cAMP response to ISO in these two 
compartments, myocytes were pre-treated with the NO donor SNAP, which activates the 
soluble guanylyl cyclase (sGC) leading to increased intracellular cGMP concentrations. 
ISO stimulation in these cells resulted in a higher cAMP response in the PKA-RI 
compartment and a smaller cAMP response it the PKA-RII compartment compared to 
control cells. Therefore it was hypothesised that PDE2 is mainly associated with the PKA-
RII compartment, while PDE3 is mainly coupled to the PKA-RI compartment in ARVM, 
and upon SNAP treatment the cGMP generated can regulate cAMP signalling in these 
domains in opposite ways, being PDE2 activated and PDE3 inhibited by cGMP. This was 
confirmed by pre-treating ARVM with SNAP and a specific PDE inhibitor for PDE2 or 
PDE3 before ISO stimulation. These findings are in agreement with previously published 
data in neonatal myocytes (Stangherlin et al. 2011). 
When cardiomyocytes expressing either RI_epac or RII_epac were treated with ANP to 
activate the particulate guanylyl cyclase (pGC), addition of ISO did not result in an 
inversion of the cAMP gradient as was observed in SNAP treated cells. ANP generated a 
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pool of cGMP which caused an increase in cAMP concentration specifically in the PKA-
RI compartment while there was no effect on the PKA-RII compartment. This data again 
suggests that PDE3 is linked to the PKA-RI compartment in adult cardiomyocytes 
Together these findings show that cGMP modulates the cAMP response to ISO in a 
compartment specific manner in adult myocytes. The functional impact that cGMP has 
depends upon its source, either pGC or sGC, which have been shown to localise in 
different compartments throughout the myocyte (Stangherlin et al. 2011). ANP mediated 
activation of pGC generated a pool of cGMP specifically in the PKA-RI compartment 
whereas sGC was able to generate cGMP in both the PKA-RI and PKA-RII compartments. 
cGMP generated by sGC decreases cAMP levels via PDE2 activation and increases cAMP 
levels via PDE3 inhibition, whereas cGMP generated by pGC selectively increases cAMP 
levels via inhibition of PDE3. 
 
This data differs from what has been reported in rat neonatal myocytes, where ANP-
mediated activation of pGC, generated a pool of cGMP selectively in the PKA-RII 
compartment which resulted in a reduced cAMP response to ISO via the activation of 
PDE2 (Stangherlin et al. 2011). It is possible that this is a developmental difference 
between neonatal and adult cardiomyocytes. It has also previously been reported that 
cGMP modulation of cAMP signalling is dependent on the intracellular concentrations of 
cGMP. At low concentrations (< 50 nM) cGMP exclusively inhibits PDE3 activity, 
whereas at high concentrations (200 – 500 nM), cGMP activates PDE2 (Zaccolo and 
Movsesian 2007). Therefore it is reasonable to assume that in this case the concentration of 
cGMP produced by ANP was not high enough to activate PDE2 or that ANP generated a 
pool of cGMP specifically in the PKA-RI region. PDE3 activity in this compartment could 
therefore be inhibited at the lower concentrations of cGMP which was produced by pGC. 
These data further support the hypothesis of a compartmentalisation of cGMP signalling as 
different stimuli which raise intracellular cGMP levels activate different downstream 
effectors.  
 
Similar experiments were carried out in hypertrophic ARVM, where SNAP treatment 
before ISO stimulation resulted in significantly less cAMP detected in the PKA-RI 
compartment compared to SNAP treated control myocytes. PDE3 is normally active in the 
PKA-RI compartment of adult myocytes; therefore an increase in cGMP levels (due to 
SNAP treatment) would normally result in an inhibition of PDE3 activity and a subsequent 
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increase in cAMP at this region. However this is not the case, but instead there is a 
reduction in cAMP in the PKA-RI compartment in hypertrophic SNAP treated myocytes 
compared to SNAP treated control myocytes. This data would suggest a loss of cGMP/ 
PDE3 interaction or alternatively an increase in PDE2 activity in this compartment. PDE2 
is found in both the PKA-RI and PKA-RII compartment of the ARVM, but is mainly 
localised to the PKA-RII compartment in hypertrophic myocytes (see Figure 5-15). It 
would be expected that SNAP treatment would generate an increase in PDE2 activity via 
cGMP activation, resulting in a reduced cAMP response in this compartment. However no 
difference was established between SNAP treated control ARVM and SNAP treated 
hypertrophic ARVM. This can be explained by the fact that cGMP levels are already raised 
in hypertrophic myocytes, and therefore PDE2 is already activated in this cell type and 
SNAP has no further effect on this PDE family.  
 
In this study (Figure 5-15), the FRET experiments indicated there was increased PDE2 
activity specifically in the PKA-RII compartment of hypertrophic myocytes but no change 
in protein or mRNA, and given that PDE2 can be activated by cGMP, it was hypothesised 
that the increased PDE2 activity may be due to increased levels of cGMP. To test this 
hypothesis, the FRET based cGMP sensor Cygnet-2.1 was expressed in both control and 
hypertrophic myocytes in order to gain basal cGMP measurements in these cell types. The 
outcome was that the basal intracellular cGMP concentrations were higher in hypertrophic 
ARVM compared to control ARVM. To further investigate whether changes in cGMP 
levels may be responsible for the altered PDE regulation in the PKA-RI and PKA-RII 
subcellular locations, the cGMP sensor cygnet-2.1 was genetically modified and targeted 
to two compartments by fusing the dimerisation/docking domains of RIα and RIIβ of PKA 
to the N-terminus to generate RI-Cygnet-2.1 and RII-Cygnet-2.1 respectively. Sensors 
were subcloned in adenoviral vector and myocytes were infected overnight before imaging. 
The data obtained showed a higher basal level of cGMP in the PKA-RI compartment 
compared to the PKA-RII compartment in control ARVM. In hypertrophic myocytes, there 
was a greater cGMP concentration recorded in both the PKA-RI and PKA-RII 
compartments, but with the greatest fold change in the PKA-RII compartment. These 
results suggest that increased PDE2 activity detected by FRET imaging in the PKA-RII 
compartment may be due to the increased cGMP levels recorded in hypertrophic myocytes. 
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Our laboratory had previously demonstrated that catecholamine stimulation leads to a 
negative feedback control loop of cAMP signalling in cardiomyocytes, where β1- and β2-
ARs produce cAMP, and stimulation of the β3 receptor leads to the production of NO, 
which, sequentially, stimulates sGC to produce cGMP. PDE2 is activated by cGMP and 
degrades cAMP, therefore acting as a balance for cyclic nucleotide signalling (Mongillo et 
al. 2006). Under normal conditions, this mechanism would exist to counteract excessive β-
adrenergic excitation but would drive cardiac impairment in heart failure by further 
reducing the already blunted cAMP response. It has been shown that in heart disease, β1-
AR and β 2-AR are downregulated or desensitised respectively, whereas there is an 
increase in β3-AR protein (Cheng et al. 2001; Moniotte et al. 2001). 
 
β3-AR signalling was investigated in this model of cardiomyocyte hypertrophy to assess if 
this mechanism may be responsible for the increased cGMP concentrations measured and 
the alteration in local PDE2 activity. 
Control and hypertrophic myocytes were infected with the targeted cGMP FRET based 
sensors RI-Cygnet-2.1 and RII-Cygent-2.1 overnight and pre-treated with 100 nM β3-AR 
inhibitor (SR59230A) 10 minutes before imaging. In control cells, β3-AR inhibition caused 
a reduction in cGMP in the PKA-RI compartment, which suggests that under normal 
conditions β3-ARs are coupled to the PKA-RI compartment. This data may explain the 
observed higher cGMP level in the PKA-RI compartment compared the PKA-RII in 
control ARVM.  
 
In hypertrophic cells treated with β3-AR inhibitor, a smaller cGMP concentration was 
detected in the PKA-RII compartment compared to the RI, suggesting that in hypertrophic 
myocytes there is a greater β3-AR activity in the PKA-RII compartment. This change in the 
compartment within which β3-AR inhibition appears to have an effect in terms of cGMP 
levels could explain why there is higher PDE2 activity in this compartment in hypertrophic 
ARVM.  
These findings indicate that there is interplay between cGMP and cAMP in a compartment 
specific manner in adult rat cardiomyocytes and that altered PDE2 activity may be due to 
modified cGMP compartmentalised signalling in hypertrophic myocytes. 
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7 Role of Phosphodiesterase type 2 in 
the development of cardiac 
hypertrophy. 
 
 
 
7.1  Introduction 
Cardiomyocyte hypertrophy is the cellular response to increased biomechanical stress and 
is defined by an increase in cardiomyocyte size, enhanced protein synthesis, and a higher 
organisation of the sarcomere. In hypertrophy, the increased size of the myocytes is 
initially a compensatory mechanism; however, sustained hypertrophic growth can 
ultimately lead to a decline in left ventricular function leading to heart failure. Although 
pathological hypertrophy is in the end a detrimental process, it is nonetheless highly 
organised by activation of specific intracellular signalling pathways. These signalling 
pathways are defined as either adaptive, as their activation is crucial for successful 
remodelling of the heart to compensate for increased stress, or as maladaptive, as 
activation of these pathways leads ultimately to contractile dysfunction and heart failure. 
The calcineurin-nuclear factor of activated T-cells (NFAT) signalling pathway, for 
example, is one of the most studied hypertrophic pathways and is considered to be 
maladaptive. Phospho-NFAT is cytosolic, but when dephosphorylated by calcineurin, it 
translocates to the nucleus and promotes transcription of pro-hypertrophic genes in 
cardiomyocytes (Hogan et al. 2003). The cGMP signalling pathway is considered to be an 
adaptive response and beneficial as cGMP has been shown to produce anti-hypertrophic 
effects via PKG mediated phosphorylation of the L-type Ca
2+
 channel and reduction of 
Ca
2+
 influx and thereby inhibiting the pro-hypertrophic effects of NFAT/ calcineurin 
signalling (Fiedler et al. 2002). 
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A number of studies have reported that production of cGMP can have anti-hypertrophic 
effects in a range of disease models. Rosenkranz and colleagues reported that increasing 
cGMP by treatment of atrial natriuretic peptide (ANP) to adult cardiomyocytes could 
prevent hypertrophy induced by angiotensin II (Ang II) stimulation (Rosenkranz et al. 
2003). Another study found that in ventricular cells cultured from the neonatal rat heart, 
ANP and the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) cause a decrease in 
NE induced hypertrophy (Calderone et al. 1998). Furthermore, transgenic mice with 
deficiencies of neuronal nitric oxide synthase (NOS1) or endothelial nitric oxide synthase 
(NOS3), causing inhibition of cGMP synthesis, lead to hypertrophic growth of the 
hearts(Barouch et al. 2003). 
 
This study has so far shown that the contribution of PDE2 to the degradation of cAMP 
generated in response to ISO is significantly increased in an in vitro model of cardiac 
hypertrophy. PDE2 expression levels were however unchanged in hypertrophic ARVM, 
thus suggesting that the increased PDE2 activity detected might be due to an increased 
activation of the enzyme. This increased activation of PDE2 was found to be 
compartmentalised and to occur specifically in the PKA-RII compartment where PKA-RII 
normally resides.  
 
Results obtained in chapter 6.2.3 of this study, indicated that cGMP basal levels were 
significantly increased in hypertrophied ARVM which was mainly associated with an 
increase of cGMP in the PKA-RII compartment. Thus, it is possible to hypothesise that 
increased local levels of cGMP might be responsible for the increased PDE2 activity found 
in hypertrophic cardiac myocytes in the PKA-RII compartment. 
It was decided to next investigate whether the increased PDE2 activity, measured in NE 
treated ARVM, contributes to the development of cardiomyocyte hypertrophy. 
 
 
 
Aims 
 Investigate the effect that PDE2 inhibition with Bay 60-7550 has on NE induced 
cardiomyocytes hypertrophy.  
 Measure the effect that increasing PDE2 activity by overexpression of the enzyme 
has on the hypertrophic growth of adult myocytes in vitro. 
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 Assess what is the signalling pathway downstream of PDE2 that is involved in the 
regulation of cardiac myocyte size. 
 
 
 
7.2  Results 
7.2.1 In vitro inhibition of PDE2 with Bay 60-7550 
prevents NE induced cardiomyocyte hypertrophy 
In order to assess whether increased PDE2 activity (due to increased PDE2 activity 
specifically in the PKA-RII compartment) promotes the advancement of cardiac 
hypertrophy, primary cultured ARVM were stimulated simultaneously with 1 μM NE and 
50 nM Bay 60-7550 overnight before the cells were either imaged to calculate changes in 
hypertrophic growth by measurement of cell size or collected for mRNA extraction to 
check for the expression of pro-hypertrophic genes using RT-PCR. As previously 
mentioned in chapter 3.5.1, cell size was calculated by measuring of longitudinal section 
area (length x width). One pixel corresponds to 0.07 µm when images are collected at 40X 
objective. 
 
As shown below (Figure 7-1A & B), cell size was significantly increased in myocytes 
treated overnight with 1 μM NE compared to untreated controls. To investigate the role of 
PDE2 in the development of hypertrophic growth in the adult system, ARVM were 
simultaneously treated with NE and pharmacological PDE 2 inhibitor Bay 60-7550 (50 
nM) overnight before measuring cell size. If the increased PDE2 activity recorded in 
hypertrophic ARVM is a compensatory mechanism elicited in the attempt to counteract 
hypertrophy, inhibition of the enzyme should lead to a more pronounced hypertrophic 
response; on the other hand, if the increased PDE2 activity contributes to the development 
of the hypertrophic phenotype, inhibition of PDE2 should reduce NE-induced hypertrophy. 
The longitudinal sectional area was significantly smaller in the myocytes treated with both 
NE and Bay 60-7550 compared to the ARVM treated with NE alone.  
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Measurements of ANP mRNA levels further confirmed that inhibition of PDE2 blunts NE-
induced hypertrophy in ARVM. As shown in Figure 7-1C, ANP mRNA levels remained at 
control levels in myocytes treated with both NE and Bay 60-7550, showing almost halved 
ANP expression compared to cells treated with NE alone. These results indicate that 
inhibition of PDE2 is able to reduce hypertrophic growth in this model of cardiomyocyte 
hypertrophy in ARVM. This would suggest that the previously recorded increase in PDE2 
activity in NE treated ARVM (Figure 5-15), adds to the development of hypertrophy rather 
than acting to offset it. 
 
 
 
Figure 7-1. Inhibition of PDE2 prevents hypertrophy induced by norepinephrine treatment in 
ARVM. 
(A) Representative images of untreated, NE (1 μM) treated and NE (1 μM) + Bay 60-7550 (50 
nM) treated isolated ARVM.  (B) Summary of cell size measurements (longitudinal area = 
length x width) in ARVM myocytes in the presence of NE or NE + Bay 60-7550. Control: n = 
137; NE: n = 142; NE + Bay 60-7550: n = 129. (C) Summary of RT-PCR results for ANP 
expression levels in NE-treated and NE + Bay 60-7550 treated cardiac myocytes. Control: 
n=29; NE: n=29; NE + Bay 60-7550:  n=12. One way ANOVA, * p<0.05, *** p<0.001. 
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7.2.2 PDE2 overexpression in ARVM induces hypertrophy 
Until now, the results presented in this thesis show that PDE2 activity is significantly 
higher in hypertrophied myocytes, due to increased PDE2 activity in the PKA-RII 
compartment, and that pharmacological inhibition of PDE2 can counteract NE induced 
hypertrophic growth in vitro. Therefore, it was decided to investigate whether hypertrophic 
growth could be induced in primary cultured adult rat cardiomyocytes by increasing PDE2 
activity as a result of overexpression of this enzyme. 
Myocytes were transduced with an adenovirus carrying PDE2A2 wild type tagged with the 
red fluorescent protein mCherry (produced by Vector Biolabs). Constructs were tagged 
with a fluorescent marker as the efficiency of infection is not 100%; therefore the presence 
of the fluorescent tag allows to easily distinguish between ARVM expressing the 
recombinant PDE2A2 enzyme from those which do not. 
The results summarised in Figure 7-2A&B show that cells overexpressing PDE2A2wt 
were significantly larger than control ARVM. This data indicates that overexpression of 
PDE2 is sufficient per se to induce hypertrophic growth of adult cardiac myocytes in vitro. 
 
A catalytically dead form of the PDE2A2wt mCherry construct was produced to establish 
whether the hypertrophic growth is simply due to the overexpression of the PDE2A2 
enzyme or if it is due to increased PDE2 activity. This construct was generated by 
substituting two aspartic acid residues with two alanine residues at positions 685 and 796 
in the catalytic site of the enzyme and had previously been demonstrated to abolish the 
ability of PDE2 to degrade cAMP (Stangherlin et al. 2011). When the catalytically dead 
PDE2 is overexpressed in cells it is expected to displace the endogenous active PDE2 from 
any anchoring site within the cell. The construction of Adenovirus containing the mutated 
PDE2A2 dn mCherry-tagged vectors and the preparation of a high titre virus batch were 
outsourced from Vector Biolabs. 
 
As illustrated in Figure 7-2C & D, the overexpression of a catalytically dead version of 
PDE2A2 (PDE2A2 dominant negative, dn) does not induce hypertrophic growth in 
ARVM. 
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Figure 7-2. Overexpression of PDE2A2 causes hypertrophic growth in isolated ARVM.  
(A) Representative images of ARVMs non-transduced or transduced with PDE2A2wt (wild 
type). (B) Summary of calculated cell size for ARVM transduced with PDE2A2wt. (C) 
Representative images of ARVMs non-transduced or transduced with PDE2A2dn (dominant 
negative). Control: n = 39; PDE2A2wt: n=29. (D) Summary of calculated cell size for ARVM 
transduced with PDE2A2dn. Control: n = 39; PDE2A2dn: n=25. Error bars represent SEM. 
Two tailed; paired t-test, *** p<0.001. 
 
 
It would be appropriate to have an additional control of ARVM overexpressing a PDE 
isoform belonging to a different family. However, given the high cost of generating an 
additional adenovirus and limited funds, it was decided that these experiments would not 
be performed. Alternatively, parallel experiments were performed in the laboratory where 
NRVM were transfected with PDE2A2-mCherry, PDE2AdnmCherry or PDE4A4. The 
results of these experiments showed that as reported in ARVM, overexpression of 
PDE2A2 induces hypertrophic growth. Cell surface area: control NRVM = 54933 ± 2709 
pixels, n = 49; PDE2A2 wild type- transfected NRVM = 75318 ± 4421 pixels, n = 50; p < 
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0.001), whereas the overexpression of the catalytically dead PDE2A2 had no effect of cell 
size (control NRVM = 56597 ± 3617 pixels, n = 33; PDE2A2-dn NRVM = 56629 ± 6227, 
n = 38; ns). The addition control illustrated that neither the overexpression of PDE4A nor 
the overexpression of its catalytically inactive form had effects on cardiac myocytes cell 
surface area (control NRVM = 53960 ± 4622, n = 29; PDE4A4wt NRVM = 46971 ± 4911, 
n = 28; ns) (control NRVM = 50041 ± 3842, n = 28; PDE4Adn NRVM = 50620 ± 4238, n 
= 28; ns) (A. Zoccarato, unpublished results). 
 
Together these results would indicate that the catalytic activity of PDE2 is required to 
induce hypertrophic growth in ARVM and NRVM. As PDE2A2dn displaces endogenous 
PDE2 from its anchor site, allowing it to freely move throughout the cell, it would appear 
that the subcellular localisation of PDE2 activity, and therefore the ability of PDE2 to 
control cAMP levels within a specific subcellular compartment, is also key in the 
promotion of hypertrophic growth. 
 
 
 
7.2.3 Exploring the effect that overexpressing the 
catalytically inactive PDE2A2 has on cAMP 
signalling dynamic in adult cardiomyocytes 
To investigate the effect displacing endogenously active PDE2 from its anchor sites has on 
local cAMP pools, using the catalytically dead PDE2 construct in adult myocytes, a FRET-
based imaging approach was applied. ARVM were co-transduced with either the targeted 
FRET-based sensors RI_epac or RII_epac and PDE2A2dn mCherry (MOI: 1000) 
overnight. The cells were then imaged the following day on an epifluorescent microscope. 
cAMP generation was stimulated by challenging the cardiomyocytes with 100 nM ISO. 
The results obtained, as illustrated in Figure 7-3A, show that in the PKA-RI compartment 
ISO stimulation induces a cAMP response which is significantly higher in cells that 
overexpress PDE2A2dn compared to control myocytes. In the PKA-RII subcellular 
compartment, there is no difference in cAMP levels upon ISO stimulation in cells 
transduced with PDE2A2dn compared to control ARVM, however the difference between 
the PKA-RI and PKA-RII compartment is abolished in myocytes transduced with 
PDE2A2dn. These data are similar to the earlier findings from chapter 4, where 
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pharmacological inhibition of PDE2 with Bay 60-7550 (50 nM) before ISO stimulation 
resulted in a comparable level of cAMP in both the PKA-RI and PKA-RII compartments, 
but the greatest effect was seen in the PKA-RI compartment (Figure 4-9). 
 
 
 
 
Figure 7-3. Summary of FRET change in ARVM overexpressing PDE2A2dn. 
Summary of FRET change induced by 100 nM isoproterenol in the presence or absence of 
(A) PDE2A2dn - RI_epac control: n = 15; RI_epac + PDE2A2dn: ΔR n = 6; RII_epac control:  n 
= 15; RII_epac + PDE2A2dn: n = 9 . (B) PDE2 inhibitor Bay 60-7550 (50 nM) (as previously 
shown in Figure 4-9). RI_epac control: n =8; RII_epac control: n = 16; RI_epac + Bay 60-
7550: n =10; RII_epac + Bay 60-7550: n = 9. Statistical significance calculated by two way 
ANOVA with Bonferroni’s post test, ** p<0.01, *** p<0.001. 
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n myocytes which had been pre-treated with 1 μM NE to induce hypertrophy, before 
transducing them with the adenovirus containing PDE2A2dn and the targeted FRET 
reports (Figure 7-4A), ISO stimulation resulted in increased cAMP generation in the PKA-
RI compartments compared to control myocytes which did not contain the PDE2A2dn 
enzyme. There was also elevation of cAMP in the PKA-RII compartment in myocytes 
transduced with PDE2A2dn after ISO stimulations. Comparison of the two compartments 
in cells with PDE2A2dn, the cAMP levels were significantly greater in the PKA-RII 
compartment compared to the PKA-RI compartment (p < 0.05). These results were again 
in agreement with the data obtained using PDE2 inhibitor Bay 60-7550 (50 nM) in NE 
treated myocytes (Figure 7-4B), where ISO (100 nM) stimulation resulted in increased 
cAMP production in both the PKA-RI and PKA-RII compartments when myocytes were 
pre incubated for 10 minutes with Bay 60-7550 compared to ISO treatment alone.  
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Figure 7-4. . Summary of FRET change in hypertrophic ARVM overexpressing PDE2A2dn. 
(A)Summary of FRET change induced by 100 nM isoproterenol in the presence or absence 
of PDE2A2dn in myocytes pre-treated with norepinephrine to induce hypertrophy. RI_epac 
hypertrophic: n = 14; RI_epac hypertrophic + PDE2A2dn: n = 6; RII_epac hypertrophic: n = 
14; RII_epac hypertrophic + PDE2A2dn: n = 10. (B) Experiment carried out in the presence of 
selective PDE2 inhibitor Bay-607550 (as shown in chapter 5.2.4). RI_epac hypertrophic: 
ΔR/R0 = n = 7; RI_epac hypertrophic + Bay 60-7550: n = 9; RII_epac hypertrophic: n = 18; 
RII_epac hypertrophic + Bay 60-7550: n = 10. Statistical significance calculated by two way 
ANOVA with Bonferroni’s post test, * p<0.05, ** p<0.01, *** p<0.001. 
 
 
Together these data support the hypothesis that cAMP signalling is altered in hypertrophic 
adult cardiomyocytes due to altered PDE2 activity. In control ARVM, PDE2 is mainly 
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coupled with the PKA-RI compartment; however with increased catecholamine 
stimulation, leading to hypertrophic growth, PDE2 activity is increased in the PKA-RII 
compartment and its activity is found to be more associated with this compartment. 
Displacement of PDE2 by PDE2A2dn or inhibition of PDE2 with Bay 60-7550 appears to 
have a similar anti-hypertrophic effect in ARVM, these results strongly indicate that PDE2 
is localised in the myocyte and the effect that its inhibition generates on cell growth 
depends on the modulation of cAMP within a restricted and localised pool of cAMP. 
Additional investigation is required to further elucidate the signalling pathway involved 
downstream of PDE2 inhibition and the consequent local rise in cyclic nucleotide levels. 
 
 
 
7.2.4 Is the anti- hypertrophic effect of PDE2 inhibition 
dependent of cAMP/PKA or cGMP/PKG downstream 
signalling? 
PDE2 is a dual specific PDE, which means it has the ability to degrade both cAMP and 
cGMP, and therefore the anti-hypertrophic effect of PDE2 inhibition described in this 
thesis could be mediated by either an increased activation of cAMP and consequent 
activation of PKA or alternatively by an increase in cGMP levels and activation of PKG. 
The cGMP/ PKG signalling pathway is widely accepted as a negative regulator in the 
cardiac remodelling process. The literature reports numerous studies where increased 
cGMP synthesis by stimulation of natriuretic peptides or NO donors or by the 
overexpression of guanylyl cyclase reduces cardiac hypertrophy.  
 
Hypertrophy stimulated in isolated ARVM by Ang II treatment was shown to be prevented 
by the addition of natriuretic peptides (Rosenkranz et al. 2003). Another investigation 
found mice lacking functional Npr1 gene, which encodes GC-A (denominated NPRA by 
the authors) throughout the body showed arterial hypertension with a disproportionate 
degree of cardiac hypertrophy, and mice with cardiac-specific NPRA deletion develop 
exaggerated hypertrophy in response to pressure overload (Oliver et al. 1997). Conversely, 
cardiac overexpression of active GC inhibits pressure-overload hypertrophy and 
remodelling (Zahabi et al. 2003). 
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PKG plays also plays an important role as a negative regulator of cardiac hypertrophy. 
Zhang and colleagues found that mice with reduced myocyte PKG activity, caused by 
PDE5 overexpression, develop exacerbated hypertrophy and remodelling in response to 
pressure overload, and normalizing PKG activity by switching off PDE5 overexpression 
improves the already established remodelling (Zhang et al. 2010). Another study reported 
that mice with cardiac-specific deletion of PKGI, revealed more pronounced remodelling 
to angiotensin II or pressure overload by transverse aortic constriction (Frantz et al. 2011).  
 
However, the role of the PKG pathway in cardiac hypertrophy is still controversial. 
Lukowski and colleagues showed that in PKG knock-out mice and mice lacking PKG 
specifically in cardiomyocytes, that there was no difference in degree of cardiac 
hypertrophy induced by chronic ISO infusion or surgical constriction of the transverse 
aorta (TAC), when compared to wild type control mice (Lukowski et al. 2010). This study 
suggests that the development of cardiac hypertrophy is not amplified by the absence of 
endogenous PKG. 
 
Recently, the involvement of the cGMP selective PDE 5 and of the dual-specific PDE1 in 
modulating hypertrophic effects both in vivo and in vitro models of cardiac hypertrophy 
has been reported (Takimoto et al. 2005; Miller et al. 2009). Takimoto reported that the 
phosphodiesterase-5A (PDE5A) inhibitor Sildenafil suppresses chamber and myocyte 
hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure 
overload induced by transverse aortic constriction. PDE5A inhibition was found to 
deactivate multiple hypertrophy signalling pathways triggered by pressure load (the 
calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signalling 
pathways) and increase the activation of cGMP-dependent protein kinase (PKG). Miller 
and colleagues discovered that inhibition of PDE1 activity prevented phenylephrine 
induced hypertrophy in neonatal and adult rat ventricular myocytes, as well as reducing 
cardiac hypertrophy induced by chronic ISO infusion in vivo. PDE1A was reported as 
significantly upregulated in both in vivo and in vitro forms of cardiomyocyte hypertrophy, 
which plays a critical role a reduction of intracellular cGMP and PKG. In both of these 
studies the anti-hypertrophic effects of PDE1 and PDE5 inhibition have been suggested to 
be mediated by activation of cGMP/PKG signalling pathways (Takimoto et al. 2005; 
Miller et al. 2009) therefore the anti-hypertrophic effects resulting from PDE2 inhibition 
was investigated to assess whether this process was mediated by cGMP/ PKG signalling. 
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To establish if cGMP/PKG is involved in the anti-hypertrophic effects of PDE2 inhibition, 
DT-2, a highly selective inhibitor of PKG (Taylor et al. 2004) was utilised. Hypertrophy 
was induced in adult rat ventricular myocytes (ARVM) by stimulation with 1 μM NE 
overnight in presence of the selective PKG-inhibitor DT-2, alone or in combination with 
either Bay 60-7550 or Sildenafil. Sildenafil was used as a control as its anti-hypertrophic 
effect is known to be mediated by PKG (Takimoto et al. 2005). The hypertrophic growth 
was judged by calculating the area of the cell (length x width) from the image of a 
longitudinal section. 
 
First, to ensure the concentration of Sildenafil used was enough to blunt NE effect on 
ARVM, cells were treated with NE in the presence of 10 nM Sildenafil or 50 nM Bay 60-
7550 (Figure 7-5A). The PDE inhibitors had similar effects on cell size and were able to 
exert anti-hypertrophic effects on the myocytes. 
 
In ARVM incubated with PKG inhibitor DT-2 in the presence of Sildenafil (Figure 7-5B), 
there was no difference in cell size compared to NE treated cells alone and therefore DT-2 
was able to block the anti-hypertrophic effect of the PDE5 inhibitor. However, DT-2 
treatment did not affect the anti-hypertrophic action of PDE2 inhibitor Bay 60-7550, as 
illustrated in Figure 7-5B.These data confirm data published by Takimoto and colleagues, 
showing that PKG activity is required for the anti-hypertrophic effects of Sildenafil to 
occur (Takimoto et al. 2005) and indicate that the anti-hypertrophic effect of Bay 60-7550 
does not involve PKG signalling. 
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Figure 7-5. The anti-hypertrophic effects of PDE2 inhibition is PKG independent.  
(A) Summary of cell area measurements of ARVM in the presence of NE ( 1μM) and a 
combination or Bay 60-7550 (50 nM) and/or Sildenafil (10 nM). Control: n = 106; NE: n = 142; 
NE + Bay 60-7550: n = 129; NE + Sildenafil: n = 55; NE + Bay 60-7550 + Sildenafil: n = 59. (B) 
cell size calculated of hypertrophic ARVM in the presence of PKG inhibitor DT-2 and Bay 60-
7550 or Sildenafil. Control: n = 97; DT-2: n = 144; DT-2 + NE: n = 158; DT-2 + NE + Bay 60-
7550: n = 160; DT-2 + NE + Sildenafil: n = 145. ANOVA with Bonferonni’s post-test,* p < 0.05, 
** p<0.01, *** p<0.001. 
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Since the anti-hypertrophic effects of PDE2 inhibition does not seem to require PKG 
activity, the involvement of the cAMP/PKA signalling pathway was explored next. The 
above experiment was repeated in the presence of selective PKA inhibitor myrPKI 
(myristoylated PKA inhibitor) (50 μM) (Islam et al. 2008). 
 
The results summarised in Figure 7-6 show that the anti-hypertrophic effects of Bay 60-
7550 are completely abolished during the selective inhibition of PKA activity by myrPKI. 
As anticipated, Sildenafil treatment, even in the presence of 50 μM myrPKI, is able to 
counteract the hypertrophic growth in ARVM induced by NE. 
These data are important as they indicate that the anti-hypertrophic effects of PDE2 
inhibition are mediated, in part, by cAMP/ PKA and confirm that the anti-hypertrophic 
effects of PDE5 inhibition are not mediated by PKA signalling but instead by cGMP/PKG. 
 
 
 
 
 
Figure 7-6. The anti-hypertrophic effects of PDE2 inhibition are PKA-dependent. 
Summary of cell size calculated in hypertrophic ARVM in the presence of PKA inhibitor 
myrPKI and Bay 60-7550 or Sildenafil. Control: n = 66; myrPKI: n = 93; myrPKI + NE: n = 66; 
myrPKI + NE + Bay 60-7550: n = 71; myrPKI + NE + Sildenafil: n = 110. Statistical analysis by 
ANOVA with Bonferonni’s post-test, *** p<0.001. 
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A classical in vitro model of cardiac hypertrophy, reported in numerous investigations, is 
persistent catecholamine stimulation of β-adrenergic receptors (β-ARs) which are coupled 
to Gαs, induces adenylyl cyclase activity leading to increased cAMP/ PKA activity. PKA 
then phosphorylates several proteins involved in cardiac excitation-contraction coupling 
and energy metabolism, including activation of L-Type Ca
2+
 channels and SERCA, 
resulting in an influx of Ca
2+
 positively chronotropic, inotropic, and lusitropic effects on 
the heart. Increased intracellular calcium is also known to activate the calcineurin-NFAT 
signalling cascade and induce cardiac hypertrophy. In addition to this, increased levels of 
circulating catecholamines are associated with β-ARs desensitisation. Phosphorylation by 
PKA can lead to receptor internalisation, uncoupling from G-proteins or downregulation of 
AR mRNA expression (Lohse et al. 2003). One study showed that transgenic mice 
overexpressing the catalytic subunit of PKA develop dilated cardiomyopathy with reduced 
cardiac contractility, arrhythmias, and susceptibility to sudden death due to PKA-mediated 
hyper-phosphorylation of the cardiac ryanodine receptor and phospholamban (Antos et al. 
2001). 
PKA is therefore generally considered to be a pro-hypertrophic stimulus. However, in this 
thesis I have presented data which illustrates that in an in vitro model of cardiac 
hypertrophy, induced by NE stimulation of ARVM, pharmacological inhibition of PDE2 
abolishes hypertrophic growth. This anti-hypertrophic effect had been shown to occur via a 
PKA dependent mechanism.  
 
To study whether enhancement of the cAMP/PKA pathway by inhibition of cAMP-raising 
agents was pro-hypertrophic in ARVM, isolated adult rat myocytes were treated overnight 
with inhibitors of PDE2, PDE3 and PDE4 and forskolin, a direct activator of adenylyl 
cyclase. 
 
Activation of the cAMP signalling pathway by forskolin (1 μM) produced a pronounced 
increase in cell size compared to control cells. Inhibition of PDE3 by cilostamide (10 μM) 
was also able to induce hypertrophic growth in primary cultured ARVM. Treatment with 
PDE2 inhibitor Bay 60-7550 (50 nM) and PDE4 inhibitor rolipram (10 μM) did not alter 
the size of the cardiomyocytes. 
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Figure 7-7. cAMP increase due to forskolin, rolipram or cilostamide, but not Bay 60-7550 
stimulation has pro-hypertrophic effects. 
Isolated ARVM were treated overnight with 50 nM PDE2 inhibitor Bay 60-7550, 10 μM PDE3 
inhibitor cilostamide, 10 μM PDE4 inhibitor rolipram or 25 μM forskolin before calculating 
changes in cell size compared with untreated myocytes. Control: n = 137; Bay 60-7550: n = 
148; cilostamide: n = 120; rolipram: n = 189; forskolin: n = 112. Statistical analysis by 
ANOVA with Bonferonni’s post-test, *p<0.05, *** p<0.001. 
 
 
Selective inhibition of PDE2 with 50 nM Bay 60-7550 blunts hypertrophic growth of 
ARVMs caused by chronic NE treatment (Figure 7-1). Selective inhibition of PDE3 and 
PDE4 was then explored to study whether it had similar anti-hypertrophic effects. 
Primary cultured adult cardiomyocytes were treated overnight with NE in the presence of 
different cAMP-raising agents and imaged the following day in order to calculate cell size. 
Unlike Bay 60-7550 treatment, inhibition of PDE4 with 10 μM rolipram or PDE3 with 10 
μM cilostamide was unable to prevent the hypertrophic growth induced by NE stimulation, 
although treatment with these inhibitors did not further increased cell size compared to NE 
treatment alone. 
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Figure 7-8. Inhibition of PDE3 or PDE4 did not affect NE-induced cardiomyocytes 
hypertrophic growth. 
Primary cultured ARVM were treated overnight with 1 μM NE in the presence of 50 nM PDE2 
inhibitor Bay 60-7550, 10 μM PDE3 inhibitor cilostamide or 10 μM PDE4 inhibitor rolipram 
before imaging for cell size measurements. NE: n = 142; NE + Bay 60-7550: n = 129; NE + 
cilostamide: n = 7; NE + rolipram: n = 66. Statistical analysis by one way ANOVA with 
Bonferronni’s post test, *** p<0.001. 
 
 
Together these results show that enhancement of intracellular cAMP via direct activation 
of adenylyl cyclases, or selective inhibition of PDE3 or of PDE4 promotes hypertrophic 
growth, whereas enhancement of cAMP via PDE2 inhibition counteracts hypertrophy. It 
was therefore hypothesised that PDE2 controls a unique pool of cAMP which has an anti-
hypertrophic effect in adult cardiomyocytes. 
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7.3  Conclusion 
The intracellular signalling pathways controlling cardiac hypertrophy can have either 
beneficial or deleterious effects. Here, the role that elevated PDE2 activity, as reported in 
chapter 4, might have on cardiomyocyte hypertrophy was assessed. Cell size measurement 
and ANP mRNA levels were compared in isolated ARVM treated with both NE and PDE2 
inhibitor Bay 60-7550. If PDE2 is involved in the development of cardiomyocyte 
hypertrophy, then its inhibition should reduce hypertrophic growth. On the contrary, if 
increased PDE2 activity is an adaptive mechanism to offset hypertrophy, inhibition should 
lead to a more pronounced hypertrophic phenotype. Results indicated that Bay 60-7550 
treatment prevented NE-induced hypertrophic growth and ANP mRNA levels were 
significantly reduced as compared to ARVM treated with NE alone. These data suggest 
that PDE2 activity contributes to the development of cardiomyocyte hypertrophy induced 
by NE treatment in vitro. In addition and importantly they show that inhibition of PDE2 
with Bay 60-7550 prevents the hypertrophic growth from occurring in primary cultured 
ARVM. 
 
Overexpression of endogenous PDE2A2 in isolated ARVM resulted in hypertrophic 
growth of the cells, while overexpression of a catalytically inactive form of PDE2A2 
(PDE2A2dn) had no effect on the calculated cell size. These results indicate that an 
increase in PDE2 activity promotes hypertrophic growth. To study the impact that 
overexpression of the catalytically inactive PDE2A2, and the consequent displacement of 
the active endogenous PDE2 from its anchor site, has on compartmentalised cAMP 
signalling, FRET imaging was applied. The results obtained were similar to earlier results 
using pharmacological PDE2 inhibitor Bay 60-7550, where in control ARVM PDE2 
activity was found mainly associated to the PKA-RI compartment but in hypertrophic 
myocytes PDE2 activity is predominantly found in the PKA-RII subcellular location. This 
data suggests that as increased PDE2 activity is a maladaptive response in hypertrophy, 
selective inhibition of PDE2 in the PKA-RII compartment could produce anti-hypertrophic 
effects. 
 
It has recently been published that PDE5 and PDE1 regulate cardiac hypertrophy in vivo 
and in vitro and the anti-hypertrophic effect upon inhibition of these PDEs is mediated by 
activation of cGMP/PKG pathways (Takimoto et al. 2005; Miller et al. 2009). As PDE2 
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has the ability to degrade both cAMP and cGMP, it was decided that the involvement of 
PKG signalling in the anti-hypertrophic effect produced by PDE2 inhibition would be 
investigated. Cell size was calculated for hypertrophied ARVM in the presence of selective 
PKG inhibitor peptide, DT-2, or PKA inhibitor peptide myrPKI and PDE inhibitors Bay 
60-7550 and Sildenafil. The results showed that in the presence of DT-2 inhibition of 
PDE2 with Bay 60-7550 still produced anti-hypertrophic effects, while inhibition of PKA 
activity prevented the anti-hypertrophic effects of PDE2 inhibition. Therefore PDE2 seems 
to regulate cardiomyocytes hypertrophy via activation of cAMP/PKA signalling pathway. 
 
Classically, activation of the cAMP/PKA signalling pathway is regarded as being pro-
hypertrophic. To investigate if activation of cAMP/PKA signalling promotes hypertrophic 
growth in adult cardiomyocytes, ARVM were incubated with cAMP raising agents. 
Adenylyl cyclase activator forskolin (1 μM), PDE3 inhibitor cilostamide (10 μM) and 
PDE4 inhibitor rolipram (10 μM) all promote cardiomyocytes hypertrophic growth, 
whereas inhibition of PDE2 with Bay 60-7550 (50 nM) has no hypertrophic effect on 
ARVM. Only inhibition of PDE2 and not PDE3 or PDE4 was found to reduce 
hypertrophic growth in ARVM induced by NE overnight treatment. These data are 
consistent with a model whereby cAMP signalling is compartmentalised and that PDE 
families are localised in distinct subcellular compartments (Mongillo et al. 2004; Mongillo 
et al. 2006). Based on this model PDEs can control different pools of cAMP which mediate 
either hypertrophic or anti-hypertrophic effects via activation of PKA. 
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8  Conclusion and Future 
Perspectives 
 
 
In this thesis, intracellular signalling and phosphodiesterase regulation of the cAMP/ PKA 
pathway in cardiac hypertrophy was investigated using real-time FRET-based imaging. 
cAMP is a ubiquitous second messenger which mediates a huge number of diverse cellular 
responses. In the heart, cAMP modulates the positive inotropic and lusitropic effects of β-
adrenergic receptor (β-AR) stimulation through its main effector PKA, promoting the 
phosphorylation and activation of key components of the excitation–contraction coupling 
(ECC) process. It has been demonstrated that cAMP signalling is compartmentalised. 
Discrete microdomains of cAMP, created by the action of phosphodiesterase enzymes, 
have been directly visualised in live cells using genetically encoded cAMP sensors and 
FRET-based imaging (Zaccolo and Pozzan 2002). PKA is anchored to specific subcellular 
targets by its interaction with A kinase anchoring proteins (AKAPs).Within the cell only 
particular pools of PKA are exposed to activating concentrations of cAMP at any one time 
(Colledge and Scott 1999). Thus, signals from one second messenger (in this case cAMP) 
can result in the activation of distinct signal transduction pathways, and diverse 
physiological responses (Buxton and Brunton 1983). 
 
Cardiomyocyte hypertrophy is the cellular response to increased hormonal or mechanical 
stress on the heart. Prolonged hypertrophy is associated with a significant increase in the 
risk for sudden death or progression to heart failure. A number of signalling pathways have 
been reported to be altered during cardiac hypertrophy, including the cAMP/ PKA 
pathway. Chronic catecholamine stimulation results in down-regulation and desensitisation 
of the β-ARs. This leads to impairment in cAMP signalling and PKA phosphorylation of 
key components of the ECC process (Frey and Olson 2003; Barry et al. 2008). It has also 
been shown that, in different models of cardiac hypertrophy, there is altered PDE 
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expression and activity (Abi-Gerges et al. 2009; Mokni et al. 2010). Therapeutic treatment 
for dilated cardiomyopathy and heart failure currently involves increasing cAMP 
generation through β-AR antagonists and PDE inhibitors to try to improve cardiac 
contractility. PDE3 inhibitors such as milrinone have been shown to have beneficial effects 
in patients with impaired cardiac function; however long-term use of such drugs resulted in 
negative side effects such as arrhythmias and increased mortality (Packer et al. 1991; 
Movsesian 2002; Movsesian and Alharethi 2002). These adverse effects may be explained 
by the fact that non-selective inhibition of PDE3 would lead to a global increase in 
intracellular cAMP and activation of PKA, resulting in generalised phosphorylation of all 
substrates of PKA (Movsesian and Alharethi 2002). It has been suggested that selective 
modulation of compartmentalised PDEs activity may result in a more effective treatment 
(Miller and Yan 2010). 
 
In the first part of this thesis, real-time FRET-based imaging approach and the targeted 
FRET-based sensors for cAMP, RI_epac and RII_epac (Di Benedetto et al. 2008), were 
utilised to study cAMP dynamics in the regions where PKA type I and PKA type II 
normally reside in adult rat ventricular myocytes (ARVM). It was established that these 
sensors localise to different compartments in ARVM, where RI_epac overlays both the M 
and Z sarcomeric lines, whereas RII_epac is found mainly on the M line. β-AR stimulation 
generated a significantly greater level of cAMP in the PKA-RII compartment compared to 
the PKA-RI compartment in this cell type. These results support the work completed 
previously in neonatal myocytes (Di Benedetto et al. 2008). The major finding in this 
chapter was that PDE activity is higher in the PKA-RI compartment compared to the PKA-
RII compartment after β-AR stimulation with isoproterenol (ISO). Selective inhibition of 
different PDE families revealed that PDE2 and PDE4 are mainly coupled with the PKA-RI 
compartment after ISO stimulation, but also regulate cAMP levels in the PKA-RII 
compartment. PDE3 was only found to be associated with the PKA-RI compartment. 
 
In the next chapter of this thesis, the same FRET-based sensors were employed to study 
cAMP dynamics in an in vitro model of catecholamine-induced cardiomyocyte 
hypertrophy.  
Primary cultured ARVMs were treated overnight with norepinephrine (NE) to establish an 
in vitro model of cardiomyocyte hypertrophy in adult rat ventricular myocytes (ARVM), 
replicating chronic catecholamine stimulation of β-ARs that can occur in vivo leading to 
Chapter 8 – Conclusion and Future Perspectives 
 
228 
heart hypertrophy. Myocytes developed a clear hypertrophic phenotype as confirmed by 
analysis of several parameters, including cell surface area and switch on of the cardiac fetal 
gene program (ANP and skeletal α-actin expression levels). Some of these parameters have 
been then utilised throughout this work as a marker of the hypertrophic phenotype.  
 
FRET-based imaging revealed that in hypertrophic myocytes the difference in cAMP 
generation between the PKA-RI and PKA-RII compartments upon ISO treatment is 
abolished. Both compartments also have a significantly reduced response compared to 
control cells, suggesting down regulation of the β-ARs. The major finding of this part of 
my work is that global cAMP-hydrolytic activity is significantly increased in hypertrophic 
ARVM after ISO stimulation and more specifically this increase in PDE activity was found 
to occur in the PKA-RII compartment. To identify which PDE family may be responsible 
for the increased enzymatic activity in hypertrophic myocytes, cells were treated with 
selective PDE inhibitors and compared with control ARVM. Altered activity was found in 
all the PDE families investigated. There was a significant increase in PDE2 and PDE4 
activity in the PKA-RII activity in hypertrophic myocytes. FRET imaging also exposed a 
loss of PDE3 and PDE4 activity in the PKA-RI compartment. 
Interestingly, analysis of both PDE2 mRNA and protein levels indicated that the increased 
PDE2 activity detected in hypertrophic myocytes does not correlate with an increase in 
PDE2 expression levels, thus suggesting that PDE2 activity might be post-transcriptionally 
regulated. Immunostaining of ARVM revealed that PDE4B and PDE4D localisation were 
altered in hypertrophic myocytes where a higher correlation with α-actinin is detected. A 
kinase anchoring proteins (AKAPs) have been shown to form complexes with PDEs in 
macromolecular complexes, for example mAKAP and Yotiao bind PDE4D3 in close 
proximity of PKA targets, which results in a tighter regulation of the cAMP signal. Altered 
PDE4 localisation could signify altered AKAP expression. Relocation of AKAPs was also 
indicated by immunofluorescence experiments where hypertrophic ARVM were treated 
with RI_epac and RII_epac then stained for α-actinin and compared to control myocytes. 
One possibility for future work would be to generate new FRET sensors targeted to 
specific AKAPs of the heart, which will give a more detailed map of cAMP signalling and 
PDE control, as well as more information on which AKAPs are relocated in disease 
models.  
In the next part of this thesis, it was demonstrated that, in ARVM, cGMP can alter cAMP 
levels through the modulation of PDE2 and PDE3 activity. Treatment with the NO donor 
Chapter 8 – Conclusion and Future Perspectives 
 
229 
SNAP resulted in an inversion of the cAMP gradients in the PKA-RI and PKA-RII 
regions, upon ISO stimulation. This inversion is dependent on cGMP generation and on the 
compartment specific modulation of PDE2 and PDE3. In particular my data indicate that 
there is a functional association between PDE3 and the PKA-RI compartment and PDE2 
and the PKA-RII compartment after cGMP production is stimulated. These results 
confirmed what had previously been published in neonatal myocytes (Stangherlin et al. 
2011). FRET microscopy experiments showed that in hypertrophied ARVM, basal cGMP 
levels are significantly higher than in control cells. It was hypothesised that the increased 
PDE2 activity recorded in hypertrophic conditions may be due to an increased cGMP-
mediated activation of this enzyme, where the largest increase in basal cGMP was recorded 
in the PKA-RII compartment. Increased cGMP levels in hypertrophic myocytes may be 
linked to altered β3-AR signalling, as β3-AR stimulation can elevate cGMP levels via 
activated NOS. β3-ARs were found to be coupled to the PKA-RI compartment in control 
ARVM, whereas these receptors are mainly associated with the PKA-RII in 
catecholamine-induced hypertrophic cardiomyocytes. 
 
In the final part of this thesis, it was demonstrated that PDE2 activity is pro-hypertrophic 
and that inhibition of PDE2 blunts the NE-induced hypertrophic growth. This hypothesis 
suggests that cGMP mediated activation of PDE2 is pro-hypertrophic. This is in contrast 
with evidence reported in the literature showing an anti-hypertrophic role of cGMP 
(Ritchie et al. 1998; Horio et al. 2000; Rosenkranz et al. 2003; Zahabi et al. 2003). One 
possible explanation for this discrepancy between these results and the literature is that in 
cardiac myocytes cGMP is also compartmentalised (Castro et al. 2006; Fischmeister et al. 
2006; Stangherlin et al. 2011), and thus it is possible to that a specific pool of cGMP, by 
activating PDE2, may play a pro-hypertrophic role, whereas cGMP in a different region 
may exert anti-hypertrophic effects. 
In support of this hypothesis, Yanaka and colleagues published data reporting that PDE2 
activity is significantly increased in rats that have undergone surgical thoracic aortic 
constriction (TAC) to induce cardiac hypertrophy by pressure-overload (Yanaka et al. 
2003). This study indicates that cGMP mediated activation of PDE2 plays a role in cardiac 
hypertrophy. Recently, Aye and co-workers reported a significant increase in PDE2 and 
PKG in the human failing heart (Aye et al. 2012). 
Furthermore, overexpression of PDE2 in ARVM with an adenovirus carrying the wild type 
enzyme was sufficient enough to induce hypertrophic growth in vitro. These data indicate 
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that PDE2 is involved in the development of cardiomyocyte hypertrophy. It would be 
interesting to explore whether PDE2 is increased in other models of cardiac hypertrophy, 
for example, in models of both adaptive (i.e. exercise induce hypertrophy) or maladaptive 
(i.e. thoracic aortic constriction (TAC) or isoproterenol infusion) cardiomyocyte 
hypertrophy, and explore the impact of PDE2 inhibition with Bay 60-7550 in these 
animals. Another interesting aspect to explore is whether inhibition of PDE2 can reverse 
the hypertrophic phenotype by investigating the effects of Bay 60-7550 treatments in 
animal models where cardiac hypertrophy is fully developed. 
 
In cardiac myocytes, activation of the cAMP/ PKA pathway is generally considered to be 
pro-hypertrophic (Iwase et al. 1996; Engelhardt et al. 1999; Antos et al. 2001). However, 
in this thesis the anti-hypertrophic effects of Bay 60-7550 were found to be mediated by 
activation of PKA. To investigate the role of cAMP/PKA signalling in the development of 
cardiomyocyte hypertrophy, cAMP levels were enhanced using selective PDE inhibitors 
and forskolin overnight to study whether they promoted hypertrophic growth. Interestingly, 
there is a noticeable increase in cell surface area of ARVM is when intracellular cAMP 
content is increased via direct activation of adenylyl cyclases, or via inhibition of PDE3 or 
PDE4. However, inhibition of PDE2 does not promote hypertrophic growth.  
Although this seems to be a contradiction, it is possible that PDE2 controls a distinct pool 
of cAMP which subsequently activates a subset of PKA that has anti-hypertrophic effects, 
whereas PDE3 and PDE4 control different pools of cAMP that mediate pro-hypertrophic 
responses. This idea suggests that in cardiac myocytes PDE2, PDE3 and PDE4 are 
compartmentalised. Immunostaining of ARVM for these PDEs revealed different 
localisations of these enzymes. Data previously published by Mongillo et al. in rat neonatal 
cardiomyocytes also supports this hypothesis (Mongillo et al. 2004; Mongillo et al. 2006). 
It was recently shown, both in vitro and in vivo, that PKA phosphorylates NFAT at the 
level of Ser245, Ser269 and Ser 294 thereby preventing its translocation into the nucleus 
(Sheridan et al. 2002). The authors showed that mutation of these serines to alanines not 
only prevents PKA phosphorylation, but also the ability of PKA to oppose calcineurin-
mediated dephosphorylation and nuclear accumulation of NFAT. It is possible that PKA 
mediated phosphorylation of NFAT may be one mechanism through which the pool 
controlled by PDE2 counteracts catecholamine-induced hypertrophy. However, further 
experiments are required to confirm this hypothesis, for example western blot analysis of 
NFAT phosphorylation levels. However, difficulties with antibodies specificity and very 
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low level of expression of endogenous NFAT may make these experiments difficult to 
complete. An alternative approach is to overexpress a GFP-tagged version of NFAT in 
ARVM to increase efficiency of an immunoprecipitation and test the level of NFAT 
phosphorylation upon treatment with NE, NE and Bay 60-7550 and a combination of NE, 
Bay 607550 and a PKA inhibitor. 
Another way in which PKA may play anti-hypertrophic role was described by Backs and 
colleagues (Backs et al. 2011). In this work the authors showed that PKA phosphorylates 
histone deacetylase 4 (HDAC4), thereby promoting the generation of an N-terminal 
HDAC4 cleavage product (HDAC4-NT) which in turn selectively inhibits the activity of 
the pro-hypertrophic myocytes enhance factor 2 (MEF2). This is a potentially interesting 
alternative target and experiments are planned to explore the possibility that this 
mechanism contributes to the anti-hypertrophic effects of PDE2 inhibition. 
 
The major limitation of this study was that cardiomyocyte hypertrophy was induced in 
vitro. As hypertrophy is a complex multifactoral disease involving a number of different 
signalling pathways, it would be more relevant to study the role of cAMP in an in vivo 
setting, either by chronic catecholamine exposure in vivo, thoracic aortic constriction 
(TAC) or genetic mouse models of hypertrophy.  However, due to time constraints and no 
experience in this type of in vivo experimentation in the lab, it was decided to use a similar 
in vitro model that had already proved successful in neonatal cardiomyocytes. The benefits 
of in vitro investigation of the cAMP signalling pathway in hypertrophy is that this type of 
treatment is quick, relatively inexpensive, highly reproducible and gives the investigator 
more control by simplifying the system under investigation, allowing direct study of the 
single pathway of interest. There are some disadvantages of this type of model, for 
example, cells are maintained under non-physiological conditions. Cell densities are often 
less than in vivo tissue, which impairs intracellular signalling. Culture conditions are also 
not homeostatic (sudden exchange of media, continuous depletion of nutrients and 
accumulation of waste products) could alter results. These factors can sometimes become 
challenging when trying to extrapolate the results back to the biology of the whole 
organism and must be taken into consideration. Future work will be carried out in TAC 
treated rats to see if the same key findings of hypertrophy induced in vitro also occur 
during in vivo hypertrophy. 
Another drawback of this study is the way in which cell size was calculated. As 
cardiomyocytes are not flat, a more accurate method to measure myocyte growth would be 
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to calculate the volume of the cell. This could be done using a confocal microscope and the 
Z-stack function to take slice by slice images of the cell which can be reconstructed to 
form a 3D image of the cardiomyocyte, giving the exact dimensions. This method was not 
applied due to time constraints. Each Z-stack image can take a number of minutes to 
produce compared to seconds using the bright field option of the epifluorescent 
microscope. The confocal microscope used was shared between a numbers of different 
departments and therefore was not always available. 
 
The results in this thesis therefore identify PDE2 as a potential therapeutic target in the 
treatment of cardiac hypertrophy, however further experiments would be required to gain a 
better understanding on the role of PDE2 in this disease state. However, as PDE2 is 
expressed in other tissues, such as the brain, in endothelial cells and in platelets (Bender et 
al. 2006), global inhibition of this enzyme may result in adverse effects, as previously 
reported after long-term use of selective PDE3 inhibitors (Packer et al. 1991; Movsesian 
and Alharethi 2002). In this study, the greatest increase in PDE2 was found to be in the 
PKA-RII compartment activity in hypertrophic ARVM. Targeted PDE inhibition may be 
an option to selectively increase cAMP in this compartment without affecting the PDE2 
activity in other areas. One possible alternative approach to overcome the potential 
undesirable effects of global pharmacological PDE inhibition would be the development of 
disrupting peptides or of small molecules designed to selectively displace the subset of 
PDE2 which is involved in hypertrophy. Further studies are therefore necessary to expose 
the specific intracellular localisation of the pro-hypertrophic pool of PDE2, as well as its 
interaction partners and its potential targets. 
 
The work presented in this thesis advances our understanding of how cAMP/PKA signals 
are regulated in the PKA-RI and PKA-RII compartments of the heart. Alterations in cAMP 
signalling and PDE modulation of these compartments have been identified in an in vitro 
model of catecholamine-induced cardiac hypertrophy.  
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